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Foreword
In economic terms, Hyperinflation means a very high and accelerating inflation 
with a huge increase in commodity prices that are going out of control, and 
thus the local currency rapidly loses its value. Therefore, Hyperinflation is the 
nightmare scenario of any economy.
This book deals with Lung Hyperinflation a medical condition as catastrophic 
as hyperinflation is for the Economy.
It is well known, that Lung Hyperinflation in severe cases imposes a huge 
mechanical load on the respiratory system that may lead to respiratory 
failure with deadly cardiopulmonary consequences.
In addition, mild hyperinflation is a very common condition in Chronic Airway 
Diseases such as Chronic Obstructive Pulmonary Disease (COPD), Asthma, 
and Bronchiectasis, significantly affecting everyday symptoms and the 
Quality of life of those patients.
The aim of this book is to introduce the concept of Lung Hyperinflation, its 
effects on the mechanics of breathing leading to dyspnea, and its negative 
consequences for the functions of the Respiratory and Cardiovascular 
systems.
Since the book is for Practicing Pulmonologists, Internists, General 
Practitioners, Respiratory Physiotherapists, Nurses and Medical Students, 
specific efforts were made to avoid, as much as it was feasible, advanced 
physiology-pathophysiology, in other words - no algebra and no complex 
mathematical equations!
Major emphasis was put on the demonstration of  a number of very effective 
modes of treatment for Lung Hyperinflation. Moreover, the authors repeatedly 
provide a compelling rationale (solidly based on mounting evidence) for lung 
deflation as the primary  goal for the management of patients with Chronic 
Airways Diseases.
Thus, the main message of the book could be “Lung Hyperinflation is a very 
important clinical condition that makes breathing very difficult but today, a 
number of treatments can reverse it”.
Finally, we wish to thank the Authors of the chapters for their excellent work 
and NOVARTIS HELLAS for supporting this project.
Prof. Nikos Siafakas Prof. Denis E O’Donnell
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Definition(s)
In simple terms lung hyperinflation means 
“Large” lungs but the accurate definition(s) 
needs measurements of Lung Volumes.
The practicing physician may suspect lung 
hyperinflation from the clinical examination 
or/and from the chest X-Rays. 
Clinical Indications of Lung hyperinflation
Physical examination could reveal signs 
of lung Hyperinflation: High position of the 
shoulders (Figure 1), pursed lip breathing, 
forward leaning posture use of accessory 
muscles, “Barrel chest”, tympanic sound on 
percussion and diminished breath sounds on 
auscultation, may indicate hyperinflation of the 
lungs. In addition, abnormal motion of the chest 
wall (Thoraco-abdominal dys-synchrony) 
or distortions (Hoover’s sign) may be seen in 
hyperinflation. 
Figure 1. Patient with lung hyperinflation showing high 
position of his shoulders.
Radiological finding of L.H.
X-Rays of the thorax could also show large 
lungs (Figure 2). There are two types of 
radiological findings of hyperinflation. The one 
of Emphysema (COPD) is with flat diaphragms, 
horizontal position of the ribs, small heart 
shadow, increased retrosternal airspace, 
attenuation of the blood vessels (Figure 3). 
The second type of X-Ray hyperinflation is that 
during an acute exacerbation of Asthma, the 
X-Rays shows similar signs as Emphysema 
but without any effect on the vessels or the 
parenchyma. However, the proper medical 
definition needs the Pulmonary Function Test 
laboratory and the measurements of Lung 
Volumes and Capacities.
 
Figure 2. X-Ray of the chest: Hyperinflation of the Lungs.
Definition(s)
Nikolaos Siafakas
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Figure 3.
PA and Lateral chest X-Rays showing radiological 
features of hyperinflation in Emphysema
Lung Hyperinflation:
1. Increase in End-Expiratory Lung Volume 
(EELV) that is the level of lung volume at 
the end of expiration. In other words, the 
increase in the Functional Residual Capacity 
(FRC)
2. An increase in Total Lung Capacity (TLC). 
More than 120% of predicted value and /or 
EELV, Residual Volume (RV), RV/TLC are 
increased and Inspiratory Capacity (IC)/
TLC is reduced. For educational purposes 
we may distinguish  two types of lung 
hyperinflation,
a) STATIC  (measured at steady state) *
b) DYNAMIC (measured during exercise)
c) or a combination of the two starting 
with STATIC and then adding a DYNAMIC 
component (Figure 4).
Finally using lung volumes we may evaluate 
the severity of hyperinflation as mild, moderate 
and severe. (Figure 5).
Suggested Reading
• G.J.Gibson: Pulmonary hyperinflation a 
clinical overview. Eur Respir J: 1996;9:2640-
2649.
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Figure 5. Mild, Moderate and Severe levels of Static lung 
hyperinflation based on the measurements of the IC and /
or of the FRC/TLC ratio.
Figure 4. Static and Dynamic Lung hyperinflation during 
exercise in a COPD patient (Red lines and symbols). 
Grey lines and symbols are of a normal subject similar 
condition. (Note that during exercise EELV decreases 
in the normal subject increasing IC. In contrast EELV 
increases in the COPD patient decreasing significantly 
the IC (Dynamic hyperinflation)
*Foot note: Even the measurement of Static hyperinflation at steady state conditions contain an element of Dynamic component. (For more 
details see Appendix)
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Α1.
The Effects of Lung Hyperinflation on the Respiratory Muscles
Key Points
1.
The respiratory muscles are the only skeletal muscles 
that life depends on, since they are the vital part of the 
ventilatory pump.
2.
Hyperinflation significantly decreases the function  
of the respiratory muscles as pressure generators  
by changing their length and geometry and by altering 
the overall mechanics of breathing  
 (area of apposition).
3.
The effect of increased radius of the diaphragm 
(Laplace’s Law) is less important.
4.
Hyperinflation increases the work of breathing 
and the oxygen (O2) consumption of the respiratory 
muscles.
5.
Hyperinflation has detrimental effects on the 
structure of the respiratory muscles.
6.
The respiratory muscles undergo significant 
adaptations during chronic hyperinflation to improve 
their function.
7.
The effects of hyperinflation on the respiratory 
muscles may lead to ventilatory failure.
Α1.
The Effects of Lung Hyperinflation on the Respiratory Muscles
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INTRODUCTION
It is well known that the act of breathing 
depends on the coordinated function of the 
brain, spinal cord, nerves, and respiratory 
muscles as parts of the vital ventilatory 
pump. The ventilatory pump consists of: a) 
the respiratory center(s) and the nerve supply 
of the respiratory muscles, b) two cavities: 
the thoracic and the abdominal, and c) the 
thoracic wall (rib cage, abdominal wall, and 
the diaphragm). The respiratory muscles are 
the important contractile part of the pump that 
maintain life. The respiratory muscles are the 
only skeletal muscles that life depends on and 
are the only ones that contract continuously 
through the whole lifespan. Figure 1 shows the 
parts of the ventilator pump and the various 
pressure differences applied on them.
Respiratory Muscles and their nerves 
(Figure 2)
The respiratory muscles are divided into 
inspiratory and expiratory, primary and 
accessory.
Inspiratory muscles: 
• Diaphragm
• External Intercostals
• Scalenes
• Sternocleidomastoids
Expiratory muscles:
• Abdominal muscles
• Internal intercostals
THE VENTILATORY PUMP
A. Respiratory centers (CNS) and nerves
B. Two Cavities
  B1) Thoracic
  B2) Abdominal
C. The Thoracic wall
  C1) Rib cage
  C2) Abdominal wall
  C2) Diaphragm 
Pg - Poes = Pdi (= 0 at FRC)
Area of
apposition
Ppl Ppl
Rib cage
Diaphragm
Chest
wall
Abdominal
carity
Thoracic
cavity
Abdominal
wall
Pab
Poes      Ppl
Pg      Pab
A B
Figure 1. 
A. The components of the ventilatory pump. B. The ventilatory pump, the pressures and the area of 
apposition (the lower part of the rib cage is driven by the 
abdominal pressure [Poes: Oesophageal; Pg: Gastric; Ppl: 
Plural; Pab: Abdominal; Pdi: Transdiaphragmatic)
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The Effects of Lung Hyperinflation on the Respiratory Muscles
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Figure 2. 
A. The respiratory muscles (inspiratory - expiratory)                  B. The innervations of the respiratory muscles.
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Diaphragm
The diaphragm is the main muscle of 
respiration and primarily of inspiration. It has 
a dome-like shape, resembling a parachute 
(Figure 3). The diaphragm contracts via the 
neural pulse originating from the respiratory 
center(s) which is then conveyed via the spinal 
cord and the phrenic nerves. The roots of the 
phrenic nerves are of the C3, C4, C5 (Figure 2B). 
By contracting the diaphragm, the pressure in 
the abdomen increases, pushing the lower 
part of the ribs outwards, and thus increasing 
the volume of the thoracic cavity. This results 
in a decrease in the intrathoracic pressure; a 
development of a negative pressure gradient 
between the alveoli and the mouth which 
causes flow of air (inspiration) into the lungs.
Intercostals
These form the wall of the chest and are located 
between the ribs. The external intercostals lift 
the ribs and expand the transverse diameter 
of the thoracic cavity. The internal intercostals 
work in the opposite direction (expiration). Both 
are innervated by the thoracic nerves (T1-T12) 
(Figure 2B).
Scalene and Sternomastoid Muscles
These are considered accessory respiratory 
muscles and take part in respiration during 
critical conditions, such as respiratory failure 
(Figure 2) or when significant increases in 
ventilation are required, e.g., exercise.
Abdominal muscles
The abdominal muscles, and in particular, 
those that form the anterior abdominal wall 
(Rectus abdominis, transversus abdominis, 
internal / external oblique), are expiratory 
muscles, which are activated during forced 
expiration, coughing, and sneezing. In addition, 
the abdominal muscles act as stabilizers of 
the diaphragm. It is shown that the abdominal 
muscles are involved in maintaining the 
shape and length of the diaphragm in order to 
facilitate its efficiency to generate pressure.
In normal conditions, expiration is a quasi-
passive phenomenon, depending on the 
relaxation of the inspiratory muscles and the 
elastic properties of the ventilatory pump. 
Histology of the Respiratory Muscles
There are three types of skeletal muscle fibers:
• Type I or Slow (oxidative): High resistance to 
fatigue
• Type IIA or Fast (oxidative): Intermediate 
resistance to fatigue
• Type IIB or Fast (glucolytic): Low resistance 
to fatigue
The compositions of the respiratory muscles in 
health are approximately:
• 50-60% of Type I (slow)
• 20-25% of Type IIA (fast)
• 20-25%of Type IIB (fast)
Structure of the Respiratory Muscles (Figure 4)
The basic structure of the diaphragm or the 
other respiratory muscles is similar to that 
of any other striated (skeletal) muscle. The 
basic structure is the myofibril that contains 
the contractile element, the sarcomere 
Figure 3. 
The shape of the 
diaphragm that 
resembles a parachute.
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(Figure 4A). The sarcomere consists of a thick 
filament of Myosin and a thin filament of actin 
(Figure 4A). In accordance with the sliding 
concept of contracting, the force is developed 
by cross bridges where the myosin and the 
actin filaments overlap (Figure 4A). Myosin 
molecules have a long tail that ends in two 
heads with Adenosine triphosphate (ATP) 
binding sites. These heads link myosin and 
actin during contraction. Muscle contraction 
is a rather complicated procedure that needs 
ATP, calcium (Ca2), magnesium (Mg2), Anti-
DNase B (ADB), troponin, tropomyosin and 
other elements to exist (Figure 4B). Finally, the 
neuromuscular junction is also involved in the 
initiation of the contraction (Figure 4B).
A
B
1
2
1
2
3
4
5
6
7
3
4
Figure 4. 
A. Muscle fiber contraction.
The myosin-acting coupling and the role 
of ATP.
1. Myosin cross bridge attaches to the actin 
myofilament.
2. The myosin head pivots bends and pulls 
the actin filament (working stroke).
3. ATP attaches to the myosin head and the 
cross bridge is detached.
4. ATP splits into adenosine diphosphate 
(ADP) and inorganic phosphate (Pi) causing 
cock of the myosin head.
B. Neuromuscular coupling.
1. Release of Acetilocholine (Ach) from the 
nerve ending.
2. Action potential is travelling along the 
sarcolemma and T-tubules.
3. Release of calcium ions (Ca2+) from 
terminal systemic of sarcolemma.
4. Calcium bind to troponin.
5. Contraction (see Figure 4A).
6. Removal of Ca2+ after action potential 
ends.
7. Contraction ends and fiber relaxes
Α1.
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Physiology of Respiratory Muscles
The function of the respiratory muscles, as 
in all skeletal muscles, is depended on the 
general principal relationships of muscle 
function Figure 5:
a) The length/tension or force relationship.
b) The velocity/tension or force relationship.
c) The firing frequency/tension relationship.
In addition, due to the shape of the diaphragm, 
the curvature of the dome affects the radius; 
thus, the pressure generated (Laplace’s Law) 
by the diaphragm (Figure 5C).
Figure 5A shows that there is an optimal resting 
length that generators figures the highest 
force. In addition, it is shown (Figure 5B) that 
as the velocity of shortening is increased, less 
force is produced. Figure 5D also demonstrates 
that above a certain firing frequency, the 
tension (force) produced by the muscle 
cannot be increased further. As we are going 
to discuss in more detail, the most important 
and detrimental effects of hyperinflation are 
primarily exerted on the diaphragm (i.e., on the 
length/tension relationship, decrease of the 
area of apposition, changes in the geometry 
(orientation of the fibers), and to a lesser 
degree, by Laplace’s law). 
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Figure 5. The main physiological principles of the 
respiratory muscles.
A. The length/force (tension) relationship (best at the 100% 
of the resting length).
B. The velocity/force relationship (best at lower velocity).
C. The shape of the diaphragm affecting its pressure 
generating capacity (Laplace’s Law).
Pdi: Transdiaphragmatic pressure.
Rdi:The radius of the diaphragm.
Pdi1, Rdi1: Normal
Pdi2, Rdi2: Hyperinflation
Pdi1>Pdi2, Rdi1<Rdi2
D. The firing frequency/tension (force), which increases 
up to 40-60 Hz.
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The Effects of Hyperinflation on the Diaphragm 
Length/tension relationship
Hyperinflation shortens the diaphragm and 
thus displaces it to a disadvantageous position 
of its length/tension curve. This results in a 
decrease in the power-generating capacity of 
the muscle. If hyperinflation becomes chronic, 
diaphragmatic function is adapted to the new 
hyperinflated state. This consists of changes 
in the structure of the muscle, especially by 
reducing the number of sarcomeres. On the 
other hand, if hyperinflation occurs acutely, 
as in an acute severe asthma attack, the 
shortening of the diaphragm may lead to acute 
compression of the T-tubules leading to reduce 
of action potential in the muscle. Thus, the 
operational length of the respiratory muscles 
is altered by hyperinflation decreasing its 
capacity to generate pressure (Figure 5A, 
Figure 6).
Area of Apposition
As shown in Figure 6, the contraction of the 
diaphragm increases the abdominal pressure 
that is exerted on the lower rib cage (the area 
of apposition), and results in the expansion of 
the lower part of the thorax. Figure 6B shows 
the position of the diaphragm in hyperinflation 
and its relationship with the area of apposition. 
It is obvious that this area is diminished or has 
disappeared in severe hyperinflation. This 
also has a significant effect in reducing the 
mechanical efficiency of the diaphragm.
Changes in Geometry
In hyperinflation, the diaphragmatic fibers at 
the insertion on the rib cage run transversally 
inwards and not cranially (Figure 6B). Thus, 
the diaphragm in severe hyperinflation 
becomes an expiratory muscle instead of been 
inspiratory. This change in geometry of the 
muscles may be the explanation of the Hoover 
sign in children. (see chapter B2)
Normal
Ribs
Area of
apposition
A Hyperinflation
Impaired blood
supply
Shortened
muscle fibers
Decreased
diaphragmatic
curvature
Decreased area
of apposition
Medial orientation of
diaphragmatic fibers
Thoracic cage elastic
recoil directed inwards Horizontal ribs
B
Figure 6. Normal and hyperinflated respiratory system.
A. Normal: Notice the area of apposition and the 
orientation of the ribs.
B. Hyperinflation: Significant reduction of the area of 
apposition, shortening of muscles fibers, expiratory or 
medial orientation of fibers.
Α1.
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Laplace’s Law (Figure 5C)
This law states that the pressure produced by 
the diaphragm is directly proportional to the 
tension developed and inversely proportional 
to the radius of curvature of the diaphragm. 
Since hyperinflation flattens the diaphragm 
(increases radius), it reduces its ability 
as a force-generating muscle. However, 
experimental observations have shown that 
geometrical changes are less important via 
Laplace’s law.
In addition, hyperinflation of the lungs, which 
flattens the diaphragm, affects its blood flow 
due to compression of its blood vessels; 
consequently, this reduces the nutritional 
supply and oxygenation of the muscle.
Effects of Hyperinflation on the Intercostals
There is experimental evidence that 
hyperinflation profoundly affects the function 
of the internal and external intercostals 
muscles. In particular, hyperinflation affects 
the function of the most important part of 
the intercostals muscles: the parasternals. 
This is due to changes in the length/tension 
relationship and in geometry: in other words, 
the changes of the angle between the muscle 
fibers and the sternum.
Effects of Hyperinflation on the Other 
Respiratory Muscles
There are very few studies on the effect of 
hyperinflation on the sternomastoids and 
scalene muscles. These studies have shown a 
minimal effect on their function.
Effects of Hyperinflation on the Expiratory 
Muscles
In hyperinflation, the expiratory muscle 
activity is rather supportive of the diaphragm’s 
function, by helping maintain the diaphragmatic 
shape and length. The action of the expiratory 
muscles contributes to the intrinsic positive 
end –expiratory pressure, altering the 
pressure-volume relation of the Respiratory 
System. (See chapter A2).
The structural changes
Finally, a number of cytological and molecular 
changes have been seen in the diaphragm 
of COPD patients with severe hyperinflation 
(Figure 7).
Figure 7. Electromyographic photos of human, 
diaphragmatic sarcomeres.
A. Normal.
B. Chronic obstructive pulmonary disease (COPD), 
showing extensive damage.
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Mechanisms and Consequences of Resting Lung Hyperinflation  
in Chronic Obstructive Pulmonary Disease
Key Points
1.
Lung hyperinflation is common in chronic obstructive 
pulmonary disease (COPD) and occurs across the continuum 
of disease severity.
2.
Increased functional residual capacity (FRC) can occur in the 
absence of a significant increase in total lung capacity (TLC) 
and can indicate presence of expiratory flow limitation during 
resting breathing. 
3.
Increased residual volume / total lung capacity (RV / TLC) ratio 
indicates pulmonary gas trapping and suggests peripheral 
airway dysfunction. 
4.
Inspiratory capacity decreases linearly as forced expiratory 
volume in one second (FEV1) worsens and is a simple indirect 
measure of increasing lung hyperinflation. 
5.
The mechanical disadvantages of lung hyperinflation are 
partially offset by adaptations that preserve respiratory 
muscle strength and protect against fatigue.
6.
In situations where ventilatory demand increases, 
hyperinflation causes functional weakness of the diaphragm 
and ribcage muscles. 
7.
Severe resting lung hyperinflation in the setting of a low 
inspiratory capacity greatly diminishes the ability to expand 
lung volume with each inspiration.
8.
Cardiac performance is impaired in the presence of 
hyperinflation as a result of reduced venous return, increased 
pulmonary vascular resistance, increased left ventricular 
afterload and external mechanical cardiac compression. 
Α2.
Mechanisms and Consequences of Resting Lung Hyperinflation  
in Chronic Obstructive Pulmonary Disease
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INTRODUCTION
While expiratory flow limitation (EFL) is 
generally regarded as the pathophysiological 
hallmark of COPD, lung hyperinflation is a 
related and clinically important manifestation of 
the disease that deserves attention. Measures 
of resting lung hyperinflation have been shown 
to be predictive of respiratory and all-cause 
mortality and relate to dyspnea and exercise 
intolerance. In this chapter we will attempt 
to clarify definitions of lung hyperinflation, 
review causative mechanisms, consider the 
natural progression of hyperinflation in COPD, 
and briefly outline the negative consequences 
of lung hyperinflation. 
Hyperinflation: Definitions and Determinants
In the absence of any consensus on the definition 
of lung hyperinflation, it is recommended 
when using this term to specify the volume 
compartment in question expressed as a 
percentage of the predicted normal value. For 
the purpose of this chapter, an increase in total 
lung capacity (TLC) (preferably measured by 
body plethysmography) exceeding either the 
upper limit of normal (ULN) or an empiric 120% 
of predicted, is consistent with the presence 
of thoracic hyperinflation. An increase in 
plethysmographic functional residual capacity 
(FRC) above either ULN or 120% of predicted 
is termed lung hyperinflation. An increase in 
plethysmographic RV exceeding either ULN 
or 120% of predicted is termed pulmonary gas 
trapping, also expressed by an increase in the 
RV/TLC ratio.
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Figure 1. Quasistatic V–P curves of lung (PL), chest wall (Pcw ), and total respiratory system (Prs) during relaxation in a 
sitting position. The static forces of the lung and chest wall are indicated by the arrows in the drawings. PL increases its 
curvature with increasing lung volume, whereas the opposite is true for the Pcw. Therefore, the fall in the compliance of 
the respiratory system at high lung volumes is mainly due to the decrease in compliance of the lung, whereas at low lung 
volumes it reflects decreased compliance of the chest wall. In the tidal volume range, the V–P relationships of both the 
lung and chest wall are nearly linear, and compliance of the lung and chest wall are about the same (approximately 4% 
vital capacity per 1 cm H2O or 0.2 L/cm H2O, in a seated position). The volume corresponding to each drawing is indicated 
by the horizontal broken lines. From: Agostini E, Mead J. Statics of the respiratory system. In: Fenn WO, Rahn H (Ed) 
Handbook of physiology. Respiration, Vol 1. Bethesda MD: American Physiological Society, 1964; 387-409.
PA G E  2 5
HYPERINFLATION OF THE LUNG AND ITS MANAGEMENT
P H Y S I O L O G Y
Α2.
Mechanisms and Consequences of Resting Lung Hyperinflation  
in Chronic Obstructive Pulmonary Disease
Total Lung Capacity
Total lung capacity is the greatest volume 
of gas in the lungs after maximal voluntary 
inspiration. It depends on the static balance 
between the outward forces generated 
by inspiratory muscles during a maximal 
inspiratory effort and the inward elastic forces 
of the chest wall and lung (Figure 1). At TLC, 
these two sets of forces are equal and opposite 
in sign. The increase in TLC in COPD usually 
reflects the increased lung compliance due to 
emphysema.
Functional Residual Capacity at Rest
Functional residual capacity, or the lung 
volume at the end of quiet expiration during 
tidal breathing (i.e., end-expiratory lung volume 
[EELV]) is increased in COPD compared with 
health. The term EELV is used interchangeably 
with FRC in the current chapter. FRC is not 
always synonymous with the static equilibrium 
volume of the relaxed respiratory system, i.e., 
relaxation volume (Vr): the volume at which the 
elastic recoil pressures of lung and relaxed 
chest wall are equal and opposite in sign 
(Figure 1). Active or passive mechanisms often 
operate to make FRC different from Vr both in 
health and in COPD. For example, in healthy 
younger subjects during exercise, activation 
of expiratory muscles commonly drives FRC 
below the Vr.
Increase in FRC measured at rest has both 
static and dynamic determinants in COPD. 
Traditionally, increase in “static” FRC refers 
to increase in the Vr due to loss of lung recoil 
which resets the balance of forces between 
the lung and chest wall (Figure 2). Accordingly, 
the static Vr is higher than that of predicted 
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Figure 2. Effect of reduced lung recoil pressure on functional residual capacity (FRC). Funtional residual capacity or end-
expiratory lung volume (EELV) in the normal lung represents the volume at which the elastic recoil pressures of lung and 
relaxed chest wall are equal and opposite in sign, i.e., the net elastic recoil pressure of the total respiratory system equals 
zero (long-dashed lines). Loss of lung elasticity due to emphysema in COPD reduces lung recoil pressure; consequently, 
FRC occurs at a higher lung volume, which defines static hyperinflation (short-dashed lines). Under this circumstance, 
the elastic recoil pressures of lung and relaxed chest wall are equal and opposite in sign, meaning that the alveolar 
pressure is still atmospheric. TLC: total lung capacity. Modified from: Ferguson GT. Why does the lung hperinflate? Proc 
Am Thorac Soc 2006; 3(2): 176-179.
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normal, and FRC (or EELV) is increased in 
COPD compared with health (Figure 2). The 
higher Vr means that the alveolar pressure at 
end-expiration remains atmospheric, i.e., is 
still zero. Of note, “static” does not necessarily 
mean “at rest”.
Resting FRC is dynamically determined. Lung 
hyperinflation is also influenced by body 
position and by body mass: for example, 
EELV decreases when adopting a supine 
position or with obesity. In this respect, FRC 
has been shown to decrease exponentially 
with increasing body mass index (BMI), with 
the largest changes occurring with BMI in the 
overweight to mild obesity range (Figure 5). 
Variable increases in EELV can also occur when 
minute ventilation (V’E) is abruptly increased 
(e.g., voluntarily, during anxiety/panic attacks, 
acute hypoxemia, or physical activity or during 
metronome pacing) or when EFL is suddenly 
worsened (e.g., increased bronchospasm or 
during exacerbation). This acute increase in 
EELV is termed dynamic lung hyperinflation 
(DH) - the temporary and variable increase of 
EELV above the resting value.
Inspiratory Capacity
Inspiratory capacity (IC) is defined as the 
maximal volume of air that can be inspired after 
a quiet expiration to EELV. The resting IC (or IC/
TLC ratio) is also used as an indirect measure of 
lung hyperinflation when TLC is stable. Resting 
IC progressively declines as airway obstruction 
worsens in COPD (Figure 3). Measurement of IC 
is motivation-dependent and is influenced by 
static strength of the inspiratory muscles and 
EELV. The IC represents the operating limits 
for tidal volume (VT) expansion during exercise 
in patients with EFL and influences breathing 
pattern and peak ventilatory capacity (see 
below). The IC is diminished in the presence 
of significant inspiratory muscle weakness. 
Patients with a resting IC of <80% predicted are 
thought to have significant EFL during resting 
breathing and are at greater risk for developing 
DH during exercise.
Residual Volume
RV refers to the volume of gas remaining in 
the lungs after full exhalation, regardless of 
the lung volume at which exhalation is started. 
In young healthy adults, RV is determined by 
the balance between expiratory muscle force 
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Figure 3. Functional residual capacity (FRC) increases and inspiratory capacity (IC) decreases progressively across the 
GOLD stages (1, 2, 3/4) of COPD severity. GOLD: Global Initiative for Chronic Obstructive Lung Disease; TLC: total lung 
capacity. Constructed with data from: Deesomchok A, et al. COPD 2010; 7(6): 428-437.
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and the outward elastic recoil of the chest wall 
(Figure 1). In older healthy adults, the normal 
loss of lung elasticity with age and associated 
decreases in maximum expiratory flow rate 
(premature airway closure and flow limitation) 
are associated with increased RV, compared to 
youth. In COPD, expiratory flow rates are very 
low near RV, and the ability to expire maximally 
may be influenced by limited breath-holding 
ability or breathlessness before expiration is 
“complete”. The result is that RV can be higher 
than predicted. An increased RV/TLC reflects 
premature airway closure and pulmonary gas 
trapping, and is well documented in early or 
mild COPD even before FRC and TLC become 
increased.  
The Natural History of Lung Hyperinflation
Insufficient data from longitudinal studies 
are available to allow us to chart the 
natural history of the development of lung 
hyperinflation in COPD. Clinical experience 
indicates that this is an insidious process 
that occurs over decades. It is acknowledged 
that such factors as genetic susceptibility, 
burden of tobacco smoke and frequency and 
severity of exacerbations collectively dictate 
the progression of hyperinflation. The 4-year 
UPLIFT® trial documented a mean rate of 
decline in pre-bronchodilator IC of 34 to 50 
mL/year in patients with moderate to very 
severe COPD. In that study, the patients with 
the lowest baseline IC were those with the 
greatest rates of exacerbation and death. A 
recent cross-sectional study in 2265 patients 
found progressive increases in pulmonary gas 
trapping and lung hyperinflation (measured by 
RV and FRC) and a corresponding decline of IC 
across the continuum of COPD severity (Figure 
3). Lung volume increases were shown to 
occur even in the earliest stages of COPD (i.e., 
Global Initiative for Chronic Obstructive Lung 
Disease [GOLD] grade 1) and increased with 
severity of airway obstruction (Figures 3 and 
4). Another study showed that an increased BMI 
was associated with lower static lung volume 
n=2,265
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Figure 4. Cross-sectional data showing that inspiratory capacity (IC) decreases linearly as the FEV1 worsens in COPD 
(n=2,265). Constructed with data from: Deesomchok A, et al. COPD 2010; 7(6): 428-437.
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components, regardless of the severity of 
airway obstruction (Figure 5).
Hyperinflation across the Continuum of COPD 
Small studies in mild COPD have reported 
increased static lung compliance, and 
quantitative computed tomography (CT) scans 
have shown emphysema and gas trapping. 
Gas trapping, as assessed by expiratory CT 
scans, can exist in the absence of structural 
emphysema and is believed to indirectly 
reflect small airway dysfunction in mild COPD. 
The presence of lung hyperinflation assessed 
by quantitative CT scans was found to predict 
a rapid annual decline in FEV1 in smokers 
with a normal FEV1. Corbin and coworkers, in 
a 4-year longitudinal study of smokers with 
chronic bronchitis, reported a progressive 
increase in lung compliance. Interestingly, 
these investigators reported that increases 
in TLC in milder COPD served to preserve 
slow vital capacity SVC and IC in the setting 
of increased RV and FRC, respectively. There 
is considerable heterogeneity in FRC and 
RV across GOLD grades, but many patients 
in each GOLD category have values that are 
above the predicted normal values. From 
cross-sectional studies, it would appear that 
RV and FRC increase exponentially as airway 
obstruction worsens.  
Physiological Adaptations to Chronic Lung 
Hyperinflation 
In the presence of lung hyperinflation, 
functional muscle weakness is mitigated, to 
some extent, by long term adaptations such 
as shortening of diaphragmatic sarcomeres 
and a decrease in sarcomere number, which 
cause a leftward shift of the length-tension 
relationship; thus, improving the ability of 
the muscles to generate force at higher 
lung volumes. In patients with chronic lung 
hyperinflation, adaptive alterations in muscle 
fiber composition (an increase in the relative 
proportion of slow-twitch, fatigue resistant, 
type I fibers) and oxidative capacity (an 
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Figure 5. Post-bronchodilator lung volume components are shown divided by GOLD stage and BMI. The Normal column 
represents measurements from an age-matched, healthy, non-smoker population. GOLD: Global Initiative for Chronic 
Obstructive Lung Disease; UW underweight (BMI 14-18.5 kg/m 2); NW: normal weight (BMI 18.5-24.99 kg/m 2); OW: 
overweight (BMI 25-29.99 kg/m 2); OB: obese (BMI 30-55 kg/m 2). From: O’Donnell DE, et al. Chest 2011; 140(2): 461-468.
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increase in mitochondrial concentration and 
efficiency of the electron transport chain) are 
believed to preserve the functional strength of 
the overburdened diaphragm and make it more 
resistant to fatigue. In this regard, Similowski 
et al. demonstrated that the reduction in the 
pressure-generating capacity of the inspiratory 
muscles of stable COPD patients was related 
to lung hyperinflation, but that diaphragmatic 
function in such patients was comparable to 
normal subjects when measurements were 
compared at the same lung volume. Despite 
these impressive temporal adaptations, the 
presence of severe lung hyperinflation means 
that ventilatory reserve in COPD is diminished 
and the ability to increase V’E when the demand 
suddenly arises (exercise or exacerbation) is 
greatly limited.
Consequences of Resting Lung Hyperinflation 
Increased EELV at rest is advantageous as it 
improves airway conductance and attenuates 
expiratory flow limitation to a variable degree. 
However, lung hyperinflation in moderate to 
severe COPD places the inspiratory muscles, 
especially the diaphragm, at a significant 
mechanical disadvantage by shortening 
its fibers, thereby compromising its force 
generating capacity by 30 to 55%. Lung 
hyperinflation also affects the capacity of 
the parasternal intercostals and scalenes to 
shorten with potential negative consequences. 
Known mechanisms of compromised 
diaphragmatic function include: 1) worsening 
of the length-tension relationship, 2) decrease 
in the area of apposition, 3) decrease in the 
curvature of the diaphragm, 4) change in the 
mechanical arrangement of costal and crural 
components of the diaphragm, and 5) increase 
in the elastic recoil of the thoracic cage. 
Lung hyperinflation decreases the resting 
length of the diaphragm and, less so, the 
rib cage muscles. The shortening of the 
diaphragm is due to a decrease in the length of 
its area of apposition, which causes a decrease 
in its pressure generating capacity. At resting 
EELV, the curvature of the diaphragm is only 
3.5% smaller in severe COPD patients than 
in healthy subjects. The radius of curvature 
also changes little over the range of IC in both 
severe COPD patients and healthy subjects. It 
follows that a change in the curvature of the 
diaphragm is likely to be less important than 
a change in length of diaphragmatic fibers in 
determining contractile force. The change 
in fiber orientation with lung hyperinflation 
decreases the ability of the diaphragm to 
generate force, and the diaphragm has an 
expiratory rather than inspiratory action on the 
rib cage.
When EELV becomes positioned above 70% of 
predicted TLC, thoracic elastic recoil is directed 
inward (i.e., increased) so that the inspiratory 
muscles have to work, not only against intrinsic 
or auto- positive end-expiratory pressure 
(PEEPi) and the elastic recoil of the lungs, but 
also against the elastic recoil of the thoracic 
cage (Figure 1). The net effect is a pronounced 
increase in the work and oxygen (O2) cost of 
breathing at rest in patients with severe COPD 
(reviewed in Loring).
 
Lung Hyperinflation and the Heart 
Severe hyperinflation, as defined as an 
IC/TLC ratio <25%, has been shown to be 
associated with increased cardiovascular 
mortality, impaired LV filling determined by 
echocardiography, and reduced exercise 
tolerance. Severe lung hyperinflation has 
recently been linked to a reduced intra-
thoracic blood volume and reduced LV end-
diastolic volume as assessed by MRI. Barr et 
al. reported that in a large population-based 
sample of smokers and non-smokers, a 10% 
increase in the percentage of emphysema 
(measured by CT) correlated with reductions 
in left ventricular (LV) diastolic volume, stroke 
volume and cardiac output, as estimated by 
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magnetic resonance imaging (MRI). Lung 
hyperinflation has the potential to impair 
cardiac function by increasing pulmonary 
vascular resistance. Increased intrathoracic 
pressure swings linked to the increased 
mechanical loading of hyperinflation may 
result in increased LV afterload as a result of 
the increased LV transmural pressure gradient 
(Figure 6). Reductions in venous return, right 
and left ventricular volumes, and LV stroke 
volume are additional consequences of the 
altered intra-thoracic pressure gradients. 
Summary
In COPD, progressive EFL and alteration in the 
elastic properties of the lung are associated 
with the development of progressive lung 
hyperinflation and decline in the resting 
IC. Severity of lung hyperinflation is an 
independent predictor of mortality in COPD. A 
number of physiological adaptations partially 
preserve diaphragmatic function in the face 
of chronic hyperinflation. However, these 
adaptations are only partially effective and 
can become quickly overwhelmed when 
ventilatory demands increase, e.g., during 
physical activity or during exacerbations. 
Severe hyperinflation is linked to increased 
threshold and elastic loading (and increased 
work of breathing) of the already weakened 
respiratory muscles. Moreover, the restrictive 
mechanical effects of a low IC limit the ability 
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Figure 6. Schematic representation of the potential deleterious effects of lung hyperinflation on cardiopulmonary 
interactions in patients with COPD. Note that most of these interactions may vary according to phase alignment between 
the respiratory and cardiac cycles. Important modulating effects of volemic status, sympathetic nervous system 
activation, ventilation-related vagal reflexes and comorbidities (e.g., pulmonary hypertension and chronic heart failure) 
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Respir Med 2014; 8(6): 731-749.
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to appropriately increase tidal volume and 
ventilation when metabolic demand acutely 
increases. Lung hyperinflation also impedes 
cardiac performance, which in certain 
circumstances has important implications for 
oxygen delivery to the tissues. 
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Key Points
1.
Dynamic hyperinflation (DH) is the temporary and 
variable increase in end-expiratory lung volume 
(EELV) above resting values in patients with 
airways obstruction.
2.
Dynamic hyperinflation is the product of 
worsening expiratory flow limitation  
and increased ventilatory demand. 
3.
Progressive bronchoconstriction in acute asthma 
is associated with increasing DH which  
acutely loads the respiratory muscles and 
restricts tidal volume (VT) expansion.
4.
During asthma attacks, DH introduces a widening 
disparity between the drive to breathe  
and the mechanical/muscular response of the 
respiratory system.
5.
Intensity of dyspnea during bronchoprovocation 
correlates well with the progressive reduction  
of inspiratory capacity and the increased ratio of 
respiratory effort to volume displacement.
6.
The impact of DH on respiratory muscle function 
(excessive loading and functional weakness) 
during acute exacerbations of COPD (AECOPD) 
depends on baseline respiratory mechanics and 
gas exchange abnormalities.
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7.
Attendant ventilation/perfusion abnormalities 
during AECOPD increase respiratory neural 
drive which amplifies DH, its negative cardio-
respiratory sequelae and dyspnea perception.
8.
Recovery of dyspnea following AECOPD 
closely follows the gradual reduction in DH 
back to pre-exacerbation levels.
9.
Although exercise limitation in COPD is 
multifactorial, acute-on-chronic DH and  
its negative mechanical, cardio-circulatory 
and sensory consequences is centrally  
important in patients with more advanced 
COPD.
10.
The known negative effects of resting and 
dynamic hyperinflation provide a strong  
physiological rationale for the development of 
targeted interventions to deflate  
overinflated lungs in patients with chronic 
airflow limitation.
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INTRODUCTION 
Dynamic lung hyperinflation DH refers to 
the temporary and variable increase in end-
expiratory lung volume (EELV) above the resting 
value in patients with obstructive airways 
disease. Dynamic hyperinflation occurs when 
expiratory flow limitation is abruptly increased 
during acute bronchospasm or exacerbation, 
often in a setting where minute ventilation (V’E) is 
also acutely increased in response to increased 
respiratory neural drive. Depending on the 
extent of baseline lung hyperinflation, further 
DH can have important negative consequences 
for the function of both the respiratory 
and cardio-circulatory systems when the 
respiratory system is suddenly stressed. 
Moreover, acute DH is increasingly implicated 
as a major cause of dyspnea – the dominant 
symptom in patients with chronic airway 
diseases. In this chapter, we will briefly review 
the mechanisms and clinical consequences of 
DH during acute bronchoconstriction in asthma 
and exacerbation in COPD. Finally, we will 
summarize the role of DH in exercise limitation 
and dyspnea causation in COPD.  
DH in Asthma
The main pathophysiological derangements 
in acute asthma are excessive airway 
narrowing/closure and lung hyperinflation. 
Acute DH occurs during bronchoconstriction 
because diffuse contraction of airway smooth 
muscle results in the non-uniform behavior of 
dynamic lung mechanics – many alveolar units 
develop delayed mechanical time constants 
for emptying. The increased airway resistance 
means delayed gas emptying as the expiratory 
time available during spontaneous breathing 
is not sufficient to allow EELV to decline to 
the normal resting relaxation volume of the 
respiratory system (Vr). In some instances, 
active “braking” of the inspiratory muscles 
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Figure 1. Relationship between decreasing forced expired volume in 1 second (FEV1) and inspiratory capacity (IC) during 
high-dose methacholine bronchoprovocation to a maximal response denoted by symptom limitation, a decrease in FEV1 
of 50% or more, or a maximum dose of 256 mg/mL (n=116). At the provocative concentration of methacholine causing a 
20% fall in FEV1 (PC20) and at the maximum response (46% fall in FEV1), IC decreased by a mean of 0.62 L (22%predicted) 
and 1.06 L (37%predicted) from baseline, respectively. Data from Lougheed MD, et al. Chest 2006; 130: 1072-1081.
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during expiration may assist in maintaining 
higher lung volumes to enhance expiratory 
flows, but this mechanism is disputed. It is well 
known that airway resistance drops at high lung 
volumes; thus, dynamic hyperinflation could be 
considered as a compensatory mechanism to 
reduce bronchoconstriction. 
The fast decline of FEV1 during progressive 
bronchospasm may simply reflect increased 
pulmonary gas trapping due to increased 
peripheral airway resistance. Accordingly, 
as residual volume (RV) and EELV increase, 
vital capacity (VC) and inspiratory capacity 
(IC) decrease. The reduced FEV1, therefore, 
mirrors the increased RV/TLC ratio and reduced 
VC. Increased EELV occurs even at low levels 
of bronchoconstriction, and is discernible in 
many patients during methacholine challenge 
when FEV1.0 has fallen by 20% of the baseline 
value (PC20) (Figure 1). While hyperinflation 
serves to maximize tidal expiratory flow rates 
during bronchoconstriction because of the 
effect of alveolar-airway inter-dependence, 
the requirement of sustained breathing at high 
lung volumes ultimately has serious negative 
mechanical and sensory consequences. As a 
result of DH, tidal volume (VT) comes closer to 
total lung capacity (TLC) and the upper non-
linear “stiffer” extreme of the respiratory 
system’s pressure-volume relationship, where 
there is significant elastic and inspiratory 
threshold loading of inspiratory muscles 
already burdened with increased resistive work. 
During acute bronchoconstriction, dynamic lung 
compliance is also decreased in association 
with the increased breathing frequency.
Acute thoracic hyperinflation adversely affects 
length-tension relationships of the inspiratory 
muscles, thereby compromising their ability 
to generate pressure. The net effect of this 
functional muscle weakness, coupled with 
excessive elastic and resistive loading, is 
that the inspiratory muscles are forced to 
utilize a large fraction of their maximal force 
generating capacity during spontaneous tidal 
breathing. As lung volume increases, the 
diaphragm is mechanically disadvantaged and 
scalene, sternomastoid and ribcage muscles 
are recruited. However, expiratory muscle 
recruitment is seldom prominent even during 
severe asthma attacks. A consequence of 
lung hyperinflation that is seldom emphasized 
is the severe mechanical constraints on VT 
expansion: VT represents a higher fraction of 
the progressively diminishing IC and inspiratory 
reserve volume (IRV) reaches its critical lower 
limit.  Thus, thoracic volume displacement is 
greatly diminished, despite patients generating 
near maximal inspiratory efforts in response to 
increasing respiratory neural drive (RND). 
In a study using high-dose methacholine 
challenge in patients with asthma, multiple 
regression analysis (where induced dyspnea 
was the dependent variable and several 
relevant mechanical parameters as 
independent variables) identified the 
decrease in IC (which reflects increased 
EELV) as the strongest contributor, 
explaining 74% of the variance in Borg 
dyspnea ratings (Figure 2). In qualitative 
terms, we established that dyspnea during 
acute bronchoconstriction is perceived 
primarily as inspiratory difficulty or 
unsatisfied inspiratory effort. Expiratory 
difficulty was less frequently reported, even 
when FEV1.0 had fallen to 50% of the baseline 
value. We have proposed that perceived 
inspiratory difficulty arises when there is a 
disparity or mismatch between respiratory 
muscular effort (which approaches 
maximum) and the mechanical response of 
the system (which is greatly restricted due 
to thoracic hyperinflation). A strong 
statistical correlation between inspiratory 
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difficulty and a crude index of 
neuromechanical dissociation (NMD) (i.e., 
the ratio of esophageal pressure swings 
relative to maximum [esophageal pressure/ 
maximum inspiratory value for Pes: Pes/
PImax] to VT/IC) supports this contention 
(Figure 3). In this context, the inspiratory 
Dyspnea 
(Borg)
Pes/PImax :VT/TLC 
ratio
r=0.74 
p<0.001
r=0.73 
p<0.001
r=0.58 
p<0.01
EELV / TLC
Figure 3.  Significant interrelationships between 
perceived breathlessness, dynamic lung hyperinflation, 
and inspiratory effort standardized for tidal volume in 
subjects with mild asthma. From Lougheed MD, et al. Am 
Rev Respir Dis 1993; 148: 1452-1459.
threshold load imposed by DH at the onset of 
inspiration reflects the pressure that is 
isometrically generated by the inspiratory 
muscles to overcome the inward recoil of 
the lung and chest wall (in an expiratory 
direction) to initiate inspiratory flow. The 
finding that applied continuous positive 
airway pressure (CPAP) effectively relieves 
dyspnea by counterbalancing the effects of 
inspiratory threshold loading on the 
inspiratory muscles during provoked 
bronchoconstriction, further supports the 
notion that DH and respiratory sensation are 
mechanistically linked. 
DH during Exacerbations of COPD
The mechanisms of DH are broadly similar 
during induced bronchoconstriction in asthma 
and during exacerbations in patients with 
COPD. However, patients with COPD, especially 
those with more severe airway obstruction, 
are more likely to have significant baseline 
abnormalities of both lung mechanics 
and pulmonary gas exchange. Thus, the 
consequences of sudden acute-on-chronic 
DH in such individuals may be serious and 
even life-threatening. During AECOPD, 
airway resistance is abruptly increased 
due to a combination of bronchospasm, 
mucosal edema and sputum inspissation, 
which worsens expiratory flow limitation 
and compromises effective lung emptying as 
previously described. Furthermore, patients 
tend to adopt a rapid, shallow breathing 
pattern during an exacerbation, which further 
limits the time available for lung emptying; 
thus promoting greater DH in a vicious 
cycle. AECOPD differs fundamentally from 
experimentally provoked bronchoconstriction 
in asthma in that respiratory neural drive is 
more likely to be increased to a greater extent 
in the former. This response reflects increased 
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Figure 2.  Change in end-expiratory lung volume, as 
measured by change in inspiratory capacity (IC), best 
predicted change in breathlessness (Borg scale) during 
induced bronchoconstriction in asthma (n=193 data 
points in n=21 subjects; p<0.001). From Lougheed MD, et 
al. Am Rev Respir Dis 1993; 148: 1452-1459.
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chemostimulation as a result of amplified 
ventilation-perfusion abnormalities. Moreover, 
subjective fear, anxiety or overt panic related to 
distressing dyspnea, with attendant increased 
sympathetic system activation, also powerfully 
influence breathing pattern to worsen DH. A 
summary of the deleterious effects of DH on 
respiratory and cardiac function (see below) 
during an AECOPD are presented in Figure 4.
During AECOPD, the respiratory muscles 
already burdened by increased resistive loading 
become subjected to increased elastic loading, 
decreased dynamic lung compliance and 
functional muscle weakness. Intrapulmonary 
pressures are positive at the end of expiration, 
representing intrinsic or auto- positive end-
expiratory pressure (PEEPi). PEEPi essentially 
acts as an inspiratory threshold load and may 
be as high as 6-9 cm H2O during quiet breathing 
at rest in clinically stable patients with severe 
resting lung hyperinflation. During acute-on-
chronic DH, PEEPi may rise precipitously and, 
together with the increased elastic (related 
to “high-end” mechanics) and resistive work, 
collectively increase the overall work and 
oxygen cost of breathing with development of 
fatigue or respiratory failure. During AECOPD, 
the mechanical output of the flow-limited and 
hyperinflated respiratory system may not 
increase in proportion to neural drive, resulting 
in critical neuromechanical dissociation of the 
respiratory system which may explain the 
worsening dyspnea (see below). 
Worsening expiratory 
flow limitation
Increased 
ventilatory drive 
COPD Exacerbation
Tachypnea 
(e.g. anxiety)
( EELV, IC)
Dynamic hyperinflation
Mechanical 
disadvantage
Gas 
exchange
Neuromechanical 
uncoupling
Cardiovascular 
effects
• PEEPi 
• Cdyn 
•  Elastic/threshold 
loading of inspiratory 
muscles 
• Inspiratory muscle 
dysfunction
•  VD/VT due to 
constraint of VT
•  Pulmonary 
arterial pressure 
•  RV preload 
•  LV afterload
• Dyspnea
•  PaO2 
• PaCO2 
• pH
Figure 4. Schematic of the negative consequences of dynamic hyperinflation during an acute exacerbation of COPD. 
Dynamic hyperinflation develops as a consequence of worsening expiratory flow limitation. EELV: end-expiratory lung 
volume; IC: inspiratory capacity; PaO2 : arterial oxygen tension; PaCO2 : arterial carbon dioxide tension; PEEPi: intrinsic 
positive end-expiratory pressure; Cdyn: dynamic compliance of the lung; VD/VT: physiological dead space; VT: tidal 
volume; RV: right ventricular; LV: left ventricular. From O’Donnell DE, Parker CM. Thorax 2006; 61: 354-361.
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Recovery from AECOPD
A study from our laboratory evaluated the 
changes occurring in various physiological 
parameters during recovery from a moderate 
AECOPD. Twenty patients with moderate 
to very severe COPD were studied within 
72 hours of an AECOPD, and underwent full 
pulmonary function testing and symptom 
assessment using the dyspnea domain of the 
Chronic Respiratory Disease Questionnaire 
(CRQ-dyspnea). At the time of study entry 
(day 0), subjects were “very” short of breath 
(mean CRQ-dyspnea score = 2.4 units), and 
showed significant airflow obstruction (FEV1 
= 41% predicted) and hyperinflation (FRC = 
164% predicted). At the end of the follow-up 
period (2 months), most patients reported 
that their dyspnea had returned to their 
pre-exacerbation level: mean CRQ-dyspnea 
score improved by 1.6 units. Indicators of 
hyperinflation and gas trapping also improved 
in parallel (Figure 5): at the final follow-
up visit, FRC and RV had decreased by an 
average of 200 and 310 mL, respectively, and 
IC had increased by 300 mL. It is noteworthy 
that lung hyperinflation above baseline 
values persisted for approximately 2 weeks, 
on average, after initial presentation despite 
maximal medical therapy. 
 
Dynamic Hyperinflation during Exercise in 
COPD
Dynamic increase in EELV is inevitable during 
exercise in patients with significant expiratory 
flow limitation in the setting of high ventilatory 
demand. Respiratory neural drive (and 
ventilatory demand) is often greatly increased 
in COPD because of the effect of increased 
wasted ventilation (high ventilation/perfusion 
ratios) and, in some instances, significant 
arterial hypoxemia and metabolic acidosis 
secondary to skeletal muscle deconditioning. 
In early exercise, mean inspiratory flow rates 
and tidal volume increase substantially, but 
expiratory time is often too short to allow 
complete gas emptying, resulting in DH. 
Increases in EELV above resting values by 0.3-
0.6 L, on average, have been shown to occur 
in as many as 85% of patients with moderate-
to-severe COPD during cycle exercise. In 
patients with advanced COPD, patterns of DH 
vary widely but the magnitude of increase 
in EELV is inversely related to the resting IC. 
Thus, in patients with a low resting IC due 
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Figure 5. Changes in lung volumes 
and mean Chronic Respiratory Disease 
Questionnaire (CRQ) dyspnea scores 
are shown during recovery from 
acute exacerbations of COPD (AECOPD) 
in patients that reached symptom-
recovery during the ~2-month study 
period. SVC: slow vital capacity; IC: 
inspiratory capacity; FRC: functional 
residual capacity; RV: residual volume. 
Values are means ± SEM; *p<0.01, 
†p<0.05 significant difference from 
day 0. Modified from Parker CM, et al. 
Eur Respir J 2005; 26” 420-428.
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to severe resting hyperinflation, VT quickly 
expands during exercise (even in the absence 
of DH) to reach a critical minimal IRV – a true 
mechanical limit where further increases in 
ventilation soon become impossible. Dynamic 
hyperinflation during exercise is even present in 
many individuals with mild airway obstruction 
(and dominant peripheral airways disease) 
as a result of the combined effects of higher 
ventilatory inefficiency and dynamic expiratory 
flow limitation. Dynamic hyperinflation occurs 
in the face of vigorous expiratory muscle effort 
and likely occurs “passively”, rather than by 
active inspiratory muscle braking throughout 
the respiratory cycle. 
Increasing lung hyperinflation as COPD 
progresses is associated with increasing 
reduction of the resting IC (Figure 6). During 
exercise when VT reaches approximately 70% 
of the prevailing IC (or end-inspiratory lung 
volume reaches approximately 90% of the 
TLC at a minimal IRV), there is an inflection or 
plateau in the VT /V’E relation (Figure 6). This 
critical point represents a mechanical limit 
where further sustainable increases in V’E 
are impossible in the face of near maximal 
respiratory neural drive. The inability to 
further expand VT is associated with tachypnea 
– the only remaining strategy available in 
response to the increasing ventilatory drive. 
As explained above, increased breathing 
frequency results in further elastic loading due 
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Figure 6. Tidal volume (VT ), breathing frequency (Fb ), dynamic inspiratory capacity (IC) and inspiratory reserve volume 
(IRV) are shown plotted against minute ventilation (V’E ) during high-intensity constant work rate exercise for each forced 
expiratory volume in 1 second (FEV1, expressed as % predicted) quartile (Q). The upper through to the lower quartiles (Q1-
Q4) represent the mildest to the most severe COPD groups, respectively. Note the clear inflection (plateau) in the VT /V’E 
relationship which coincides with an inflection in the IRV as end-inspiratory lung volume approaches total lung capacity 
(TLC). After this point, further increases in V’E  are accomplished by accelerating Fb . Data plotted are mean values at rest, 
isotime (2-min, 4-min), the VT /V’E inflection point and peak exercise. From O’Donnell DE, et al. Chest 2012; 141: 753-762.
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to DH and the increased velocity of shortening 
of the inspiratory muscles, with associated 
functional weakness and decreased dynamic 
lung compliance. In this setting, RND (indirectly 
assessed by diaphragm electromyography 
[EMGdi]) reaches >70% of the maximal possible 
value and tidal esophageal pressure swings 
increase to about 50-60 % of the maximal value. 
The work and O2 cost of breathing required 
to achieve a given increase in V’E steadily 
increases to a high percentage of the total 
oxygen uptake. These collective derangements 
can predispose to critical inspiratory muscle 
functional weakness, fatigue or even overt 
respiratory failure with carbon dioxide (CO2) 
retention. 
Cardio-circulatory impairment
Dynamic hyperinflation adversely affects 
dynamic cardiac function, by contributing 
to pulmonary hypertension by reducing 
right ventricular pre-load (reduced venous 
return) and, in some cases, by increasing 
left ventricular afterload. In the absence of 
cardiac disease, cardiac output has been 
found to increase normally as a function of 
oxygen uptake during submaximal exercise 
in COPD, although stroke volume is generally 
smaller and heart rate correspondingly 
higher than in health. Of note, peak cardiac 
output reaches a lower maximal value during 
exercise in COPD, which may be due, in part, 
to abnormal ventilatory mechanics. Finally, it 
has recently been postulated that competition 
between the overworked ventilatory muscles 
and the active peripheral muscles for a 
reduced cardiac output may compromise 
blood flow and oxygen delivery to the latter, 
with negative consequences for exercise 
performance. However, the impact of dynamic 
lung hyperinflation on cardiac output and 
ventilatory/locomotor muscle competition 
during exercise needs further study.
Respiratory mechanical abnormalities and 
dyspnea
Dyspnea is a common symptom in patients 
with COPD across the continuum of the disease 
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Figure 7. Relationships between exertional dyspnea intensity and ventilation and the ratio of tidal volume to inspiratory 
capacity (VT /IC) are shown during symptom-limited cycle exercise in COPD. There is a progressive increase in the 
dyspnea/ventilation curve with worsening disease. After the VT /IC ratio plateaus (corresponding to the VT inflection 
point), dyspnea rises steeply to intolerable levels. Quartiles (Q) of COPD severity are based on forced expiratory volume 
in 1 second (FEV1 ) expressed as percent predicted (ranges: Q1 = 54.5–85.1; Q2 = 43.8–54.1; Q3 = 34.9–43.6; Q4 = 16.5–
34.9). Data plotted are mean values at steady-state rest, isotime (i.e., 2 min, 4 min), the VT /V’E inflection point and peak 
exercise. From O’Donnell DE, et al. Chest 2012; 141: 753-762.
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and is often the proximate cause of exercise 
limitation. The increase in dyspnea intensity 
at any given ventilation as COPD severity 
increases (compared to health), reflects the 
progressively increasing intrinsic mechanical 
loading of the respiratory muscles (Figure 7). 
The rise in dyspnea intensity ratings during 
exercise correlates strongly with indirect 
indices of increased respiratory neural drive 
(central motor command output), such as tidal 
electromyographic activation of the diaphragm 
relative to maximum, tidal esophageal 
pressure swings relative to maximum and 
ventilation relative to peak ventilatory capacity. 
It is speculated that the amplitude of central 
neural drive (originating from motor cortical 
and medullary centers in the brain) to the 
respiratory muscles is sensed via neural inter-
connections (i.e., central corollary discharge) 
between cortical motor and medullary centers 
in the brain and the somato-sensory cortex.
Dyspnea intensity is more closely correlated 
with the reduction in IRV during exercise 
than the change in EELV (i.e., DH), per se. 
The VT/V’E inflection corresponds with the 
IRV/V’E inflection during exercise and marks 
the point where dyspnea intensity sharply 
increases towards end-exercise; it also marks 
the point where the dominant descriptor of 
dyspnea selected by patients’ changes from 
increased effort to unsatisfied inspiration. 
The VT inflection represents the onset of 
a widening disparity between increasing 
central neural drive and the mechanical/
muscular response of the respiratory system. 
In advanced COPD, the ratio of respired effort 
(and presumably neural drive) to VT increases 
steeply from rest to peak exercise, reflecting 
progressive neuromechanical dissociation of 
the respiratory system. As in asthma during 
imposed acute DH, exertional dyspnea in COPD 
also closely correlates with indices of effort-
volume displacement dissociation (e.g., the ratio 
of Pes/PImax to VT /IC). The consequence is that 
effective relief of dyspnea in COPD following 
bronchodilators (deflators) or lung volume 
reduction surgery are explained by partial 
restoration of effort-displacement ratios and 
reduced neuromechanical dissociation. 
Summary
Dynamic hyperinflation occurs when 
expiratory flow limitation is acutely amplified 
during episodes of bronchoconstriction. It 
follows that DH is fundamental to the clinical 
expression of exacerbations of asthma and 
COPD. Dynamic hyperinflation in these clinical 
situations is often further compounded by the 
effects of concomitant increases in respiratory 
neural drive and ventilation. Similarly, during 
exercise in COPD the combined factors of 
worsening EFL, breathing pattern alterations 
and increasing respiratory neural drive dictate 
the pattern and extent of DH. The clinical 
consequences of DH in a given patient will 
depend on the baseline mechanical and gas 
exchange abnormalities that are present. In all 
of the above clinical situations, further reduction 
of the already diminished IC due to DH critically 
restricts VT expansion, mechanically loads and 
weakens the inspiratory muscles, forces early 
respiratory mechanical limitation to exercise 
and compromises integrated respiratory and 
cardio-circulatory function. These critical 
mechanical and cardiac abnormalities can 
lead to profound functional respiratory muscle 
weakness, fatigue and even overt respiratory 
failure. Additionally, the growing disparity 
between increased respiratory neural drive 
and the blunted respiratory muscular/
mechanical response after the VT inflection 
is mechanistically linked to perceptions of 
respiratory discomfort and distress (dyspnea).
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Key Points
1.
The correct diagnosis of Lung Hyperinflation at rest 
and during exercise is highly dependent on the validity, 
reliability, and underlying assumptions of the tools 
used to measure lung volumes.
2.
Increases in functional residual capacity, residual lung 
volume, and total lung capacity relative to predicted 
values provide evidence of resting Lung Hyperinflation.
3.
Plethysmography, N2 washout, and multiple breath 
inert gas dilution are three commonly used methods 
to measure functional residual capacity.
4.
N2 washout and the inert gas dilution methods 
underestimate functional residual capacity and 
Hyperinflation, since they do not measure trapped gas 
in patients with obstructive lung diseases.
5.
The most common method of measuring 
Hyperinflation during exercise is to have patients 
perform inspiratory capacity maneuvers throughout 
exercise.
6.
Inspiratory capacity maneuvers are reliable even in 
large multicenter clinical trials.
7.
A comprehensive evaluation of ventilatory limitations 
during exercise can be achieved through flow-volume 
loop analysis and operating lung volume plots. 
These approaches are dependent on the accurate 
measurement of inspiratory capacity throughout 
exercise.
Α4.
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INTRODUCTION
The accurate diagnosis of Lung Hyperinflation 
(LH) at rest and during exercise is critically 
dependent on the measurement techniques 
used to assess lung volumes. It is important 
for the clinician to have a comprehensive 
understanding of the various lung volume 
components and their physiological 
determinants in order to appropriately 
classify a patient as having static or dynamic 
Hyperinflation. Recognizing the limitations of 
various measurement techniques is equally 
important for the correct interpretation of LH. 
Accordingly, the purpose of this chapter is to 
review the lung volumes and capacities used 
to assess Hyperinflation and to provide a 
general overview of the various methods used 
to quantify LH at rest and particularly during 
exercise.
There is no universal definition of LH, but it 
is generally accepted that Hyperinflation is 
characterized by an increase in total lung 
capacity (TLC), residual volume (RV), and 
functional residual capacity (FRC) relative to 
predicted normal values and/or an increase 
in the ratio between these variables (e.g., RV/
TLC, FRC/TLC). A firm cut-off has not been 
established, but values exceeding 120-130% 
predicted usually indicate clinically significant 
Hyperinflation.
Lung Volumes and Capacities
Figure 1 provides a schematic representation 
of lung volumes and capacities using a 
volume-time spirogram. There are four 
volumes including the tidal volume (VT), 
inspiratory reserve volume (IRV), expiratory 
reserve volume (ERV), and residual volume 
(RV). Capacities are derived from two or 
more of these lung volumes and include the 
functional residual capacity (FRC), inspiratory 
capacity (IC), vital capacity (VC), and total lung 
capacity (TLC).
The volume of air on inspiration and expiration 
during normal quiet breathing is the VT. The 
maximum volume of air that can be inspired 
from the end of a tidal inspiration is the IRV. 
The maximum volume of air that can be 
expired from the end of tidal expiration is the 
Figure 1. Volume time plot showing different lung 
volumes and capacities. VT : tidal volume; IRV: inspiratory 
reserve volume; ERV: expiratory reserve volume; RV: 
residual volume; FRC: functional residual capacity; IC: 
inspiratory capacity; VC: vital capacity; TLC: total lung 
capacity.
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ERV. The volume of air remaining in the lungs 
after maximum expiration is the RV. Functional 
residual capacity refers to the volume of 
air remaining in the lungs at the end of tidal 
expiration (i.e., the sum of ERV and RV) and is 
often referred to as the end expiratory lung 
volume (EELV). The maximum volume of air 
that can be inspired from FRC is the IC whereas 
the volume of air expired from full inspiration 
to full expiration is the VC. Finally, TLC is the 
volume of air in the lungs when the lungs 
are maximally filled (i.e., sum of all volume 
components). Many of these volumes and 
capacities can be obtained from a spirometer, 
but the most important indices of LH (i.e., 
TLC, FRC, and RV) require more sophisticated 
measurement techniques, as described below.
Determinants of FRC, TLC, and RV
Specific determinants of absolute lung 
volumes have been detailed previously (see 
recommended reading). Briefly, static FRC 
is determined by the balance between the 
inward elastic recoil forces of the lungs and the 
outward elastic recoil forces of the chest wall. 
Total lung capacity is determined by the balance 
between the inward elastic recoil forces of the 
respiratory system (primarily the lungs) and 
the outward forces of the inspiratory muscles 
generated during maximal inspiration. 
Residual volume is determined statically by 
the balance between the elastic recoil forces of 
the respiratory system (primarily chest wall) 
and expiratory muscle forces, at least in young 
healthy adults. In older adults and particularly 
in those with obstructive lung disease, RV 
is determined by “dynamic” mechanisms as 
described in other sections of this book.
Measurement of FRC
Ultimately, the goal when quantifying 
Hyperinflation is to measure FRC, because TLC 
and RV can simply be derived from FRC and 
the two components of VC (i.e., IC and ERV). The 
methods used to measure FRC include body 
plethysmography (FRCpleth), nitrogen washout 
(FRCN2)and inert (helium) gas dilution (FRCHe); 
all of which have inherent limitations that can 
influence the interpretation and diagnosis 
of LH. The decision to use a specific method 
depends on a number of factors, including 
cost, availability of equipment and the patient 
population being studied. As such, it is 
important to clearly specify which method is 
used when reporting FRC values (e.g., FRCpleth, 
FRCN2, FRCHe). This chapter will provide a brief 
overview of the theory surrounding each 
measurement technique and the potential 
drawbacks that should be considered 
when interpreting LH. Lung volumes and 
Hyperinflation can also be assessed using 
conventional radiographs, computed 
tomography (CT), and magnetic resonance 
imaging (MRI). However, due to the lack of 
standardization and the limited published 
data, the American Thoracic Society/European 
Respiratory Society (ATS/ERS) does not 
make specific recommendations on the most 
appropriate imaging modality for measuring 
lung volumes. As such, imaging methods will 
not be discussed further in this chapter.
Body Plethysmography
Body plethysmography measures the volume 
of gas within the thorax and is the gold 
standard method for measuring FRC. This 
method requires the patient to sit inside of a 
sealed, rigid-walled body plethysmograph, 
or “body box”. The patient breathes normally 
for several breaths and then pants against a 
closed shutter. The change in pressure in the 
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lungs is measured at the mouth via a pressure 
transducer and is plotted against the change 
in thoracic volume as estimated by changes 
in body box volume. How the body box volume 
is measured depends on the type of body box 
used (e.g., volume-displacement box, variable 
pressure box and flow box). Functional residual 
capacity is then determined using Boyle’s 
law, which states that the volume of gas at a 
constant temperature is inversely related to 
the pressure applied to it. Plethysmography 
or thoracic gas volume (TGV) is calculated as 
follows:
TGV = -(ΔV/ΔP) x Pb
where ΔV/ΔP is the slope of body box volume 
and alveolar pressure line during panting 
and Pb is barometric pressure in cmH2O (less 
water vapor).
Body plethysmography includes both ventilated 
and non-ventilated lung regions resulting 
in higher FRC values compared with other 
methods; particularly in those with obstructive 
lung diseases. Overestimation of FRC with 
body plethysmography can be minimized by 
using a lower panting frequency (≤ 1 Hz) and 
minimizing the compliance of the extrathoracic 
airway by having patients support their cheeks 
during panting. Despite these strategies, 
plethysmography may still overestimate 
FRC in those with severe airflow limitation. 
Nevertheless, body plethysmography remains 
the method of choice when assessing LH, 
particularly in those with obstructive lung 
conditions. Other disadvantages of this 
technique relative to other methods are that it is 
expensive and it requires patient cooperation.
Nitrogen (N2 ) Washout
The multiple breath open-circuit N2 washout 
method is based on the removal (i.e., washing 
out) of N2 gas from the lungs by having the 
patient breathe 100% O2 for several minutes.
The patient is asked to breathe normally at rest 
on the mouthpiece for approximately 30-60 
seconds to become familiar with the breathing 
apparatus and to ensure stability of FRC. The 
patient is then switched from breathing room 
air to 100% O2. The concentration of N2 is then 
monitored during the washout phase. The test 
is terminated when the concentration of N2 
decreases below 1.5% for three consecutive 
breaths or if a leak is detected. FRCN2 is 
calculated as follows:
FRC N2
 = (volume N2 washed out) – (N2 tissue excretion)
              initial – final lung N2 concentration
where N2 tissue excretion is estimated using a 
standard prediction equation.
FRC measured using N2 washout generally 
agrees well with plethysmography and other 
methods (e.g., gas dilution and imaging), 
at least in healthy adults. However, this 
technique is limited for the assessment of LH 
in patients with respiratory diseases because 
it only measures well ventilated regions of 
the lungs. This methodological limitation has 
been shown to cause an underestimation of 
FRC compared with plethysmography. Thus, 
caution is warranted when making a diagnosis 
of LH using this method, particularly in patients 
with respiratory conditions that are typically 
associated with gas trapping.
Multiple Breath Inert Gas Dilution
The inert gas dilution method measures FRC 
by diluting a known volume and concentration 
of an inert gas (usually helium) in the lungs by 
breathing the gas mixture (contains helium, N2 
and O2) in a closed system. The patient begins 
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the test by breathing room air for approximately 
1 minute while wearing nose clips. This period 
of resting breathing familiarizes the patient 
with the breathing apparatus and ensures 
stability of FRC. The patient is then switched to 
breathing the helium gas mixture at FRC and 
the patient continues to breathe until the helium 
equilibrates in the lungs. Equilibration occurs 
when the helium concentration is <0.02% for 
30 seconds. The test typically takes less than 
10 minutes to complete in most patients. Inert 
gas dilution is calculated as follows:
FRCHe = Vapp (C1 – C2) / C2
where Vapp is the volume of the breathing 
apparatus, C1 is the initial concentration of 
helium, and C2 is the concentration of helium 
after equilibration.
The inert gas dilution method is a widely 
used, simple, reproducible, and relatively 
inexpensive method for determining FRC. 
However, this method only measures the gas 
volume in the lungs in communication with the 
mouth; like the N2 washout technique, the inert 
gas dilution method does not measure trapped 
gas which will ultimately underestimate FRC in 
patients with obstructive lung diseases. Thus, 
diagnosis of LH based on FRCHe must also be 
made with caution.
Measurement of RV and TLC
There are two recommended methods for 
determining TLC and RV from FRC. The 
preferred approach is to measure ERV and slow 
inspiratory vital capacity (IVC) immediately 
after measuring FRC. The patient should 
remain on the mouthpiece for all maneuvers 
since they are performed in a “linked” fashion. 
Values for RV and TLC are determined as 
follows:
RV = FRCmean – ERVmean
TLC = RV + IVClargest
The alternative approach involves the 
measurement of IC immediately following 
the measurement of FRC. The VC can be 
performed separately using either a slow IVC 
or slow expiratory VC. The patient is allowed to 
come off the mouthpiece between linked FRC 
and IC measurements and between separate 
VC maneuvers. This approach may be required 
for the severely dyspneic patient that is not 
capable of performing the FRC measurement 
with a linked ERV maneuver. Values for RV and 
TLC are determined as follows:
RV = TLCmean – VClargest
TLC = FRCmean + IC
Measuring Hyperinflation during Exercise
Dynamic LH during exercise refers to the 
increase in EELV relative to resting values. 
The physiological, sensory, and clinical 
consequences of Hyperinflation have been 
described in detail in other chapters of this 
book. EELV can be measured during exercise 
using gas dilution techniques, optoelectronic 
plethysmography or respiratory inductance 
plethysmography. However, these techniques 
can be technically challenging and are not 
routinely used for clinical diagnostic purposes. 
The most common and widely accepted 
method of measuring EELV during exercise is 
to have patients perform serial IC maneuvers 
throughout a cardiopulmonary exercise test. An 
example of an IC maneuver is shown in Figure 
2. This is a relatively simple measurement to 
perform and most commercially available 
metabolic systems have the required software 
to obtain ICs during exercise. Despite the 
simplicity of this measurement relative to other 
methods, there are several important factors 
Α4.
Measurement of Hyperinflation during Rest and Exercise
P H Y S I O L O G Y
PA G E  5 0
HYPERINFLATION OF THE LUNG AND ITS MANAGEMENT
and assumptions that must be considered 
in order to accurately measure EELV during 
exercise. This chapter will describe the 
important methodological considerations of 
this technique and will describe the wealth of 
data that can be obtained from IC maneuvers.
Assumptions
The EELV during exercise is calculated as the 
difference between TLC and IC. The accuracy 
of this approach critically depends on TLC 
remaining constant throughout exercise. If one 
assumes TLC does not change as supported 
by previous studies in health and chronic 
obstructive pulmonary disease (COPD), then 
it is reasonable to conclude that changes in 
IC reflect changes in EELV. Equally important 
is that subjects reach TLC when performing 
the IC maneuver. This can be difficult to 
verify, but standardized instructions and 
verbal encouragement as described later can 
mitigate concerns surrounding the attainment 
of TLC during the maneuver.
The ability to accurately track changes in 
EELV during exercise using the IC maneuver 
clearly depends on the reproducibility of this 
method. Indeed, several studies confirm that 
IC maneuvers are reproducible, at least in 
patients with COPD during cycle exercise. 
Even in the setting of large multicenter clinical 
trials, the IC appears to be highly reproducible 
at rest and throughout exercise. However, 
limited data exists on the reproducibility of the 
IC in different clinical populations and using 
different exercise modalities (e.g., treadmill).
Performing IC maneuvers
The presence of dynamic Hyperinflation (DH) is 
based on the changes in EELV (or IC) relative to 
resting values. Thus, the first step is to establish 
a reproducible baseline measurement of IC. 
During baseline IC maneuvers, the patient 
should assume the same position that they will 
use during the cardiopulmonary exercise test. 
Patients should perform at least 3 minutes of 
resting tidal breathing to become accustomed 
to the breathing apparatus and to minimize 
their anxiety due to the anticipation of exercise. 
Generally, patients should perform a minimum 
of 3 acceptable IC maneuvers during the resting 
Figure 2. Example of a correctly performed 
inspiratory capacity maneuver. The blue dashed 
line represents the correct way of anchoring the 
IC to the appropriate EELV.EILV: end-inspiratory 
lung volume; EELV: end-expiratory lung volume; 
VT : tidal volume; IC: inspiratory capacity.
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period. Limited data is available on the criteria 
for reproducibility of ICs, but it is suggested 
for measurements to agree within 5% or 60 
millilitres of the mean, whichever is greater. 
Although this is a stringent cut-off, it provides 
some general guidelines on reproducibility. 
The mean of the two most reproducible IC 
measurements can be used as the baseline 
value. Once the resting period is completed, 
an IC maneuver should be performed near 
the end of each exercise stage. If using an 
incremental exercise test, it is recommended 
to use stepwise increases in work rate rather 
than ramp increases. The step increases in 
work rate (e.g., 20W every 2 minutes) will 
allow for more stable ventilations compared 
to a ramp protocol where subtle incremental 
increases in work rate and ventilation can 
influence the anchoring of IC measurements to 
the appropriate EELV.
Detailed instructions before and during the 
maneuver have been described previously. 
Briefly, the subject should be encouraged to 
perform a maximal inspiration from a stable 
EELV to TLC. The technician should provide a 
prompt for the maneuver (e.g., “at the end of 
a normal breath out, take a deep breath all 
the way in, until you are completely full”). The 
maneuver should be performed quickly and 
forcefully to ensure that the subject is fully 
inflated. Providing a demonstration to the 
patient can also be very helpful. Enthusiastic 
verbal encouragement during the IC maneuver 
is strongly recommended (e.g., “in, in, in,”).
Some subjects have a difficult time initiating 
the IC maneuver at a stable EELV or they have 
marked alterations in their breathing pattern 
for several breaths prior to the maneuver. This 
can usually be identified during the rest period 
or early during exercise. The technician should 
attempt to re-explain the maneuver if the 
patient continues to have difficulties. Patients 
who have significant alterations in their 
breathing pattern for several breaths after 
the prompt is given should be encouraged to 
perform the maneuver as soon as possible. 
In some cases, the instructions may need to 
be modified if patients are taking too long to 
perform the maneuver (e.g., “at the end of the 
next breath out, take a deep breath all the way 
in until you are completely full”).
Data Analysis
It is important to emphasize that the 
accuracy of the IC is dependent on measuring 
both inspiratory and expiratory volumes 
continuously throughout the test. This 
allows the technician to anchor the IC to the 
appropriate EELV (Figure 2). If inspiratory 
volume alone is measured, it can lead to 
incorrect values for the IC, because it will not 
allow the investigator to account for the EELV 
preceding the maneuver. For example, subjects 
may prematurely initiate the IC maneuver 
before reaching the appropriate EELV. If the 
technician only measures the volume of the IC 
breath without accounting for the EELV of the 
previous breaths, then they will significantly 
underestimate the IC. Similarly, if the subject 
expires beyond the baseline EELV, then the IC 
would be overestimated. The blue dashed lines 
in Figure 2 demonstrate the correct way of 
anchoring the IC to the appropriate EELV. Some 
commercially available systems allow the 
user to drag a horizontal line to the appropriate 
EELV. It is important for the breaths used to 
determine EELV to be corrected for signal drift. 
Some degree of drift occurs in all flow sensing 
devices and most commercially available 
systems account for this.
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Interpretation
The absolute increase in EELV (or decrease 
in IC) that classifies a patient as a dynamic 
hyperinflator has not been firmly established. 
There is also no grading system available 
to classify the severity of DH. Some have 
defined DH as a decrease in IC from rest 
> 150ml or 4.5% predicted during exercise. 
This is based on the work of O’Donnell et 
al. who found that that the 95% confidence 
interval for the resting IC measurement 
was ± 0.14 litres or ± 4.5% predicted, indicating 
that reproducibility criteria of within 150ml 
is appropriate for testing IC; at least in COPD 
patients. The 95% CI for peak exercise IC was 
similar. Others have defined DH as a decrease 
by more than 1.96 standard deviations below 
the baseline IC measurements, a decrease 
in IC by 10% from baseline or 10% below 
predicted, or as a slope higher than zero from 
the linear regression of EELV as a function of 
time. Clearly there is no accepted operational 
definition of DH and future research is needed 
before definitive recommendations can be 
made.
The regulation of EELV appears to be highly 
variable in patients with COPD. For example, 
different patterns of DH have been identified 
such as “early hyperinflators” and “late 
hyperinflators”. It is also becoming increasingly 
recognized that a subset of COPD patients 
(~15%) do not dynamically hyperinflate during 
exercise. Non-hyperinflators have been termed 
“euvolumics”. Figure 3 shows three individual 
patients with COPD with differing patterns of 
EELV regulation during constant load cycle 
exercise. Patient A immediately increases 
EELV during exercise (“early hyperinflator”) 
and at peak exercise the EELV was 1.09l above 
resting values. In contrast, patient B does 
not increase EELV until later during exercise 
(“late hyperinflator”). The magnitude of DH is 
significantly smaller in patient B compared 
to patient A (blue shaded region). At peak 
exercise, EELV was 0.34l above resting values 
in patient B. Finally, patient C does not increase 
EELV during exercise (i.e., non-hyperinflator).
This patient’s EELV actually decreases relative 
to resting values throughout exercise.
Additional Information Gained from Inspiratory 
Capacity Maneuvers
Operating lung volume plots as shown in Figure 
3 also provide visualization and quantification 
of important lung volumes such as the end-
inspiratory lung volume (EILV) and IRV. Simply 
assessing the change in EELV relative to rest 
without considering these other lung volumes 
can be misleading when diagnosing ventilatory 
limitations during exercise. For example, 
patient A demonstrates a substantial amount 
of DH during exercise compared to patient B 
and C (Figure 3). However, patient B and C have 
much higher EILV values relative to TLC and 
thus a smaller IRV. Some suggest that perhaps 
the EILV is as important, if not more important, 
than EELV during exercise. Patient C does not 
dynamically hyperinflate during exercise, but 
still has constraints on tidal volume expansion 
and breathes close to TLC where the elastic 
work of breathing is high. Patients that do 
not dynamically hyperinflate but still breathe 
close to TLC often have a smaller resting IC 
and high levels of static Hyperinflation. Thus, 
it is important that ventilatory limitations be 
assessed by examining all operating lung 
volumes during exercise in conjunction with 
resting measures of LH. 
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Figure 3. Examples of different operating 
lung volume plots in three patients with 
chronic obstructive pulmonary disease. 
The green region represents the IRV, 
the red region represents VT and the 
blue region represents the increase in 
EELV relative to resting values (i.e.,: DH).
TLC: total lung capacity; IRV: inspiratory 
reserve volume; VT : tidal volume; EILV: 
end-inspiratory lung volume; EELV: end-
expiratory lung volume; EELVrest : resting 
end-expiratory lung volume.
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Figure 4. Example of tidal flow volume loops 
at rest (green line) and peak exercise (red line) 
superimposed within a MFVL (blue line) in a patient 
with mild chronic obstructive pulmonary disease. 
The magnitude of expiratory flow limitation can 
be calculated as the volume that overlaps the 
MFVL divided by the VT . Dynamic hyperinflation 
is characterized by a leftward shift (i.e.: increase) 
in end-expiratory lung volume compared to rest.
MFVL: maximum flow volume loop; EFL: expiratory 
flow limitation; VFL : volume of tidal breath that is 
flow limited; VT : tidal volume; EELV: end-expiratory 
lung volume; EILV: end-inspiratory lung volume; 
IC: inspiratory capacity; TLC: total lung capacity; 
IRV: inspiratory reserve volume; ERV: expiratory 
reserve volume. Modified and reproduced with 
permission from Guenette et al. (Pulm Med: 2013).
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The IC maneuver not only allows the clinician 
to measure DH during exercise, but it also 
provides considerable insight into other 
indices of ventilatory limitation. For example, 
Figure 4 shows resting and peak exercise tidal 
flow-volume loops plotted within a maximal 
flow-volume loop in a patient with mild COPD. 
The IC maneuver permits the determination of 
EELV which allows for the correct placement 
of the tidal breaths along the volume axis of 
the maximal flow-volume loop. These plots 
allow the clinician to easily view factors other 
than just DH during exercise (e.g., inspiratory 
and expiratory flow reserves, expiratory 
flow limitation, IRV, etc.). Most commercially 
available metabolic systems allow users to 
construct flow-volume loop plots. However, 
caution must be exercised when interpreting 
expiratory flow limitation using these plots 
if thoracic gas compression and exercise 
induced bronchodilation are not accounted for 
in the maximum flow-volume loop.
CONCLUSION
Lung Hyperinflation at rest and during exercise 
is associated with a number of adverse clinical 
consequences as outlined in this book. The 
correct diagnosis of both static and dynamic 
Hyperinflation is clearly dependent on the 
validity, reliability, and underlying assumptions 
of the various methods used to measure lung 
volumes. Resting Hyperinflation depends on 
the accurate measurement of FRC, which is 
used to calculate RV and TLC. Increases in these 
parameters >120-130% predicted is usually 
indicative of resting LH. Plethysmography, 
N2 washout, and multiple breath inert gas 
dilution are three commonly used methods to 
measure FRC. In contrast to plethysmography, 
N2 washout and the inert gas dilution methods 
do not measure trapped gas in patients with 
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obstructive lung diseases. Thus, FRC values 
will be underestimated using these methods 
compared to the gold standard method of 
plethysmography. The most commonly used 
method of assessing Hyperinflation during 
exercise is to have subjects perform serial 
IC maneuvers in order to track changes in 
EELV relative to resting values. In addition 
to measuring dynamic Hyperinflation, IC 
maneuvers can be used to examine other 
important lung volumes during exercise such 
as EILV and IRV. Additional valuable insight can 
be gained when combining this information 
with detailed flow-volume loop analysis.
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Key Points
1.
Clinical signs of lung hyperinflation are high 
position of the shoulders and pursed lip 
breathing.
2.
Tympanic and diminished breath sound, 
abnormal movements of the thoracic wall, 
Hoover’s sign and pulsus paradoxus may also 
be found during clinical examination.
3.
Dyspnea is the cardinal symptom of lung 
hyperinflation, primarily during  
exertion-limiting exercise.
4.
Dyspnea due to lung hyperinflation leads 
to reduced physical activity, deconditioning, 
anxiety and depression; thus significantly 
affecting quality of life.
5.
Lung hyperinflation has detrimental effects on 
the cardiovascular system.
6.
Lung hyperinflation is related to increased 
mortality and morbidity.             
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INTRODUCTION
In previous chapters, the importance of lung 
hyperinflation (LH) in the mechanics of breath-
ing was analyzed. It is shown that LH increas-
es the work of breathing, and in turn causes 
fatigue of the respiratory muscles and respi-
ratory failure. Lung hyperinflation may be ob-
served at rest (static hyperinflation developed 
over the years), but it may be exaggerated 
transiently during hyperventilatory conditions, 
i.e., exercise and exacerbation, that we define 
as dynamic hyperinflation (DH). 
In this chapter we are going to discuss the 
clinical signs and symptoms that are attributed 
to LH, the effect of LH on quality of life, the 
effects of LH on morbidity and mortality and 
the clinical effects of LH on the cardiovascular 
system.
Clinical Signs of LH
Clinical examination can reveal the following 
signs of LH:
• High position of the shoulders and barrel 
chest (consequences of LH on the rib cage);
• Pursed lip breathing, which is a 
compensatory mechanism to fight the 
intrinsic positive end-expiratory pressure 
(PEEP) produced by LH;
• Forward leading posture due to severe LH;
• Tympanic sounds and diminished motion 
of the diaphragm on percussion and 
diminished breath sounds on auscultation;
• Abnormal movements of the chest wall, 
such as asynchronous motions (time lag 
between the motion of the ribcage and 
abdominal compartments), paradoxical 
motion (one compartment moving in the 
opposite direction of the other), respiratory 
alternates (increase in the breath-to-breath 
variability of the relative contribution of the 
rib cage and abdomen). All the above signs 
could indicate respiratory muscle fatigue;
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Figure 1.  Volumes of the rib cage and abdominal compartments and of total chest wall in (A) early hyperinflators (EH) 
and (B) late hyperinflators (LH) expressed in absolute values during quiet breathing (QB), exercise, and recovery (R1 
and R2). Open circles indicate end of inspiration; closed circles indicate end of expiration; triangles indicate chest wall 
volumes at total lung capacity. †Significant differences in time points between groups.
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• Hoover’s sign, showing distortions of the 
ventilator pump (see chapter B2);
• Pulsus paradoxus, which is a sign of the 
drop of systolic blood pressure of more than 
10 mm of Mercury when measured at high 
lung volumes (LH in asthma).
Clinical Symptoms of LH (Dyspnea)
The major clinical symptom related to 
LH is dyspnea. In chapters A2-A3, the 
relationship of LH and the symptom of 
dyspnea was discussed in detail from 
the pathophysiological point of view. This 
cardinal symptom is more prominent during 
exertion and has as a consequence exercise 
intolerance and limitation.
Hyperinflation and Exertional Dyspnea/Exercise 
Intolerance
Exertional dyspnea is one of the main factors 
limiting physical activity in patients with 
chronic obstructive pulmonary disease 
(COPD). The mechanism for the ventilatory 
limitation of exercise in COPD patients is 
related to expiratory flow limitation and 
dynamic hyperinflation (DH). Initially, DH acts 
as a compensatory mechanism in an attempt 
to increase expiratory flows to accomplish 
the increase in tidal volume needed for 
hyperventilation during exercise. Dynamic 
hyperinflation is a better exercise strategy in 
COPD than expiratory muscle recruitment, but 
the benefit it confers is small. 
It is interesting to mention that not all COPD 
patients who adopt the strategy to hyperinflate 
during exercise follow the same time 
course of DH during exercise. In a study with 
measurements of operational lung volumes via 
optoelectronic plethysmography, it was shown 
that there are two distinct patterns of change in 
the chest wall volume response to exercise in 
patients with severe COPD (Figure 1); namely 
early hyperinflators and late hyperinflators. 
These two groups did not differ in terms of 
resting lung volumes or exercise tolerance 
measures. In the early hyperinflator patients, 
the end-expiratory lung volume (EELV) 
increases from the beginning of exercise and 
keeps increasing progressively throughout 
exercise; while in the late hyperinflator 
group, the EELV remains unchanged up to 
66% peak work rate (Wpeak), but increases 
significantly at Wpeak. Although at the limit of 
tolerance the increase in EELV was significantly 
greater in the early hyperinflator group than 
in the late hyperinflator group, both reached 
similar values of Wpeak, inspiratory reserve 
volume (IRV) and dyspnea. Furthermore, the 
sensations of dyspnea and leg discomfort 
tended to be higher in the early hyperinflator 
group than in the late hyperinflator group 
(Figure 2). However, the differences between 
the groups were not significant.
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Figure 2. Perceptions of (A) dyspnea and (B) leg 
discomfort at quiet breathing (QB) and during exercise 
between early (closed symbols) and late hyperinflators 
(open symbols).
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Although DH during exercise is a compensatory 
mechanism that increases expiratory flow, it 
has several disadvantages including 
• Dynamic hyperinflation, as mentioned 
above, shifts the tidal breathing range closer 
to total lung capacity (TLC) with a consequent 
decrease in IRV, and reduces the ability of 
tidal volume to expand appropriately during 
exercise;
• In some COPD patients, this mechanical 
constraint on tidal volume expansion may 
lead to hypercapnia and arterial oxygen 
desaturation during exercise;
• By producing a positive end-expiratory 
alveolar pressure (intrinsic PEEP) that must 
be overcome to initiate the next breath, the 
load is increased on the inspiratory muscles; 
thus increasing the work and oxygen cost of 
breathing;
• Dynamic hyperinflation results in an 
operational inspiratory muscle weakness 
with reduction in maximal inspiratory 
pressure (MIP) measured at the mouth 
(Figure 3) by shortening the muscle fibers 
in the diaphragm and consequently placing 
the inspiratory muscles at a mechanical 
disadvantage due to length-tension effects 
(Figure 4);
• Dynamic hyperinflation adversely affects 
the dynamic cardiac function; 
All of the above negative effects of DH are 
clearly interdependent and contribute, 
in a complex, integrated manner to the 
development of exertional dyspnea. Exertional 
dyspnea in COPD, which is related mostly to DH 
during exercise, among other factors, leads to 
exercise intolerance.
However, it should be noted that dyspnea with 
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Figure 3. The MIP is 100 percent of its predicted value 
when the RV/TLC is in its normal range (20 to 35 percent 
depending on age). Maximal inspiratory pressure 
decreases as RV/TLC increases, because diaphragm 
muscles begin to operate at a mechanical disadvantage. 
As an example (dashed lines), a 55-year-old man with 
severe COPD and severe hyperinflation (RV/TLC of 85 
percent) has a MIP that is only 50 percent of its predicted 
value (50 cmH2O instead of 100 cmH2O), despite having 
good nutrition and normal inspiratory muscle strength.
MIP: maximal inspiratory pressure; TLC: total lung 
capacity; RV: residual volume.
Adapted from: Rochester DF. Tests of respiratory muscle 
function. Clinics Chest Med 1988; 9:249-261.
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Figure 4. Hyperinflation (decreased muscle length) 
causes reduced maximal inspiratory pressure (MIP) in 
many patients with COPD. The MIP is 100 percent of its 
predicted value when the muscle length is in its normal 
range. MIP decreases as muscle length decreases.
PA G E  6 3
HYPERINFLATION OF THE LUNG AND ITS MANAGEMENT
C L I N I C A L
B1.
Clinical Consequences of Lung Hyperinflation
exertion and impaired exercise capacity are 
nonspecific complaints in patients with COPD 
and are not attributed only to DH. Additional 
causes of dyspnea with exertion may include:
• Blood gas abnormalities;
• Respiratory muscle weakness;
• Peripheral skeletal muscle weakness/
atrophy;
• Impaired cardiac performance during 
exercise;
• Increased ventilatory demand due to 
physiologic dead space, hypoxemia, 
hypercapnia, early onset lactic acidosis, 
deconditioning, and/or poor nutrition;
• Increased symptom perception; and
• Psychological disorders (anxiety, 
depression).
Thus, a patient with COPD who complains about 
dyspnea with exertion cannot be assumed to 
have only DH: additional diagnostic testing is 
required.
Finally, due to dyspnea on exertion, COPD 
patients progressively reduce motions. This 
has other deteriorating effects, such as 
skeletal muscle deconditioning, anxiety and 
depression. This is the so-called “vicious 
circle of dyspnea on exertion” (Figure 5). As a 
result of the above, the QoL of those patients is 
tremendously decreased.   
Hyperinflation and Cardiovascular Performance
There is growing recognition that COPD and 
its frequent cardiovascular comorbidities, 
such as arterial hypertension, coronary artery 
disease or congestive heart failure, are related 
not only to the common risk factor of cigarette 
smoking and ageing, but appear to be linked by 
an underlying systemic inflammatory status 
as well. The inflammation associated with 
COPD is not limited to the lung, but can also 
affect non-pulmonary organs such as the 
cardiovascular system. 
At the same time, lung mechanics and cardiac 
performance are deeply dependent on each 
other. Both may be responsible for exercise 
limitation, exertional dyspnea, and poor QoL in 
the presence of irreversible airflow limitation 
and LH. Furthermore, muscle mass depletion, 
especially in patients with pulmonary 
emphysema among the COPD population, may 
also contribute to cardiovascular response 
to exercise. Interestingly, in pulmonary 
emphysema, changes both in lung mechanics 
and in skeletal muscle pump may impair the 
cardiovascular function per se. 
Hyperinflation and the Left Heart
Apart from the well-known effect of dilated 
right ventricle (due to the development of 
chronic pulmonary hypertension in COPD) in the 
leftward displacement of the interventricular 
septum and the consequent decrease in size 
of the left ventricle, pulmonary hyperinflation 
per se can significantly affect heart size and its 
function. The recently published Multi-Ethnic 
Study of Atherosclerosis (MESA) COPD Study 
documented that pulmonary hyperinflation is 
associated with greater left ventricular mass.
By means of magnetic resonance technique, 
ACTIVITY DYSPNEA
AECOPD INACTIVITY
ANXIETY
DECONDITIONING 
THE VICIOUS CIRCLE
OF DYSPNEA
FEAR
MORTALITY DEPRESSION
Figure 5. The vicious circle of dyspnea: activity. Produce 
dyspnea that make the patient deconditioned due to anxiety. 
Deconditioning makes the patient more dyspnoic. In addition 
acute exacerbations (AECOPD)induce more dyspnea and 
enhance the fear of death, thus drammaticaly affect the Qol.
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Jörgensen et al. studied patients with 
severe emphysema and found a decrease in 
intrathoracic blood volume in the left ventricular 
and right ventricular end-diastolic volumes 
and an impaired stroke volume and stroke 
work in hyperinflated lungs, as compared to 
controls. The authors argued that there are at 
least two main explanations of these findings: 
in the presence of hyperinflated lungs, a high 
PEEPi could cause intrathoracic hypovolemia 
and small end-diastolic dimensions of both 
the left and right ventricular chambers. The 
redistribution of pulmonary circulation in 
emphysema might occur, not only because 
of a direct parenchymal destruction or 
hypoxia vasoconstriction, but also because 
of decreased compliance of the pulmonary 
vascular bed. Secondly, the right and left 
ventricular chambers could be mechanically 
compressed by hyperinflated lungs that could 
worsen end-diastolic stiffness. According to 
the Frank-Starling law, a low preload finally 
reduces ventricular performance in terms of 
stroke volume and stroke work.
In a large sample of COPD patients ranging 
from GOLD stage 1 to 4, Watz et al. found 
that the degree of COPD severity was directly 
correlated to heart dysfunction. Interestingly, 
in this study, the cardiac chamber sizes 
and impaired left ventricular diastolic filling 
pattern correlated more to the degree of static 
hyperinflation, as assessed by inspiratory 
capacity-to-total lung capacity ratio (IC/TLC), 
than to the degree of airway obstruction, 
expressed as forced expiratory volume in 1 
second (FEV1) % pred., or to diffusion capacity 
to carbon monoxide. Furthermore, IC/TLC was 
an independent predictor of cardiac chamber 
sizes after adjustment for body surface area.
In line with the findings by Watz et al., Malerba 
et al. reported a frequent subclinical left 
ventricular filling impairment in COPD patients 
at the earlier stage of the disease, even in the 
absence of any other cardiovascular disorder. 
Furthermore, Smith et al. have recently shown 
a reduction of pulmonary vein dimension 
in COPD which is related to emphysema; 
thereby supporting a mechanism of upstream 
pulmonary causes for left ventricle underfilling.
Interestingly, pulmonary hyperinflation may 
have negative effects, but pulmonary deflation 
has the potential to improve the cardiac function 
in patients with pulmonary emphysema. In 
severely hyperinflated patients, Come et al. 
recently found that decreased hyperinflation 
through lung volume reduction surgery is 
significantly associated with an improvement 
in oxygen pulse, which may be considered 
as a noninvasive marker of cardiovascular 
efficiency and a measure of stroke volume.
It is of note that the extent of emphysema as 
detected by computed tomography (CT) may 
be associated with impaired cardiac function, 
even in patients without very severe lung 
disease. In a recent population-based study, a 
greater extent of emphysema on CT scanning 
was linearly related to impaired left ventricular 
filling, reduced stroke volume and lower 
cardiac output, without changes in the ejection 
fraction; whereas smoking status significantly 
worsened these associations. Accordingly, 
the authors hypothesized that due to the 
mechanisms of the impaired left ventricular 
filling in too early, mild emphysema might be 
the subclinical loss of capillary bed due to the 
apoptotic effect of smoking on the pulmonary 
endothelium.
Cardiovascular Response to Exercise and 
Dynamic Hyperinflation
As mentioned above, DH is responsible for 
limitation of exercise in COPD patients and for 
the onset of exertional dyspnea. Accordingly, 
it is conceivable that, during exercise, DH can 
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further worsen a poor resting cardiac function 
in patients with COPD.
Both ventilatory and cardiac responses to 
exercise can be studied sufficiently with a 
cardiopulmonary exercise test (CPET). The 
cardiopulmonary exercise tests is a relatively 
noninvasive method to test tolerance to 
maximal exercise, and gives several pieces 
of information about how cardiovascular, 
respiratory and muscle apparatuses respond 
to exercise. Notably, the assessment of DH is 
based on the comparison of the IC performed at 
rest and during exercise. A positive difference 
between them is an indication of DH; assuming 
that TLC remains constant during exercise.
Dynamic hyperinflation, which impairs the 
cardiovascular function in COPD patients, may 
be documented during rapidly incremental 
CPET. Vassaux et al. first observed that DH is 
negatively associated with oxygen pulse at 
peak of exercise in patients with severe COPD. 
These results were confirmed and extended 
in COPD patients with different degrees of 
severity, by showing a significant relationship 
between DH and a battery of noninvasive 
measures of cardiovascular function during 
exercise.
Importantly, it has been recently shown that in 
patients with severe pulmonary emphysema, 
the reduction in DH after lung volume 
reduction surgery was significantly associated 
with an improvement in cardiac response 
to exercise; both in terms of oxygen pulse 
and pulse pressure, which is the difference 
between systolic and diastolic blood pressure. 
It is of note that pulmonary rehabilitation may 
lower the ventilatory demand during exercise, 
resulting in the prolongation of expiration 
time, and, subsequently, in the reduction of 
DH. Accordingly, one may hypothesize that, 
in COPD patients, pulmonary rehabilitation 
may improve the cardiovascular response to 
exercise by enhancing the ventilatory function. 
Mortality and LH
A number of important studies have shown 
a relationship between mortality rates or 
survival and LH. Figure 6 illustrates the 
results of one of those studies; showing that if 
IC<80% pred. then the overall cause as well as 
respiratory cause mortality of these patients 
is significantly increased. In addition, there is 
a strong relationship between the degree of 
hyperinflation and hospital admissions due 
to COPD. It is obvious that LH affects QoL, 
morbidity and mortality of those patients 
significantly.
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Figure 6. Hyperinflation evaluated by IC, affecting 
respiratory bul also all-cause mortality. (TANLUCCI et al)
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Lung hyperinflation in Asthma
A multi-national European study (European 
Network For Understanding Mechanisms Of 
Severe Asthma [ENFUMOSA]) has shown that 
patients suffering from severe asthma had an 
increased RV/TLC ratio compared to those with 
controlled asthma. This signifies that severe 
asthmatics, even at a steady stage condition, 
had a degree of LH. That was also postulated 
by the decrease seen in maximal inspiratory 
pressure (MIP) and maximal expiratory 
pressure (MEP). It is obvious that this static 
hyperinflation increases significantly during 
exercise or an acute dynamic attack. Figure 
7 shows the effect of a 6min walking test 
on dyspnea index in controlled and severe 
asthmatics. As discussed in other chapters 
DH is a rather compensatory mechanism 
to counterbalance airway obstruction and 
airflow limitation; but the increase in work of 
breathing and respiratory muscle insufficiency 
could lead to respiratory failure or even death. 
This is seen in the severe attack of status 
asthmaticus.
CONCLUSIONS
Lung hyperinflation is a frequent 
pathophysiological condition of the chronic 
airway diseases. It affects the QoL of patients 
significantly and has been associated with high 
morbidity and mortality.
Therefore, physicians taking care of these 
patients must have adequate knowledge of 
this condition and of the modes of treatment 
that could reverse LH.
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Figure 7.  The effect of 6 min 
waking test on dyspnea measured 
by Borg scale in well controled and 
severe asthmatics (unpuplised 
data).
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Key Points
1.
A number of essential differences in airway 
resistance, lung volume, efficiency and endurance 
of respiratory muscles between adults and 
children should be taken into account for the 
correct assessment and interpretation of 
hyperinflation in children.
2.
Hyperinflation is present in a high proportion 
of asthmatic children, is correlated with the 
disease severity and responds to treatment with 
bronchodilators and inhaled corticosteroids.
3.
Children with acute bronchiolitis commonly show 
hyperinflation that correlates with the degree 
of obstruction, which in turn remits with age 
in the majority. In bronchiolitis obliterans, the 
hyperinflation tents to persist for many years.
4.
Hyperinflation is detected early in the course 
of cystic fibrosis and is correlated with disease 
severity, genotypes, microbial colonization and 
exercise ability.
5.
Classic spirometry parameters are poor 
markers of the small airway disease leading 
to hyperinflation. Lung volumes or air trapping 
quantification by high-resolution computed 
tomography should be included in the evaluation 
of chronic respiratory diseases in childhood.
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INTRODUCTION
In clinical practice, hyperinflation is a common 
feature (otherwise known as air trapping) 
in obstructive pulmonary diseases such 
as chronic obstructive pulmonary disease 
(COPD), asthma, bronchiolitis, bronchiectasis, 
and cystic fibrosis (CF). 
Although pediatric patients are commonly 
presented with airway obstructive diseases 
such as asthma, bronchiolitis or CF, 
hyperinflation is not extensively studied in 
these patients.
As shown in previous chapters of this book, 
hyperinflation and its consequences on the 
human lung depend on various factors, such 
as airway resistance, lung volume, efficiency 
and the endurance of respiratory muscles. 
There are a number of essential differences in 
lung mechanics between adults and children 
that should be taken into consideration for 
the correct assessment of any ill child and 
the interpretation of any pulmonary function 
performed in young children.
Clinically, the most important difference is that 
the basal metabolic rate is higher in infants 
than in adults. Moreover, oxygen consumption 
is three times higher compared to that of 
adults (7 ml/kg/min in children, compared to 
3 ml/kg/min in adults). Additionally, it should 
be mentioned that infants present high 
respiratory and cardiovascular activity at rest 
accompanied with lower functional residual 
capacity (FRC) compared to that of adults. 
These factors reduce the respiratory reserve 
and facilitate dyspnea and fatigue of the 
respiratory muscles during stressful events. 
It is well known that the lungs and airways 
do not grow isotropically, since the bronchial 
system is fully developed at the sixth month 
of gestation before the alveolar development 
begins. Most alveoli are developed after birth 
until the third year of life through multiplication; 
this means that infants and young children 
have increased lower airway resistance and 
decreased elastic recoil. Moreover, since 
the airways of children are comparatively 
smaller, even minor changes in airway radius 
(i.e., asthma, bronchiolitis) can cause a major 
increase in airflow resistance which increases 
by the fourth power of any reduction in radius. 
Contrary to the adult lung where periphery 
contributes less than 20% to the total airway 
resistance, the contribution of the small 
peripheral airways in infants is 50%. This is the 
reason of the significantly severe problems 
caused by diseases such as bronchiolitis, which 
mostly affects lung periphery. Despite lower 
airway resistance, upper airway resistance 
is increased as well, due to nasal breathing, 
larger tongue and increased compliance of 
infant’s larynx, trachea and bronchi. 
The chest wall of infants has horizontally 
placed, high compliant ribs and poorly 
developed intercostal muscles. During 
inspiration, contraction of the diaphragm 
(which is more horizontal than that of 
adults) will move the rib inward. In case of 
hyperinflation, the diaphragm is flat and spends 
energy to overcome this by constriction of the 
costal margin during inspiration. This inward 
motion of the costal margin, paradoxically 
present during inspiration, is called Hoover’s 
sign, and is a common symptom of peripheral 
obstruction and hyperinflation in infants 
(Figure 1).The same paradoxical inward motion 
has been recorded in patients with COPD and 
hyperinflation. 
The basic features of hyperinflation in most 
common pediatric diseases such as asthma, 
bronchiolitis, CF and in some rare diseases will 
be discussed in the following pages.
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Asthma
Asthma is the most common chronic childhood 
disease that presents hyperinflation which 
could be documented either by increases of the 
residual volume (RV), of the ratio of residual 
volume to total lung capacity (RV/TLC) or of 
the functional residual capacity (FRC), or by 
chest high-resolution CT (HRCT) or magnetic 
resonance imaging (MRI) scans.
The degree of hyperinflation in asthma usually 
correlates with the severity of bronchospasm. 
In conditions of bronchoconstriction, the 
hyperinflation is mostly determined by 
dynamic factors. The major contributing factor 
to dynamic hyperinflation is increased airway 
resistance with prolonged expiratory time 
constants, resulting in slower and incomplete 
lung emptying (air trapping). Physiologically, 
this is expressed as elevation at end expiratory 
lung volume (EELV) above the relaxation 
volume of the lung (Vr). Hyperinflation is often 
present in some degree at rest and increases 
further on exercise or exacerbations where 
the obstruction is augmented (dynamic 
hyperinflation). In healthy individuals during 
exercise, the increased respiratory demands 
cause an elevation of the respiratory rate and 
tidal volume (VT) expansion. This increased 
expiratory effort progressively decreases 
EELV in order to allow complete exhalation 
of the expanded inhaled VT before the next 
inhalation (Figure 2).
In contrast, due to bronchoconstriction in 
asthmatics, the elevated resistance results 
in an increased mechanical time constant for 
lung emptying. With increased respiratory rate 
and existing flow limitation, expiration towards 
Vr becomes increasingly prolonged and the 
next inspiration begins before Vr is reached 
(Figure 2).
Additionally, studies in adults have shown, 
especially when bronchoconstriction is induced 
acutely (i.e., histamine or methacholine), 
tonic inspiratory muscle activity remains 
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Figure 1. Mechanism behind Hoover’s sign. 1*) Accessory muscles; 2*) hyper-expansion of the lungs; 3*) alteration of rib 
orientation to horizontal; 4*) flattened diaphragm and 5*) decreased zone of apposition.
Adapted from Mason: Murray and Nadel’s Textbook of Respiratory Medicine, 4th Edition.
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throughout expiration and tends to slow it 
down, contributing to hyperinflation. Similarly, 
glottic constriction during bronchospasm 
limits expiration, and contributes to air 
trapping as well. It should be mentioned that 
hyperinflation which is developed as a result 
of acute airflow obstruction during an asthma 
attack tends to increase airway caliber, reduce 
airway resistance and improve expiratory flow 
(Figure 3). However, the reduction of airway 
resistance and the beneficial effect on gas 
exchange is accomplished at the expense of 
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Figure 2. -Dynamic Hyperinflation (Black lines) during an acute asthmatic attack.
-Red lines: normal subjects or ARDS
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increased mechanical load of the respiratory 
muscles. 
Early studies of asymptomatic asthmatic 
children have demonstrated that classic 
spirometry is not correlated with lung volume 
abnormalities such as RV, TLC or RV/TLC 
elevations. In a study of 178 asymptomatic 
asthmatic children, the RV, TLC or RV/TLC 
values were abnormally high in 26%, 33% and 
41% of these patients respectively, although 
their forced expiratory volume in 1 second 
(FEV1), FEV1/FVC and forced expiratory flow 
25–75% (FEF25–75%) fell within the normal 
range; indicating that hyperinflation is present 
even in well-controlled asthma in children. 
These results were verified in recent studies 
in preschool children, where the increase of 
the patient’s FRC correlated with the disease 
severity. It should be mentioned that in 
the same group of children, a concomitant 
reduction of compliance was monitored when 
they were symptomatic. It is worth mentioning 
that both abnormalities were improved after 
bronchodilator treatment. 
Interestingly, hyperinflation expressed as FRC 
measurement also was reduced after a six-
week treatment in asthmatic preschoolers. 
Similar results are recorded in a double-
blind study of asthmatic children treated with 
budesonide for 28 weeks. In this study, the 
reduction of both RV and TLC was evident from 
the 8th week of treatment. Increased TLC was 
found also in an early study of Greaves et al. in 
asthmatic adults with childhood onset asthma: 
the patients of the same study with adult onset 
asthma had normal TLC values, indicating 
that episodes of bronchoconstriction in 
childhood might predispose to changes in 
the lung that may follow the patient after the 
remission of the symptoms.
Most asthmatic children, regardless of their 
severity, seem to have normal lung function; 
indicating that spirometry parameters are 
not a sensitive marker of severity in pediatric 
asthma. On the contrary, as in a recent study 
of Mahut et al. in 160 asthmatic children 
has shown, 11% of the patients with normal 
spirometric parameters correlated with small 
airways (e.g., forced expiratory flow at 50% 
[FEF50%]) presented hyperinflation. Moreover, 
from a study by the same group in subjects 
with asthma of different severity, it was 
found that although there were no differences 
in forced expiratory flows of children who 
experienced severe exacerbation compared to 
that of their less symptomatic peers, their RV/
TLC was higher. 
It seems that, as found in adults, hyperinflation 
might be a sensitive marker of disease severity 
in children.  The above-mentioned studies 
emphasize the usefulness of the assessment 
of lung volumes and their response to 
treatment since they are better indicators of 
the degree of the small airway disease and 
hyperinflation, which apparently, cannot be 
monitored by spirometry. 
Only taking the imaging of hyperinflation 
chest radiographs mostly obtained at TLC into 
consideration might be misleading regarding 
the severity of hyperinflation. Moreover, 
pediatric studies have indicated the relative 
insensitivity of chest radiographs in the 
detection of hyperinflation.
Chest HRCTs and MRIs were recently evaluated 
by a number of studies in adults and children 
with asthma. The degree of air trapping found 
on HRCT was correlated with abnormalities 
of RV, TLC and FRC values and was quantified 
using CT attenuation values. The quantitative 
CT was recently evaluated in asthmatic children 
and was correlated with the TLC% and thoracic 
gas volume (TGV) parameters. Moreover, in a 
recent multivariate analysis of risk factors for 
air trapping using quantitative CT analysis in 
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adolescent and adult asthmatics, it was found 
that factors such as duration of asthma, history 
of pneumonia, neutrophilic lung inflammation 
and atopy were independent risk factors for 
the presence of air trapping.
In conclusion, hyperinflation is present in a high 
proportion of asthmatic children, is correlated 
with the disease severity and responds to 
treatment with bronchodilators and inhaled 
corticosteroids. Since classic spirometry 
parameters are poor markers of small airway 
disease and of the severity of the disease, lung 
volumes or air trapping quantification by HRCT 
should be included in the follow up of selected 
groups of asthmatic children (e.g., difficult-to-
treat asthma).
Bronchiolitis
Most children with acute viral bronchiolitis 
present small airway obstruction and 
hyperinflation on chest radiograph. Early 
studies in infants with bronchiolitis have 
shown that hyperinflation, expressed as TGV 
(Thoracic Gas Volume) at the end of expiration, 
was increased in 77% of the patients at the 
acute phase of the disease, remained 
detectable in 43% of them after three months 
and in 17% one year after the initial episode. 
The values of TGV did not correlate with the 
respiratory syncytial virus (RSV) isolation, 
atopy, history of prematurity or the age of the 
subjects at admission. 
Pathophysiologically, the increased airway 
resistance together with the decreased 
elastic recoil due to small airway disease or 
collapse, seem to be the main factors leading 
to hyperinflation in acute bronchiolitis.
A study in low birth weight preterm infants 
with a history of respiratory distress 
syndrome (RDS) at the neonatal period, 
studied at 10 months of age, recorded both 
remaining increased airway resistance and 
air trapping correlated with the severity of 
bronchoconstriction. The same group found 
that the symptomatic low birth weight preterm 
infants with history of RDS have more severe 
hyperinflation compared with their non-
symptomatic peers, indicating correlation of 
hyperinflation with severity of bronchiolitis.
Recently, scientific interests have focused on 
recurrent episodes of wheezing bronchiolitis 
and their link to asthma or COPD in adult 
life. A recent study in infants and toddlers 
with a history of at least three episodes of 
wheezing reported that when the patients 
were asymptomatic, their lungs presented 
no evidence of small airway damage or air 
trapping.
Bronchiolitis obliterans or constrictive 
bronchiolitis, which is characterized by 
excessive air trapping, increased lung 
volumes and a mosaic pattern on HRCT 
films, is also worth mentioning. Interestingly, 
a recent study reported many similarities 
of constrictive bronchiolitis with severe 
problematic asthma regarding their chest 
HRCT findings.  Children with history of post-
infectious bronchiolitis obliterans at the age 
of three, when evaluated at the age of ten, had 
hyperinflation and airflow obstruction. It is of 
interest that their peak aerobic capacity was 
inversely proportional to the severity of their 
rest hyperinflation, reduction of activities and/
or quality of life (QoL).
Conclusively, children with acute bronchiolitis 
commonly present hyperinflation correlated 
with the degree of obstruction, and in most 
children, remits with age. In bronchiolitis 
obliterans, hyperinflation is relative to the 
severity of the disease and the aerobic capacity 
of the patients and tends to persist for many 
years.
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Cystic Fibrosis
Cystic fibrosis is a chronic pulmonary disease 
presented mostly with airway inflammation, 
progressive obstruction and hyperinflation. 
Pulmonary hyperinflation may be detected 
early in life of CF patients and may progress 
during childhood.
Pathophysiologically, both static and dynamic 
hyperinflation seem to be consequences of 
the reported air trapping in CF. In moderate to 
severe CF, the presence of airway obstruction 
and the changes in the elastic properties of 
the lung result in an elevation of the (EELV) 
at rest (static hyperinflation). During exercise, 
the respiratory rate increases and VT expands 
to cover the elevated needs (Figure 2). In CF 
patients, during worsening of expiratory flow 
(exacerbation) or increased ventilatory needs 
(exercise), the decreased elastic recoil pressure 
and the increased airway resistance result in 
progressively prolonged expiration leading to 
elevated EELV (dynamic hyperinflation) with 
detrimental mechanical effects.
As a recent study has suggested, hyperinflation 
in CF seems to be recorded very early in life. It 
was found that nearly 70% of studied infants 
with CF in their study had elevated FRC.
Various studies have reported a correlation 
of hyperinflation with the infective pathogen 
density in distal or smaller airways.
A different group showed that 39% of CF 
patients aged 6-8 years had hyperinflation, 
and that this percentage reached 67% by the 
age of 18 years old. 
Interestingly, the group of patients colonized 
with Pseudomonas aeruginosa presented 
more profound disease progression. Moreover, 
the same study recorded that the alterations of 
the lung function were correlated with specific 
cystic fibrosis transmembrane conductance 
(CFTR) genotypes. 
The above findings suggest that measurements 
of lung volume may provide valuable 
information about disease progression and 
phenotyping, and evaluate the benefit of 
antibiotic treatment in CF patients.
Regarding imaging of the CF children with 
plain chest radiographs, early studies 
have used scoring systems such as the 
Brasfield score to quantify pulmonary 
hyperinflation. Nevertheless, due to the 
possible overestimation of hyperinflation 
in chest radiographs, the need for more 
accurate assessments has evolved. Computed 
tomography seems to be more sensitive than 
chest radiographs in CF children. Various low 
dose techniques and limited slices protocols 
have been evaluated to overcome the concerns 
over radiations. At the Australian Respiratory 
Early Surveillance Team for Cystic Fibrosis 
(AREST-CF) cohort, CT scans in asymptomatic 
infants at 3 months of age recorded gas 
trapping in 67% of the subjects. In contrast, 
in patients of the London Cystic Fibrosis 
Collaboration (LCFC) cohort, most of the CT 
scans were classified as normal, indicating 
the need for further validation of CT scoring 
systems in very young infants.
In conclusion, hyperinflation is detected early in 
the course of CF and is correlated with disease 
severity, microbial colonization and exercise 
ability. The above characteristics make the 
assessment of the degree of hyperinflation 
profoundly valuable in young CF patients.
Neonatal Chronic Lung Disease (CLD), Primary 
Ciliary Dyskinesia (PCD), Alpha-1 Antitrypsin 
(A1AT) Deficiency
A number of rare childhood pulmonary 
diseases such as CLD, PCD and A1AT deficiency 
may present hyperinflation.
A limited number of studies have indicated that 
FRC, RV or RV/TLC were increased in infants 
with history of prematurity and CLD.
C L I N I C A L
PA G E  7 6
HYPERINFLATION OF THE LUNG AND ITS MANAGEMENT
B2.
Lung Hyperinflation in Respiratory Childhood Diseases
In children with PCD, hyperinflation is 
recorded as increased RV and RV/TLC. In 
these children, hyperinflation documented 
by plethysmography was correlated with the 
P. aeruginosa infection and HRCT findings. 
Magnin et al. reported that 50% of the PCD 
children had hyperinflated lungs in HRCT 
scans.
Hyperinflation has also been reported in a 
study of children with A1AT deficiency with liver 
disease.
In conclusion, most childhood pulmonary 
diseases either with airway obstruction 
or lung parenchyma destruction or both, 
frequently present hyperinflation of varying 
severity. Hyperinflation is usually correlated 
with disease severity, predicts the disease 
progression in a few cases and plays a cardinal 
role in the pathophysiology of the clinical 
conditions at rest, exercise and exacerbations. 
A systematic quantitive assessment of 
pulmonary hyperinflation in common pediatric 
diseases such as asthma and CF will enrich our 
knowledge of pathophysiological mechanisms 
and improve disease treatment and follow-up.
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Key Points
1.
Bronchodilators of all classes and duration 
of action have been shown to decrease lung 
hyperinflation (deflators) and pulmonary gas 
trapping with reciprocal increases in inspiratory 
capacity and vital capacity, respectively, in patients 
with chronic obstructive pulmonary disease. 
2.
Bronchodilator-induced reductions in lung 
hyperinflation at rest and during exercise have 
beneficial effects on exertional dyspnea, exercise 
tolerance and health status in chronic obstructive 
pulmonary disease.
3.
Patients with the greatest lung hyperinflation 
at rest have the greatest lung deflation 
improvements in response to a bronchodilator.
4.
A significant bronchodilator response may 
not be uncovered by evaluation of changes in 
forced expiratory volume in 1 second, since 
improvements in lung volumes can often occur 
independently of changes in maximal expiratory 
flow rates.
5.
Improvements in dyspnea and exercise tolerance 
following pharmacological lung volume reduction 
are closely related to the release of tidal volume 
restriction and enhanced neuromechanical 
coupling of the respiratory system.
6.
Dual long-acting muscarinic antagonist/ long 
acting β2-agonist bronchodilators (deflators) 
in a single device have superior effects on 
hyperinflation compared to mono-components.
T R E AT M E N T
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INTRODUCTION
Lung hyperinflation, chronic dyspnea, reduced 
exercise capacity and physical inactivity are 
independent predictors of increased mortality 
in chronic obstructive pulmonary disease 
(COPD). Therefore, it is no surprise that a major 
goal of management is to therapeutically 
reduce lung hyperinflation (deflation) in the 
hope of improving dyspnea and exercise 
tolerance. The negative effects of lung 
hyperinflation in COPD are well established, 
including direct evidence to support its 
relationship with activity-related dyspnea 
and exercise limitation. Indirect evidence 
of the importance of lung hyperinflation in 
dyspnea causation and exercise intolerance 
in COPD comes from multiple studies which 
have examined therapeutic interventions that 
reduce or counterbalance the effect of lung 
hyperinflation. In this regard, pharmacological 
treatments that reduce resting and/or dynamic 
lung hyperinflation have the potential to 
improve dyspnea and exercise capacity, as 
well as other related clinical outcomes such as 
health status or even survival. 
Bronchodilator therapy
Effects on measurements of lung hyperinflation 
at rest
Bronchodilators reduce airway smooth 
muscle tone, reduce airway resistance, im-
prove airflow, and accelerate the mechani-
cal time constants for lung emptying. In this 
way, inhaled bronchodilators favorably alter 
the dynamically-determined components of 
resting lung hyperinflation and help deflate 
the overinflated lung (Figure 1). Bronchodi-
lators of all classes and duration of action 
have consistently been shown to decrease 
measurements of lung hyperinflation (func-
tional residual capacity [FRC]) and pulmo-
nary gas trapping (residual volume [RV]) 
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Figure 1. Typical bronchodilator-induced changes in (A) maximal and tidal flow-volume loops and (B) lung volumes 
at rest. With a bronchodilator, maximal expiratory flows increase allowing inspiratory capacity (IC) to increase and 
functional residual capacity (FRC) to decrease. TLC: total lung capacity.
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with reciprocal increases in inspiratory ca-
pacity (IC) and vital capacity (VC) in patients 
with COPD. 
End-expiratory lung volume (EELV) is a term 
that has been used interchangeably with FRC; 
however, EELV more accurately reflects the 
combined dynamic and “static” determinants 
of this operating lung volume at rest and 
throughout exercise. Since spirometric 
measurements are simple to perform, 
changes in IC have often been used to track 
changes in EELV both at rest and throughout 
exercise. However, bronchodilator-induced 
improvements in IC may underestimate the 
reduction in resting EELV since total lung 
capacity (TLC) has been shown to fall by small 
amounts in the order of 0.1-0.2L. As single 
agents, both classes of inhaled bronchodilators 
(beta2-agonists and muscarinic antagonists) 
have been shown to increase the resting IC in 
patients with COPD by approximately 0.2-0.4L 
or 10-15%. The largest post-bronchodilator 
improvements in IC are seen in patients with 
the greatest resting lung hyperinflation (e.g., 
baseline IC<80%pred.). Decreases in lung 
volume of the magnitude seen in response to 
bronchodilators are associated with reduced 
intrinsic mechanical loading and increased 
functional strength of the respiratory 
muscles. Such mechanical improvements are 
particularly important in dyspneic patients 
with more severe COPD who gain the greatest 
subjective benefit.
Improvements in forced expiratory volume 
in 1 second (FEV1) following a bronchodilator, 
especially in more advanced COPD, commonly 
indicate lung volume recruitment (increased 
VC) as a result of reduced pulmonary gas 
trapping (decreased RV). Thus, studies have 
shown a preserved or decreased FEV1/FVC ratio 
in response to all classes of bronchodilators. 
This pattern of lung volume recruitment is 
noted particularly in patients with more severe 
lung hyperinflation. Moreover, a lack of change 
in FEV1 after bronchodilator treatment does 
not necessarily reflect a lack of change in 
lung hyperinflation or associated subjective 
benefits for the patient. 
The combination of a long-acting muscarinic 
antagonist (LAMA) and a long-acting β2-
agonist (LABA) can have additive effects on 
reducing lung hyperinflation. Van Noord et al. 
were the first to study the combined effect of 
two long-acting bronchodilators (tiotropium 
and formoterol) on IC over a 24-hour period in 
patients with moderate-to-severe COPD. After 
the 2-week treatment periods, they confirmed 
additive effects on lung deflation with significant 
increases in average daily IC and daytime peak 
IC with the combination treatment versus 
tiotropium alone. Importantly, the mechanical 
benefits were also evident throughout the 
night. More recent studies have also shown 
slightly greater improvements in resting lung 
hyperinflation (increases in IC) with long-
acting bronchodilator combinations or fixed-
dose dual products (such as indacaterol/
glycopyrronium) over tiotropium monotherapy.
Effects on lung hyperinflation during exercise
Bronchodilators do not necessarily abolish 
expiratory flow limitation in patients with 
more advanced COPD, but allow patients 
to generate the same or greater respired 
flow rates at lower operating lung volumes 
(deflation). There has recently been interest 
in measuring increases in IC as a surrogate 
measure of lung deflation during exercise in 
response to bronchodilator treatment in COPD. 
This approach seems reasonable, as there is 
evidence that TLC and the elastic properties 
of the respiratory system are not changed by 
exercise in health or disease. There is also 
evidence that patients with COPD are able to 
maximally activate their diaphragm during 
inspiratory efforts to TLC while exercising. 
Inhaled bronchodilators have been shown 
to reduce lung hyperinflation (increase IC) at 
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standardized exercise work rates/times and 
at peak exercise. Such bronchodilator-induced 
increases in exercise IC have consistently been 
associated with improvements in exertional 
dyspnea and exercise endurance time in 
patients with moderate-to-severe COPD.
The IC indicates the position of tidal volume 
(VT) relative to TLC on the sigmoidal pressure-
volume relation of the respiratory system. 
Therefore, a post-bronchodilator increase 
in IC indicates reduced elastic/inspiratory 
threshold loading of the inspiratory muscles, 
an important determinant of dyspnea. An 
increased IC and lower operating lung 
volumes allow patients to achieve the required 
ventilation (VE) during rest and exercise with 
reduced contractile muscle effort and at a 
lower oxygen cost of breathing. By increasing 
resting IC, bronchodilators (deflators) also 
increase the available dynamic inspiratory 
reserve volume (IRV), and thereby delay 
the onset of critical respiratory-mechanical 
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Figure 2. The ratio between respiratory effort 
(esophageal pressure relative to maximum 
[Pes/PImax]) and tidal volume displacement (VT 
standardized as a fraction of predicted vital 
capacity [VC]), an index of neuromechanical 
dissociation, is shown during exercise after a 
bronchodilator (tiotropium) versus placebo in 
COPD compared with a group of age-matched 
healthy controls. The effort-displacement 
ratio is increased in COPD compared to normal 
throughout exercise, with an upward trend 
towards the end of exercise that did not occur 
in the healthy subjects. Post-bronchodilator, 
this ratio was reduced throughout exercise in 
COPD. From O’Donnell DE, et al. J Appl Physiol 
2006; 101: 1025-1035.
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Figure 3. Operating lung volumes during exercise are shown pre- and post-bronchodilator in COPD compared with 
healthy normal subjects. Bronchodilators result in an increase in inspiratory capacity (IC) and a parallel downward shift 
in the end-expiratory lung volume (EELV) over the course of exercise, thus allowing greater expansion of tidal volume 
(VT ). From Laveneziana P, O’Donnell DE. Dis Manage Health Outcomes 2007; 15(2): 91-100.
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constraints on VT expansion (and thereby VE) 
during exercise. Thus, throughout exercise, 
less respiratory muscle effort is required to 
achieve greater tidal volume expansion: the 
dissociation between central respiratory drive 
and the mechanical response of the respiratory 
system is partially reversed. Improvements in 
dyspnea and exercise tolerance are closely 
related to this release of VT restriction and 
enhanced neuromechanical coupling of the 
respiratory system. Thus, for any given exercise 
intensity or ventilation, patients breathe on the 
more linear portion of the respiratory system’s 
pressure-volume curve, which delays the 
onset of neuromechanical dissociation and the 
attendant dyspnea (Figure 2).
Dynamic lung hyperinflation (DH) is defined 
as the acute (temporary) increase in EELV (or 
decrease in IC) relative to resting values. The 
rate of DH is often not changed by administration 
of a bronchodilator, possibly due to the higher 
levels of VE that can be achieved secondary to 
the release of VT restriction that occurs with 
lung deflation. In other words, bronchodilators 
result in a parallel downward shift in the 
EELV over the course of the exercise test/
task, reflecting the reduction in resting lung 
hyperinflation (Figure 3). The physiological 
effects of pharmacological lung volume 
deflation are summarized in Table 1.
• Reduced respiratory muscle load.
• Increased inspiratory muscle strength.
• Enhanced neuromechanical coupling.
• Delayed ventilatory limitation to exercise.
• Reduced exertional dyspnea.
• Improved cardiac function.
Table 1. Beneficial effects of lung deflation.
Effects on activity-related dyspnea and exercise 
endurance
Randomized controlled trials have examined 
the effects of LABA, LAMA and LABA/LAMA 
combinations on dyspnea intensity ratings 
during exercise and/or dyspnea related 
to activities of daily living in patients with 
moderate-to-severe COPD. Bronchodilator-
LABA 
LAMA 
LABA/LAMANS
NS
NS
NS
p=0.052
peak
p=0.07
p=0.06
NS
NS
NS
NS
O’ Donnell, 2004a
Man, 2004
O’ Donnell, 2006a
Neder, 2007
Worth, 2010
O’ Donnell, 2011
Beeh, 2011
O’ Donnell, 2004b
Maltais, 2005
O’ Donnell, 2006b
Maltais, 2011
Beeh, 2012
Beeh, 2014
Beeh, 2014
IC at isotime (L) Endurance time (sec) Dyspnea at isotime (Borg)
0,0 0,1 0,2 0,3 0,4 0 0,0 -0,5 -1,0 -2,0-1,530 60 90 120 150 180
Figure 4. Improvements in response to long-acting beta2-agonists (LABA), long-acting muscarinic antagonists (LAMA) 
and LABA/LAMA combinations compared with placebo are shown for exercise measurements of inspiratory capacity 
(IC) at a standardized time during exercise (isotime), constant-work rate cycle exercise endurance time, and dyspnea 
intensity ratings at isotime. Treatment differences in these randomized, placebo-controlled studies are statistically 
significant (p<0.05) unless indicated otherwise. NS: not significant. 
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induced improvements in perceived dyspnea 
intensity during constant work rate cycle 
exercise are variable, possibly due to 
measurement variability in this outcome, as 
well as the modest numbers of patients in many 
of these studies (Figure 4). Despite variability in 
improvements in exertional dyspnea, increases 
in IC at a standardized time near end-exercise 
(isotime) and in exercise endurance time with 
long-acting bronchodilators compared with 
placebo appear to be more consistent (Figure 
4). Increases in cycle exercise endurance time 
in response to bronchodilator therapy are in 
the order of 20% on average. Such increases in 
cycling endurance time are typically within the 
range that is thought to be clinically important, 
i.e., about 100 seconds. It is possible that 
LABA/LAMA fixed-dose combinations may 
extend the improvements seen with single 
agents; however, there is currently limited 
information on exercise responses with dual 
bronchodilator therapy.
The effects of long-acting bronchodilators 
on the Transition Dyspnea Index (TDI) are 
shown in Figure 5. Although variability in 
this outcome is evident, the improvements in 
TDI total scores were approximately 1.0 unit 
compared with placebo, which corresponds 
to the minimal clinically important difference 
(MCID). Recent studies show that two approved 
combinations of a LABA and a LAMA in a single 
dry powder inhaler provided significant and 
clinically meaningful improvements in TDI 
total scores compared with placebo at six 
weeks and at 24 weeks. In these studies, the 
magnitude of improvement in the TDI with 
dual bronchodilators was numerically greater 
than with a single bronchodilator, but only 
marginally or not statistically significant.
Effects on physical activity and health status
There is considerable interest in evaluating 
the impact of modern pharmacotherapy on 
increasing physical activity in COPD. While 
pharmacological lung volume deflation is 
consistently associated with improved exercise 
capacity, translation to improved functional 
status and spontaneous increases in habitual 
physical activity does not necessarily follow. 
Thus, inactivity in COPD is multifactorial, and 
in many patients, ventilatory limitation and 
LABA
LAMA
LABA/LAMA
0,0 0,5 1,0 1,5 2,0
Mahler, 1999
Donohue, 2002
Mahler 2002
Hanania, 2003
Brusasco, 2003
Kornman, 2011
Aalbers, 2002
Aalbers, 2002
Dahl, 2010
Dahl, 2010
Dahl, 2010
Kornman, 2011
Gotfried, 2012
Kinoshita, 2012
Kinoshita, 2012
Donohue, 2010
Donohue, 2010
Casaburi, 2002
Donohue, 2002
Brusasco, 2003
O'Donnell, 2004
Verkindre, 2006
Kerwin, 2012
Maltais, 2011
Kerwin, 2012
Kerwin, 2012
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Figure 5. Treatment differences for the Transition 
Dyspnea Index (TDI) measured in response to long-
acting beta2-agonists (LABA), long-acting muscarinic 
antagonists (LAMA) and LABA/LAMA combinations 
compared with placebo. The dashed line represents the 
accepted minimal clinically important difference (MCID) 
of 1 unit. Treatment differences in these randomized, 
placebo-controlled studies are statistically significant 
(p<0.05) unless indicated otherwise. NS: not significant. 
Drugs and dosages shown are as follows: s50, salmeterol 
50 μgb.i.d.; f12 and f24, formoterol 12 and 24 μgb.i.d.; i75, 
i150, i300 and i600, indacaterol 75, 150, 300 and 600 μg 
once daily; t18, tiotropium 18 μg once daily; a200 and a400, 
aclidinium 200 and 400 μg b.i.d.; g50, glycopyrronium 50 
μgonce daily; i110/g50, indacaterol/glycopyrronium 110/50 
μg once daily; u62.5/v25 and u125/v25, umeclidinium/
vilanterol 62.5/25 and 125/25 μg once daily.
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dyspnea (which are delayed by bronchodilator 
therapy) may not be the dominant exercise-
limiting symptoms that underscore habitual 
inactivity. Recent studies which have 
examined the impact of bronchodilator therapy 
on physical activity (measured by activity 
monitors) have yielded variable results that 
are difficult to interpret. It seems likely that 
additional behavioral modification, preferably 
in the context of pulmonary rehabilitation, is 
required to achieve sustained improvements 
of this important clinical outcome in individual 
patients. 
Any intervention that can improve respiratory 
symptoms or the ability to perform activities 
is also likely to improve disease-specific 
health status and quality of life. The St. 
George’s Respiratory Questionnaire (SGRQ) 
is a standardized index of health status that 
is commonly used as an outcome measure 
in pharmacological studies in patients with 
COPD. Treatment changes in SGRQ total score 
in response to long-acting bronchodilators 
tend to fall at or below the level thought to be 
clinically meaningful, i.e., -4 units (Figure 6).
ICS and ICS/LABA combinations
Most large randomized clinical trials evaluating 
the efficacy of inhaled corticosteroid (ICS) and 
LABA combination therapy have been designed 
to evaluate simple spirometry, exacerbations or 
health status as primary outcome measures. 
Several studies have reported activity-related 
dyspnea as a secondary outcome and have 
shown consistent improvements with ICS/
LABA therapy compared to a placebo; however, 
only a few have shown significant benefit when 
compared to its LABA component. 
The combination of an ICS with a bronchodilator 
has been shown to have beneficial effects on 
resting IC compared to placebo. The fluticasone/
salmeterol combination was shown to reduce 
resting and dynamic hyperinflation, as well as to 
increase exercise endurance time compared to 
placebo, but not vs. salmeterol. The budesonide/
formoterol combination was reported to 
reduce resting and dynamic hyperinflation and 
increase exercise endurance compared to both 
placebo and formoterol. A more recent study 
found that fluticasone/salmeterol increased 
IC at rest and throughout exercise in patients 
with mild-to-moderate COPD, but without 
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Figure 6. Treatment differences for the St. George’s 
Respiratory Questionnaire (SGRQ) total score measured 
in response to long-acting beta2-agonists (LABA), long-
acting muscarinic antagonists (LAMA) and LABA/LAMA 
combinations compared with placebo. The dashed line 
represents the accepted minimal clinically important 
difference (MCID) of 4 units. Treatment differences in these 
randomized, placebo-controlled studies are statistically 
significant (p<0.05) unless indicated otherwise. NS: not 
significant. Drugs and dosages shown are as follows: 
s50, salmeterol 50 μgb.i.d.; f12, formoterol 12 μgb.i.d.; i75, 
i150, i300 and i600, indacaterol 75, 150, 300 and 600μg 
once daily; t18, tiotropium 18 μg once daily; v25, vilanterol 
25 μg once daily; a200 and a400, aclidinium 200 and 400 
μg b.i.d.; g50, glycopyrronium 50 μg once daily; u62.5/v25 
and u125/v25, umeclidinium/vilanterol 62.5/25 and 125/25 
μg once daily.
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consistent improvements in dyspnea intensity 
or exercise endurance. This is not surprising, 
since increased leg discomfort was a dominant 
exercise-limiting symptom during the baseline 
test in this group of patients with milder disease 
severity.
The beclomethasone/formoterol combination 
has been reported to improve resting lung 
volumes more than fluticasone/salmeterol. 
In addition, the budesonide/formoterol 
combination was found to show a faster rate of 
onset than fluticasone/salmeterol combination 
or formoterol alone. The bronchodilator 
combination of tiotropium and salmeterol was 
more effective than fluticasone/salmeterol for 
improving resting lung volumes in hyperinflated 
COPD patients, although exercise endurance 
time was not significantly different between 
these treatment combinations.
When ICS is given as monotherapy, small 
improvements in airway function have been 
shown compared with placebo. Inhaled 
corticosteroid monotherapy added to a 
foundation of long-acting bronchodilator 
therapy has also been shown to decrease lung 
hyperinflation at rest and during exercise, and to 
improve exercise endurance. The mechanism 
for an effect of ICS on hyperinflation is unclear, 
but may involve a direct local action on the 
micro-vasculature of the airway mucosa, e.g. 
vasoconstriction. Inhaled extra-fine particles 
targeting the peripheral lung are a particularly 
attractive strategy to pharmacologically 
deflate patients with COPD, as increased 
small airway resistance is a key mechanism 
of air trapping in these patients. An extra-fine 
combination of budesonide and formoterol, 
which has been shown to result in high and 
homogenous deposition rates in the airways, 
has been shown to be superior to a regular-
size fluticasone plus salmeterol combination in 
reducing residual volume and dyspnea scores 
in hyperinflated COPD patients. Interestingly, 
FVC increased to a greater extent with this 
combination than budesonide/formoterol and 
formoterol alone, and FEV1 increased more 
than with a fluticasone/salmeterol combination 
in two larger randomized clinical trials. These 
data suggest that part of the deflating effects 
of inhaled ICS/LABA combinations might be 
due to the anti-inflammatory effects of the 
ICS in the small airways. More head-to-head 
comparisons with detailed physiological 
measurements will however be necessary for 
any definitive conclusions. 
 
Other pharmacotherapies
Chrystyn et al. (Br Med J 1988) were the first to 
show a dose-response relationship between 
oral theophylline administration and reduction 
in FRC. Theophylline has been reported to 
improve lung volumes and exercise endurance, 
possibly through improved respiratory muscle 
performance secondary to unmeasured lung 
volume reduction.
The oral phosphodiesterase-4 (PDE4) inhibitor, 
roflumilast, was associated with progressive 
improvements in resting airway function, but 
not in resting lung hyperinflation compared with 
placebo after 12 weeks of treatment. Roflumilast 
treatment had small but consistent effects on air 
trapping during exercise (IC increased by 0.12L 
at isotime compared with placebo; p=0.008), but 
this was not sufficient to improve dyspnea or 
exercise endurance time. 
Treatment with the mucoactive/antioxidant 
n-acetylcysteine (NAC) has been shown to 
have beneficial effects on small airway function 
and air trapping. One study in stable patients 
with moderate-to-severe COPD showed 
improvements in post-exercise measurements 
of lung hyperinflation (IC, RV/TLC) and modest 
increases in cycle exercise endurance time 
following 6 weeks of treatment with NAC 
compared with placebo. Another study showed 
significant improvements in small airway 
function and exacerbation frequency after 1 year 
of NAC treatment in patients with stable COPD, 
PA G E  8 9
HYPERINFLATION OF THE LUNG AND ITS MANAGEMENT
T R E AT M E N T
C1.
Pharmacotherapy of Lung Hyperinflation
but failed to demonstrate any improvement in 
IC, in exercise performance measured by the 
6-minute walk test, or in dyspnea measured by 
the modified MRC dyspnea scale.
SUMMARY
Over-reliance on FEV1 as the main outcome 
measure for the evaluation of bronchodilator 
efficacy in clinical trials has resulted in 
underestimation of beneficial clinical effects 
in many patients. In this context, important 
decreases in lung hyperinflation can occur in 
the setting of minor or no changes in traditional 
spirometry, especially in patients with more 
severe airway obstruction. Pharmacological 
lung volume reduction (deflation) provides 
a solid mechanistic rationale for observed 
improvements in dyspnea and exercise tolerance 
in COPD. All classes of short- and long-acting 
bronchodilators (deflators) have been shown 
to consistently reduce lung hyperinflation 
across the continuum of COPD, with attendant 
improvements in exercise endurance and 
perceived health status. More recently, dual 
LABA/LAMA bronchodilators delivered in a 
single device have been shown to have superior 
effects on lung deflation compared with the 
mono-components. The expectation is that 
such sustained improvements in respiratory 
mechanics will lead to long term improvements 
in dyspnea and physical activity and, ultimately, 
to improved health status over a longer life 
duration.
References of Figure 4, 5, 6 are cited at the end 
of the book
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Key Points
1.
Several non-pharmacological treatment options are 
available that can help to either 1) directly reduce 
dynamic hyperinflation; 2) indirectly improve dynamic 
hyperinflation by reducing ventilatory needs for a 
given level of exertion or 3) assist the overburdened 
respiratory muscles to better cope with the increased 
loads and improve symptoms during exertion.   
2.
Decreases in ventilatory demands with exercise training 
and oxygen supplementation in some patients result in 
less dynamic hyperinflation for a given work rate and 
better tolerance to physical exertion.
3.
In addition to variable effects on resting lung 
hyperinflation, heliox breathing can decrease the rate of 
dynamic hyperinflation for a given level of ventilation in 
selected patients.
4.
Pressure-generating capacity of the overburdened 
inspiratory muscles can be passively (via non-invasive 
ventilatory support) or actively (via inspiratory muscle 
training) improved with beneficial effects on dyspnea in 
selected patients.
5.
Several simple breathing strategies (e.g. pursed lips 
breathing, active expiration, and body positioning 
techniques) that are sometimes used spontaneously 
may be taught to patients to improve symptoms at rest 
and during exercise.
6.
Subjective benefits in terms of dyspnea improvement 
during exertion need to be evaluated in individual 
patients and weighed against the costs, risks, and time 
investment of the different interventions. 
T R E AT M E N T
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INTRODUCTION
Lung hyperinflation is highly prevalent in 
patients with chronic obstructive pulmonary 
disease (COPD) and occurs across the 
continuum of the disease. A growing body of 
evidence suggests that lung hyperinflation 
contributes to dyspnea and activity limitation 
in COPD, and is an important independent risk 
factor for mortality and disease exacerbations. 
Important negative consequences of dynamic 
hyperinflation (DH) during activities include:  1) 
limits on tidal volume (VT) expansion, resulting 
in early ventilatory mechanical limitation; 2) 
increased elastic and threshold loading on the 
inspiratory muscles, resulting in increased 
work and oxygen cost of breathing (reduced 
efficiency); 3) functional inspiratory muscle 
weakening due to mechanical disadvantage 
(i.e., operating at shorter lengths) and 
increased velocity of shortening needed to 
generate higher inspiratory flow; 4) negative 
impact of increased inspiratory muscle work 
on leg blood flow and muscle fatigue; 5) 
carbon dioxide (CO2) retention; and 6) adverse 
effects on cardiac function and central 
hemodynamics. 
The growing disparity between increased 
central neural drive and the reduced 
respiratory muscular / mechanical 
response due to hyperinflation contributes 
importantly to the perception of respiratory 
discomfort during exertion. In this chapter, 
the physiological rationale and efficacy of 
selected non-pharmacological interventions 
aimed at improving symptoms caused by 
these alterations will be discussed. Several 
non-pharmacological treatment options are 
available that can help to either 1) directly 
reduce dynamic hyperinflation during 
activities (heliox breathing); 2) indirectly 
improve dynamic hyperinflation by reducing 
ventilatory needs for a given level of exertion 
(exercise training and oxygen); or 3) assist the 
overburdened respiratory muscles to better 
cope with the increased loads and improve 
symptoms during exertion (breathing exercises 
and non-invasive ventilatory support).
Exercise Training
Rehabilitative exercise training improves 
exercise capacity and reduces symptoms 
of dyspnea in patients with COPD.  The 
improvements observed in constant load 
cycling tasks after properly conducted 
exercise training programs are larger than 
those observed with any other intervention. 
Several physiological and psychological 
factors have been proposed to explain these 
improvements. Reduction in DH has been put 
forward as one of them. There are indications 
that improvements in the affective perception 
of dyspnea can also occur without changes in 
dynamic respiratory mechanics. 
It is generally accepted that exercise training 
does not have an impact on resting pulmonary 
mechanics. Εxercise training primarily 
reduces ventilatory needs for a given level of 
exertion and thereby reduces DH for a given 
work rate. This reduction in ventilatory needs 
is probably mainly related to improvements 
in peripheral muscle function after training, 
with accompanying reductions in reliance 
on anaerobic metabolism during exercise. 
Reducing ventilation will allow patients to 
decrease their breathing frequency, increase 
VT and reduce end-expiratory lung volume 
(EELV) for a given workload, and thereby 
result in reduced symptoms of dyspnea and 
improved exercise endurance. A larger VT 
will result in a decreased dead space/VT 
ratio, thus further reducing the ventilatory 
requirements during exercise. For a given 
level of ventilation, EELV does not seem to be 
altered after exercise training. 
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Although the evidence for exercise training is 
strong, there exists a proportion of patients 
who do not achieve meaningful gains in 
exercise capacity after this intervention. 
These patients are characterized by more 
severe expiratory flow limitation and profound 
ventilatory limitation during exercise, resulting 
in severe symptoms of dyspnea. Several other 
treatment options are available that might be 
useful to alleviate the negative consequences 
of DH during exercise.
Non-invasive Ventilatory Support
The use of non-invasive ventilation (NIV) 
consistently increases endurance time and 
reduces dyspnea perception during constant 
load cycling tasks in selected patients 
with COPD. Assisting ventilation by either 
continuous positive airway pressure (CPAP) 
or inspiratory pressure support (IPS) does 
not directly improve hyperinflation at rest 
or the increase in EELV during exercise. 
Improvements in exercise capacity in response 
to these interventions are likely achieved by 
unloading the inspiratory muscles during 
exercise, thus improving the demand/capacity 
imbalance of the respiratory muscles. This is 
supported by data showing that patients with 
pronounced inspiratory muscle weakness are 
more likely to achieve larger improvements 
in exercise endurance (Figure 1). Optimal 
CPAP counterbalances intrinsic positive 
end-expiratory pressure (PEEPi), thereby 
minimizing the elastic threshold load on the 
inspiratory muscles, while IPS provides variable 
resistive and elastic unloading of ventilatory 
muscles during exercise. Unloading of the 
respiratory muscles by proportional assisted 
ventilation (PAV) has been shown to improve 
leg blood flow and exercise performance 
during sustained high intensity exercise in 
healthy trained cyclists. In patients with COPD, 
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Figure 1. Relationship (r=-0.49, p=0.001) between improvement in exercise endurance and maximal inspiratory 
pressure (PI,max). IPS10: inspiratory pressure support of 10 cmH2O. • patients with a change in exercise endurance 
<100%; • patients with a change in exercise endurance of ≥100% (at least doubled). The vertical dashed line helps illustrate 
that most responders had severely reduced pressure generating capacity of inspiratory muscles (PI,max<60cmH2O). 
Adapted from: van ‘t Hul A et al. Acute effects of inspiratory pressure support during exercise in patients with COPD. Eur 
Respir J 2004;23(1):34-40.
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respiratory muscle unloading by PAV during 
a relatively short constant load cycling task 
showed positive effects on endurance time, 
leg muscle oxygenation, and dyspnea and leg 
fatigue symptoms. Reductions in leg muscle 
fatigue after exercise in response to unloading 
the inspiratory muscles by combining PAV 
with heliox has also been shown. These 
data support the hypothesis of a competition 
between limb and respiratory muscles for the 
available O2 delivery during exercise. These 
interventions require individual guidance 
and full supervision if they are implemented 
in clinical practice (e.g., during an exercise 
training intervention) and are not tolerated 
well by all patients. These factors need to 
be taken into account when considering the 
implementation of these interventions into 
rehabilitation interventions. 
Several small randomized clinical trials (RCTs) 
have demonstrated that the addition of NIV 
to an exercise training program in COPD can 
result in higher training intensities and larger 
improvements in exercise capacity. A meta-
analysis published in the Cochrane library 
(Menadue C) quantified the improvement in 
endurance exercise capacity by an average 
of 59% in two studies that provided NIV during 
training, compared with training without NIV or 
training with sham NIV. Acute improvements 
in exercise endurance are more consistent 
when using inspiratory pressure support than 
other ventilator modes. This, together with its 
relative ease of use, suggests that this method 
is probably the first choice for NIV-assisted 
training. Time requirements and required 
expertise in implementation and titration will 
likely limit the practical use of this adjunct to 
a few centers. 
Manipulations of Inspired Gas Delivery
Supplemental O2 during exercise has been 
shown to consistently improve exercise 
capacity and to reduce ventilation and 
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Figure 2. Operating lung volumes are shown during constant work rate cycle exercise in COPD patients during hyperoxia 
versus room air breathing. End-expiratory (EELV) and end-inspiratory lung volumes (EILV) were reduced at rest (0 min) 
and throughout exercise during hyperoxia compared to room air breathing. The magnitude of dynamic hyperinflation (i.e., 
the difference in EELV from resting values) was similar at peak exercise during hyperoxia compared with room air in a 
hypoxemic patient with COPD. IRV, inspiratory reserve volume; TLC, total lung capacity; VT , tidal volume. 
Adapted from: Guenette JA et al. Inspiratory capacity during exercise: measurement, analysis, and interpretation. Pulm 
Med 2013; e956081.
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breathlessness at a standardized time 
(isotime) during exercise testing in COPD 
patients with and without resting hypoxemia. 
O2 supplementation during exercise delays 
ventilatory limitation and accompanying 
dyspnea mainly by reducing ventilatory 
demand. O2 supplementation has variable 
effects on DH and reduced DH is not a 
prerequisite for dyspnea relief (Figure 2). Both 
improved oxygen delivery to the peripheral 
muscles (resulting in less reliance on 
anaerobic metabolism) with altered afferent 
inputs from leg muscle mechanoreceptors, 
and attenuated peripheral chemoreceptor 
stimulation are possible explanations for 
the reduction in ventilatory demand for a 
given level of exertion. Despite the good 
physiological rationale supporting the 
use of this intervention, six out of seven 
published RCTs failed to demonstrate an 
additional benefit of oxygen supplementation 
on training benefits in patients with COPD. 
Only one well-designed study by Emtner 
and colleagues documented higher work 
rates during training in the oxygen group, 
which consequently resulted in larger 
improvements in exercise capacity. The latest 
American Thoracic Society/European Society 
statement on pulmonary rehabilitation (Spruit 
et al.) suggests that individualized oxygen 
trials should be used to identify patients who 
might benefit from oxygen supplementation 
during exercise training.  
Heliox is a low density gas mixture (79% helium, 
21% oxygen) that has been used in patients 
with COPD to reduce airflow resistance during 
the increasing ventilatory needs of exercise. 
Heliox supplementation has been shown to 
improve exercise performance in patients with 
COPD in comparison with room air breathing. 
Studies evaluating shortness of breath at 
a standardized time (isotime) during an 
endurance cycling task have also consistently 
shown significant reductions in dyspnea 
perception. Heliox breathing increases the 
size of the maximal resting flow-volume 
envelope and seems to actually slow down the 
increase in EELV during exercise by decreasing 
airflow resistance, thereby directly altering 
DH.  Improvements in exercise capacity were 
correlated with the magnitude of changes in 
EELV during exercise. In three studies, the 
response to hyperoxic helium (60-70% helium, 
30-40% oxygen) and oxygen supplementation 
alone was compared during a constant load 
cycling task in patients with moderate (non-
hypoxemic), severe, and very severe (patients 
on long term O2 therapy) symptoms. These 
studies all found significant differences in 
endurance time in favor of the hyperoxic 
helium group. They further demonstrated 
reductions in the resistive work of breathing 
and reductions in exercise-induced DH in 
comparison with hyperoxia alone. Three RCTs 
have investigated the effects of heliox as an 
adjunct during exercise training in COPD with 
conflicting results. The complexity of applying 
helium gas mixtures during exercise training, 
together with the added expense and lack of 
conclusive clinical benefits, suggests that, 
despite the strong physiological rationale, this 
therapy currently does not play a routine role 
in pulmonary rehabilitation.
Breathing Exercises
Deep and slow breathing
Training patients to transiently breathe 
slowly and deeply during exercise has been 
hypothesized to decrease hyperinflation, work 
of breathing, and improve symptoms and 
exercise capacity. Some patients with severe 
airflow obstruction and lung hyperinflation 
spontaneously use pursed lip breathing 
(PLB) to reduce expiratory flow and slow 
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down respiratory rate in conjunction with 
improvements in dyspnea both at rest and 
during exercise. Patients who do not adopt 
PLB spontaneously show variable responses. 
During PLB, patients perform a moderately 
active expiration through half-opened lips, 
thereby inducing expiratory mouth pressures 
of about 5cmH2O. It has been shown that 
slowing down expiratory flow reduces the 
tendency of airways to collapse as well as 
the resultant air trapping. This is probably the 
reason why this technique seems to be most 
effective in patients with severe loss of lung 
elastic recoil pressure and tracheobronchial 
collapse. Adopting PLB at rest reduces 
breathing frequency and increases VT, while 
ventilation is usually maintained or slightly 
reduced. Reducing dead space and improving 
alveolar ventilation in this way likely explains 
the improvements in gas exchange that are 
typically observed. These effects have also 
been observed when a slower and deeper 
breathing pattern was adopted without 
using PLB. In a small study Pomidori, L. et 
al., teaching COPD patients  yoga breathing 
resulted in a slower, deeper pattern of 
breathing and improvements in oxygen 
saturation with no increases in symptoms. 
Effects of long-term breathing retraining 
interventions on changes in spontaneous 
ventilatory pattern are still lacking. Data from 
Bianchi and colleagues obtained by using 
optoelectronic plethysmography, contribute 
to our understanding as to why not all patients 
with COPD obtain symptom relief from PLB 
(and thus do not spontaneously use it). They 
observed that reductions in breathing frequency 
and increases in VT during PLB were achieved 
by either increasing or decreasing EELV. The 
group that hyperinflated during PLB (n=19) did 
not perceive symptomatic benefits, whereas 
patients who decreased their EELV (n=11) did. 
Reductions in EELV were positively correlated 
with improvements in Borg Dyspnea scores 
(r=0.71, p<0.001) and with a greater level of 
expiratory flow limitation (r=0.45, p<0.02). 
Pursed lip breathing during exercise has only 
been studied in few small studies, with mixed 
results in terms of dyspnea reduction and 
improvements in exercise capacity. Spahija 
and colleagues performed the only study (n=8) 
that measured changes in EELV and respiratory 
muscle effort after PLB during constant 
work bicycle exercise. They found a strong 
correlation between changes in dyspnea 
sensation during exercise and both changes in 
EELV (r2=0.82, p=0.002) and inspiratory muscle 
effort (r2=0.84, p=0.001) occurring with PLB. 
Interestingly, while all patients reduced their 
breathing frequency during PLB, only two out 
of eight subjects were able to reduce their EELV 
and to decrease their inspiratory effort. These 
were also the only patients who perceived 
improvements in dyspnea during exercise. 
Patients who increased their EELV during 
PLB experienced worsening of symptoms. 
Reductions in EELV with PLB again seemed 
to be related to levels of static hyperinflation 
(more hyperinflated patients tended to 
improve more) but the sample size was too 
small to demonstrate a statistically significant 
relationship (r=0.54, p=0.17). Further research 
is needed to identify and select patients who 
might benefit from PLB during exercise. It 
will also be important to standardize the 
technique and to define the amount of training, 
instruction and reinforcement needed to apply 
it successfully.
Collins and colleagues used a computerized 
ventilation feedback intervention aimed at 
slowing respiratory rate during exercise, in 
combination with an exercise training program. 
They showed reductions in respiratory rate, 
ventilation and DH at isotime during a constant 
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load cycling task. These improvements were 
related to improvements in dyspnea during 
exercise. Feasibility and persistence of the 
these positive effects in the absence of the 
feedback still need to be determined in order 
to make this approach applicable for clinical 
practice.
Active expiration
In healthy subjects, active expiration is not 
present during resting breathing and only 
occurs with increased ventilation (e.g., 
physical activity). In patients with COPD, 
abdominal muscle activity is often present 
during resting breathing and this occurs more 
often in patients with more severe airflow 
obstruction. Contraction of abdominal muscles 
increases abdominal pressure during active 
expiration. It has been hypothesized that, while 
this increase in abdominal pressure is unlikely 
to facilitate lung emptying or contribute to 
lowering of EELV, it should result in lengthening 
of the diaphragm, thereby optimizing its end-
expiratory length tension characteristics.
Diaphragm displacement and its contribution 
to tidal volume during resting breathing has 
been shown not to be different in COPD patients 
in comparison to healthy subjects. Recently, 
it was also demonstrated that increased 
expiratory muscle activity in patients with 
COPD was accompanied by preserved dynamic 
diaphragm function in comparison with healthy 
controls during exercise. In patients with very 
severe airflow obstruction and hyperinflation, 
the contribution of the diaphragm during 
exercise was reduced.
It is not clear whether the spontaneously 
present activity of expiratory muscles should 
be further stimulated in patients with COPD. 
Reybrouck and colleagues observed larger 
decreases in functional residual capacity 
(FRC) and improvements in pressure 
generating capacity of inspiratory muscles 
in patients performing active expiration with 
electromyography feedback compared to 
patients who received instructions without 
myofeedback. Symptomatic benefits were 
unfortunately not assessed and no studies on 
the effects of active expiration training during 
exercise have been performed so far. Casciari 
and colleagues studied a range of breathing 
retraining strategies including PLB and active 
expiration techniques and found additional 
improvements in exercise capacity in those 
patients who performed their rehab program 
in combination with breathing retraining 
strategies. The relative contribution of each 
of the different components of the breathing 
retraining program to the observed benefits 
is, however, unclear. Dodd et al. studied the 
effects of a belt strapped around the abdomen 
to improve length-tension characteristics of 
the diaphragm during exercise. While this 
intervention resulted in improved maximal 
transdiaphragmatic pressure generation it 
increased relative load on the diaphragm and 
the diaphragmatic tension time index during 
exercise and decreased endurance time on 
the bicycle in comparison with unstrapped 
exercise. 
In summary, spontaneous activity of the 
abdominal muscles is, depending on the 
severity of hyperinflation and expiratory 
flow limitation, often already present at rest 
in patients with COPD and probably helps to 
preserve diaphragmatic function during rest 
and exercise. Whether further improvements 
in diaphragmatic function after stimulated 
active expiration can result in improvements 
in dyspnea and exercise capacity needs to be 
further explored.
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Body positioning techniques
A forward leaning posture is (analogous to 
active expiration and PLB) often spontaneously 
used by patients in an attempt to decrease 
dyspnea, possibly by improving the length-
tension relationships of the diaphragm. Relief 
of dyspnea is often experienced by patients 
in the forward leaning position. Patients with 
pronounced hyperinflation or even paradoxical 
abdominal movements during inspiration have 
been shown to perceive the greatest relief 
of dyspnea in this position. Forward leaning 
is associated with a significant reduction in 
electromyographic activity of scalene and 
sternocleidomastoid muscles, an increase in 
pressure generating capacity of inspiratory 
muscles and diaphragm efficiency (Figure 
3), and significant improvements in thoraco-
abdominal movements. In addition, forward 
leaning with arm support allows accessory 
muscles (pectoralis minor and major) to 
significantly contribute to rib cage elevation. 
Use of a rollator while ambulating allows 
forward leaning with arm support, decreases 
dyspnea, and increases exercise capacity. 
Diaphragmatic breathing
Several studies have described an increase in 
rib cage contribution to chest wall motion and/
or asynchrony between rib cage and abdominal 
motion in patients with COPD that correlates 
with airflow obstruction and hyperinflation of 
the rib cage. During diaphragmatic breathing, 
patients are instructed to move the abdominal 
wall predominantly during inspiration and to 
reduce upper rib cage motion. This aims to: 1) 
improve chest wall motion and the distribution 
of ventilation; 2) decrease the contribution of rib 
cage muscles to the energy cost of breathing; 
and 3) improve dyspnea and exercise 
performance. It has been consistently shown 
that patients with COPD are able to voluntarily 
change their breathing pattern and to use 
more abdominal movement and less thoracic 
excursion during diaphragmatic breathing. 
Diaphragmatic breathing however often results 
in more asynchronous breathing movements 
and has not been shown to improve breathing 
pattern and ventilation distribution. In most 
patients, mechanical efficiency of breathing 
has decreased, whereas work and oxygen 
cost of breathing has increased, resulting in 
worsening of dyspnea. In summary, there 
is no evidence from controlled studies to 
support the use of diaphragmatic breathing in 
hyperinflated patients with COPD.
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Figure 3. Mean data for 4 subjects with COPD in supine, 
standing, erect sitting, and forward leaning position. 
∆Edi = inspiratory phasic change in diaphragmatic 
electromyograph; ∆Pdi = inspiratory phasic change in 
transdiaphragmatic pressure. The ratio ∆Pdi%/∆Edi% is 
an index of the efficiency of the diaphragm. 
Adapted from: Druz WS and Sharp JT. Electrical and 
mechanical activity of the diaphragm accompanying 
body position in severe chronic obstructive pulmonary 
disease. Am Rev Resp Dis 1982; 125:275-280.
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Inspiratory Muscle Training (IMT)
Strengthening of the inspiratory muscles by 
specific training programs has been applied 
frequently in patients with COPD to alleviate 
dyspnea symptoms and improve exercise 
capacity. The rationale for IMT is to compensate 
for the negative consequences of dynamic 
hyperinflation on the demand/capacity 
imbalance of the already compromised 
respiratory muscles. Inspiratory muscle 
training has been shown to improve 
inspiratory muscle function (both pressure 
generating capacity and endurance) and to 
reduce dyspnea and improve exercise capacity 
when applied as a stand-alone intervention 
with controlled training loads. The intervention 
seems to be most effective in patients with 
compromised inspiratory muscle function. 
Effects on dyspnea symptoms and exercise 
capacity when combining IMT with an exercise 
training intervention remain inconclusive. In 
this context, it should be noted that additional 
effects of other interventions exerting acute 
physiological effects during exercise testing 
(e.g., heliox or oxygen supplementation, and 
assisted ventilation techniques) have also been 
difficult to establish when combining them with 
an exercise training program. Larger studies 
will be needed to show additional effects of 
interventions that are combined with exercise 
training since the latter is by itself already a 
very effective intervention.
Significant enhancement in the velocity of 
inspiratory muscle shortening during resistive 
breathing tasks and increases in the size of 
type II muscle fibres following IMT have been 
previously observed in patients with COPD. 
These improvements might be of clinical 
relevance to patients with respiratory muscle 
weakness secondary to lung hyperinflation, 
since improved muscle performance 
characteristics may improve dynamic function 
during exercise. Similar to non-invasive 
ventilator support, IMT is not likely to directly 
affect hyperinflation at rest or the increase 
in EELV during exercise. Improvements in 
dyspnea during exercise in response to IMT 
and NIV are likely related most to adjustments 
in the demand/capacity imbalance in the 
setting of high inspiratory muscle work and 
functional weakening induced by DH. However, 
detailed measurements of inspiratory muscle 
function during exercise in response to IMT 
have not yet been performed. The beneficial 
effects of IMT were only observed in studies 
with careful control of training intensity (i.e., 
training loads greater than 30% Pi, max) and 
patient selection. Patients with impaired 
inspiratory muscle strength and a ventilatory 
limitation to exercise with dyspnea as the main 
factor limiting exercise seem to have greater 
potential to benefit.
CONCLUSIONS
Strong evidence supports the use of exercise 
training to reduce symptoms, increase 
exercise capacity and improve quality of life 
in patients with COPD. Properly conducted 
exercise training has been shown to reduce 
ventilatory needs and DH during exercise at a 
given workrate. Several interventions might 
be useful adjuncts to exercise in primarily 
ventilatory-limited and hyperinflated patients 
who experience severe breathlessness during 
activities. Non-invasive ventilatory support 
and heliox breathing might be options for 
specialized centers. Oxygen supplementation 
and breathing exercises might be applied 
on a controlled trial and error basis, taking 
into account perceived benefits in terms of 
symptom reduction. Even though the evidence 
base for most breathing exercises (except 
for inspiratory muscle training) is small, 
the application of these techniques might 
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be worthwhile (except for diaphragmatic 
breathing), since even modest benefits, when 
achieved with simple, non-invasive, and 
inexpensive interventions such as PLB, active 
expiration and body positioning, are of value to 
severely breathless patients. With all of these 
interventions, careful patient selection, proper 
and repeated instruction, control of techniques, 
and repeated assessments of perceived benefit 
in terms of symptom improvements are 
necessary. The transfer effects of controlled 
breathing exercises from resting to exercise 
conditions are not well established and further 
research should be performed in this area.
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Key Points
1.
The respiratory consequences of hyperinflation in 
spontaneously breathing, mechanically ventilated 
patients, are increased work of breathing, 
overdistention of the ventilatory pump (pump 
insufficiency), and wasted or ineffective efforts.
2.
The hemodynamic consequences of 
hyperinflation are decreased venous return, 
cardiac output and hypotension. These events are 
more pronounced in patients in intensive care 
units under mechanical ventilator support.
3.
The reduction of hyperinflation is the prime aim of 
the management of respiratory failure in intensive 
care units. However, this is not always feasible, 
since ventilator support modes may potentially 
increase overdistention of the respiratory system.
4.
Therapeutic approaches should include 
decreasing the level of extensive ventilator 
assistance by using the appropriate extrinsic 
PEEP and prolonging the time of expiration by 
reducing machine inspiratory timing (Ti) or by 
increasing the expiratory trigger threshold.
5.
Reducing wasted efforts of the patient is another 
complimentary therapeutic strategy.
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INTRODUCTION
The consequences of hyperinflation in 
spontaneously breathing mechanically 
ventilated patients are respiratory (i.e., 
increased work of breathing, overdistention 
of the respiratory system and wasted or 
ineffective efforts) and hemodynamic 
compromise. In the passive patient (exhibiting 
no respiratory muscle activity) under controlled 
mechanical ventilation, the consequences 
of hyperinflation are overdistention and 
hemodynamic compromise.
Respiratory Consequences of Hyperinflation
The pathophysiology of hyperinflation of 
the respiratory system in spontaneously 
breathing mechanically ventilated patients can 
be illustrated using the Campbell diagram.
Campbell diagram
The Campbell diagram is constructed by 
plotting the dynamic relation between pleural 
pressure (measured with an esophageal 
balloon) and lung volume during breathing 
in relation to the passive pressure-volume 
curves of the lung Pel(L) and the chest wall 
Pel(cw) (Figure 1). The Pel(cw) is constructed by 
connecting the values taken by the esophageal 
pressure during passive inflation (i.e., with 
no respiratory muscle activity) when the 
airways are closed at different lung volumes. 
Unfortunately, as this is difficult to do, since it 
requires passive inflation and often muscle 
paralysis, a theoretical value for the slope 
of this curve is frequently used. However, 
if a patient is passively ventilated and an 
esophageal balloon is placed, a true value 
for the volume–pressure relationship of the 
chest wall during passive tidal breathing can 
be obtained. This passive pressure–volume 
relationship can be used as a reference value 
for subsequent calculations when the patient 
develops spontaneous inspiratory efforts. Any 
change in esophageal pressure is referred 
Normal breath from the relaxation volume 
of the respiratory system
with expiratory muscle use 
PexpPinsp
End of inspiration
Beginning of
expiratory effort
inspiratory
muscle
relaxation 
 
 
Pleural pressure
Pel(L)
0
Pel(cw)
VL
Relaxation
Volume
Figure 1. In normal subjects, inspiration starts from 
the relaxation volume of the respiratory system, where 
the passive pressure-volume curves of the lung (Pel(L)) 
and chest wall (Pel(cw)) intersect. Inspiratory muscle 
action results in pressure development (Pinsp) on the left 
of the pressure-volume curve of the chest wall (Pel(cw)) 
. Inspiratory flow, and thus increases in lung volume 
(VL) take place on the left of the pressure-volume curve 
of lung and coincide with the beginning of inspiratory 
muscle action. Inspiration ends on the pressure-volume 
curve of the lung and the inspiratory muscles relax (so 
that pressure returns on the pressure volume curve of 
the chest wall). In the case shown, expiration is active 
so that pressure develops on the right of the pressure 
volume curve of the chest wall due to activity of expiratory 
muscles (Pexp). This returns volume back to the relaxation 
volume of the respiratory system.
to this line in the Campbell diagram in order 
to calculate the true muscular pressure 
developed by the patient. In normal subjects, 
inspiration starts from the relaxation volume of 
the respiratory system (Vr), where the Pel(L) and 
Pel(cw) intersect (i.e., where the tendency of the 
lung to recoil inward is equal to the tendency of 
the chest wall to expand; Figure 1). Inspiratory 
muscle action results in pressure development 
(Pinsp) on the left of the Pel(cw). Inspiratory flow, 
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and thus increases in lung volume (VL), take 
place on the left of the Pel(L) and coincide with 
the beginning of inspiratory muscle action. At 
any volume, the horizontal distance between 
the Pel(cw) and Pel(L) represents the portion of 
inspiratory muscle action devoted to expanding 
the lung at this volume with open airways 
(elastic pressure), and the portion on the left 
of the Pel(L) represents the pressure dissipated 
to generate airflow (resistive pressure). 
Inspiration ends on the Pel(L) (point of zero 
flow) and the inspiratory muscles relax so that 
pressure returns on the Pel(cw). Expiration is 
usually passive, and the respiratory system 
returns to its relaxation volume along the 
Pel(cw); however, in patients with respiratory 
distress, such as mechanically ventilated 
chronic obstructive pulmonary disease (COPD) 
patients, expiration is frequently active. In the 
case of active expiration, pressure develops 
on the right of the Pel(cw) due to activity of 
expiratory muscles (Pexp). This returns volume 
back towards the relaxation volume of the 
respiratory system. 
In mechanically ventilated patients, inspiratory 
muscle action has to overcome the trigger 
sensitivity (Ptr) of the ventilator (horizontal 
distance between the Pel(L) curve and Ptr; 
Figure 2) before it results in inspiratory flow 
and thus increases in VL. Thus, the beginning 
of inspiratory effort does not coincide with 
the beginning of inspiratory flow. Instead, 
the initial inspiratory effort (orange line in 
Figure 2) is horizontal (no flow, only pressure 
development) until it crosses the Ptr line at 
which time it deviates upward, indicating 
inspiratory flow, and thus increases in VL. 
Work of breathing
Measuring work of breathing (WOB) is a useful 
approach to calculate the total expenditure of 
energy by the respiratory muscles and/or the 
ventilator. In general, the work performed 
during each respiratory cycle is mathematically 
expressed as WOB = ∫ Pressure x Volume, 
i.e., the area on a pressure–volume diagram 
(Figure 1-2). Esophageal pressure is usually 
taken as a surrogate for intrathoracic (pleural) 
pressure. Esophageal pressure swings 
during inspiration are needed to overcome 
two forces: the elastic forces of the lung 
parenchyma and chest wall, and the resistive 
forces generated by the movement of gas 
through the airways. One can calculate these 
two components (elastic and resistive) by 
comparing the difference between esophageal 
pressure during the patient’s effort during 
the breath and the pressure value in passive 
Normal breath overcoming ventilator trigger 
from the relaxation volume 
of the respiratory system with 
expiratory muscle use
Pleural pressure
Pel(L)
0
Pel(cw)
VL
Relaxation
VolumePtr
Figure 2. In mechanically ventilated patients, inspiratory 
muscle action has to overcome the trigger sensitivity 
of the ventilator (horizontal distance between the Pel(L) 
curve and Ptr ) before it results in inspiratory flow and 
thus increases in VL . Thus, the beginning of inspiratory 
effort does not coincide with the beginning of inspiratory 
flow. Instead, the initial inspiratory effort (orange line) 
is horizontal (no flow, only pressure development) until 
it crosses the Ptr line at which time it deviates upward 
indicating inspiratory flow and thus increases in VL . In the 
case shown, the trigger sensitivity is pressure triggering.
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conditions, represented by the static Pel(cw). The 
area between the Pel(L) and Pel(cw) represents 
the elastic work of breathing. The area on 
the left of the Pel(L) represents the resistive 
work of breathing. The area on the right of the 
Pel(cw) represents the work of breathing of the 
expiratory muscles.
The WOB is normally expressed in joules (J). 
One J is the energy needed to move 1L of gas 
through a 10-cmH2O pressure gradient. The 
work per liter of ventilation (J/L) is the work per 
cycle divided by the tidal volume (expressed in 
liters). In a healthy subject the normal value is 
around 0.35 J/L. Lastly, WOB can be expressed 
in work per unit of time, multiplying joules 
per cycle by the respiratory rate (expressed 
in breaths per minute) to obtain the power of 
breathing (joules/minute). In a healthy subject 
the normal value is around 2.4 J/min. 
As illustrated by the Campbell diagram, 
hyperinflation increases the WOB: the higher 
the End-expiratory lung volume (EELV), i.e., 
the higher the intrinsic positive end-expiratory 
pressure (PEEPi), the larger the area of the work 
of breathing on the Campbell diagram. This is 
because the Pel(L) and Pel(cw) both deviate as 
lung volume increases. Consequently, with a 
constant tidal volume (VT), the higher the EELV, 
the larger the elastic component of the work of 
breathing, and thus the total work of breathing. 
Intrinsic positive end-expiratory pressure can 
be quite high, especially in patients with COPD, 
and may represent a high proportion of the total 
WOB. For example, a patient who displaces 
0.5L of tidal volume through a 7-cmH2O 
pressure gradient will perform an amount of 
work of 0.35J/cycle. If nothing else changes 
except that this patient develops 5 cmH2O of 
PEEPi, 0.25J will be required to counterbalance 
this, meaning that the total WOB will be 0.60J 
(0.35 + 0.25), which represents around 40% of 
the total work required for the inspiration.
Overdistention
In patients with hyperinflation, inspiration 
starts from an increased EELV, which 
predisposes to overdistention. The higher the 
hyperinflation and the higher the inspiratory 
pressure or volume delivered by the ventilator, 
the higher the risk of overdistention. The 
presence of overdistention can be inferred 
from the airway pressure over time tracing of 
the ventilator screens when late inspiratory 
upstroke develops (Figure 3).
Wasted efforts
Wasted or ineffective efforts are inspiratory 
efforts that fail to trigger the ventilator. 
Nearly 25% of mechanically ventilated 
patients exhibit ineffective efforts, which 
are even more frequent in COPD patients. 
Wasted efforts are a major cause of patient-
ventilator dyssynchrony that increase the 
energy expenditure of the respiratory muscles 
and may injure them. Understanding their 
pathophysiology is essential to properly 
adjust the ventilator settings to attenuate or 
eliminate them. Wasted efforts should be 
searched for before any change in ventilator 
settings is implemented during assisted 
modes of mechanical ventilation, since any 
ensuing (after the change in ventilator settings) 
increase in ventilator rate might be caused by 
the attenuation of wasted efforts (the ventilator 
rate now approaching the patient’s respiratory 
controller rate) and not by the development of 
respiratory distress with the new settings.
How can wasted efforts be detected at the 
bedside?
Wasted efforts can be clinically detected 
when the breaths delivered by the ventilator 
(measured rate on the ventilator display) are 
less than the number of inspiratory efforts 
of the patient (on clinical examination) over 
the same time interval. On modern ventilator 
screens, ineffective efforts can be detected as 
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Why are spontaneously breathing mechanically 
ventilated COPD patients prone to develop 
wasted/ineffective efforts? 
In COPD patients with hyperinflation, 
inspiration starts from an increased end-
expiratory lung volume (Figure 4). Inspiratory 
muscle action has to overcome the PEEPi (red 
dashed line, horizontal distance between the 
Pel(L) and Pel(cw)) before it results in inspiratory 
flow and thus increases in VL. In mechanically 
ventilated patients, inspiratory muscle action 
has to additionally overcome the Ptr of the 
Effects of PEEP on wasted efforts
in the presence of dynamic
hyperinflation and PEEPi.
PEEP=0
PEEP=10
Chao DC et al, Chest 1997;112:1592-9
Figure 3. Upper panel: Esopageal (Peso ) and airway (Pao 
) pressures and flow at the tracheostomy in a patient 
with wasted efforts (black arrows) on flow-controlled, 
volume-cycled (assist/control) mode. Wasted efforts can 
be detected as abrupt airway pressure drop simultaneous 
to an abrupt decrease in expiratory flow (from the flow 
trajectory established earlier during expiration) caused by 
the inspiratory effort and not followed by a machine breath. 
The units are cm H20 for the pressure tracing and L/min for 
flow. The patient’s inspiratory efforts are identified by the 
negative Peso swings. The PEEP is set at 0. Pao appropriately 
drops to 0 during expiration; demonstrating little circuit or 
valve resistance. Wasted efforts (black arrows) are evident, 
with one triggered breath (white arrow) every two to three 
inspiratory efforts. Prolonged expiratory flow is due to 
airflow limitation. Lower panel: PEEP is now increased to 
10 cm H20 so the Pao during expiration is now 10 cm H20. 
There is persistent flow at end-expiration, thus PEEPi is still 
present. Wasted efforts (black arrows) have been reduced 
with one breath triggered every other inspiratory effort. 
Peak inspiratory pressure and the Peso have increased 
slightly compared to the upper panel, most likely indicating 
a higher end-expiratory lung volume and total PEEP level.
PEEPi
Dynamic
Hyperinflation
 
Wasted effort
 
Breath from increased end-expiratory 
lung volume due to the presence of 
dynamic hyperinflation in COPD 
Pleural pressure
Pel(L)
0
Pel(cw)
VL
Ptr
Relaxation
Volume
Figure 4. In COPD patients with dynamic hyperinflation, 
inspiration starts from an increased end-expiratory 
lung volume. Inspiratory muscle action has to overcome 
the intrinsic positive end expiratory pressure (PEEPi, 
horizontal distance between the between the Pel(L) and 
Pel(cw)) before it results in inspiratory flow and thus 
increases in volume. In mechanically ventilated patients, 
inspiratory muscle action has to overcome PEEPi plus the 
trigger sensitivity (Ptr) before it results in inspiratory flow 
and thus increases in volume (VL). When the magnitude of 
inspiratory muscle action is less than the sum of PEEPi + 
Ptr , this inspiratory effort (orange horizontal line) cannot 
trigger the ventilator, and consequently does not result in 
inspiratory flow and thus increases in volume (VL). This 
inspiratory effort is called ineffective or wasted.
abrupt airway pressure drops simultaneous 
to an abrupt decrease in expiratory flow (from 
the flow trajectory established earlier during 
expiration) caused by the inspiratory effort, and 
not followed by a machine breath (Figure 3). 
Monitors that can automatically detect wasted 
efforts are available.
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ventilator (horizontal distance between the 
Pel(L) and Ptr) before it results in inspiratory flow 
and thus increases in VL; thus, in mechanically 
ventilated COPD patients, inspiratory muscle 
action has to overcome PEEPi plus the Ptr. 
When the magnitude of inspiratory muscle 
action is less than the sum of PEEPi plus Ptr, 
this inspiratory effort (Figure 4, orange line) 
cannot trigger the ventilator, and consequently 
does not result in inspiratory flow and thus 
increases in VL. This inspiratory effort is called 
“ineffective” or “wasted”.
Hyperinflation not only increases PEEPi, but 
at the same time renders the respiratory 
muscles weaker for a variety of reasons: (see 
chapter A1).
The greater the degree of hyperinflation, the 
higher the PEEPi, and the weaker become the 
respiratory muscles. The net effect is a greater 
predisposition to wasted efforts.
Is the Campbell diagram useful for estimating 
the work of breathing during wasted efforts?
The Campbell diagram is not useful to estimate 
inspiratory work of breathing when inspiratory 
triggering does not happen (i.e., during wasted 
efforts): work is physically defined as the area 
subtended in a pressure/volume loop. Since 
there is no inspiratory volume, the work is zero 
(albeit muscles, indeed, consume energy). 
The energy expenditure during non-triggered 
wasted inspiratory efforts can be estimated by 
the pressure/time product: the product of the 
pressure developed by the inspiratory muscles 
(difference between the measured esophageal 
pressure and the Pel(cw)) multiplied by the time 
of muscle contraction (i.e., neural inspiratory 
time [Ti]).
How are ventilator settings affecting the 
incidence of wasted/ineffective efforts?
Excessive ventilator support predisposes to 
ineffective efforts irrespective of the mode of 
mechanical ventilation used. This is because, 
in the case of COPD, excessive pressure or 
volume delivered by the ventilator results in 
increased EELV, and this combined with the 
long time constant of the respiratory system 
(which retards lung emptying) and/or a short 
imposed expiratory time (in case of volume or 
pressure control) results in further increased 
EELV before the next inspiratory effort begins 
(Figure 5, green curve). 
At the same time, excessive ventilator 
assistance reduces inspiratory muscle 
effort, via either a phenomenon called 
neuromechanical inhibition (the main 
mechanism most likely being the Hering–
Breuer reflex), and/or by producing alkalemia 
via excessive CO2 reduction in patients with 
chronic bicarbonate elevation, thus reducing 
the drive to the respiratory muscles. 
The ensuing inspiratory effort is inadequate to 
overcome PEEPi plus Ptr; thus, this inspiratory 
effort fails to trigger the ventilator (ineffective 
or wasted effort) (Figure 5, red line). This 
is, of course, exaggerated in the presence 
of respiratory muscle weakness. The next 
expiratory effort (Figure 5, blue curve) 
decreases the EELV. When EELV decreases 
to a level where the ensuing inspiratory 
effort exceeds PEEPi plus Ptr, the ventilator 
is triggered again to deliver a machine breath 
(Figure 5, purple curve). The breath-to-breath 
variability in breathing pattern contributes 
to the variability in the EELV and thus to the 
frequency of ineffective efforts. 
During assist volume or pressure control 
mechanical ventilation, prolonged imposed 
inspiratory time (machine Ti) greater than the 
patient’s neural Ti results in a situation where 
the ventilator is inflating the patient long after 
the inspiratory muscles have stopped their 
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contraction, i.e., during the neural expiration. 
This results in increased EELV and a shorter 
time available for expiration, both of which 
increase EELV (more hyperinflation) and thus 
predispose to wasted efforts.
During pressure support ventilation, a low 
expiratory trigger threshold (percentage of 
peak inspiratory flow at which the ventilator 
cycles to expiration) might lead to pressure 
support being delivered well beyond the 
patient’s neural Ti. The next inspiratory 
effort (controlled by the patient’s respiratory 
controller) begins during the early phase of 
ventilator expiration, i.e., at an increased VL. 
This effort might not be sufficient to overcome 
PEEPi plus Ptr, and thus, this inspiratory effort 
also fails to trigger the ventilator.
Therapeutic approach to overdistention
An obvious solution to reduce overdistention 
is to decrease the level of excessive ventilator 
assistance (i.e., the delivered pressure or 
volume). This will decrease EELV. However, 
this might not be always clinically feasible, 
since it might lead to respiratory distress and 
derangement of blood gases.
Another not mutually exclusive approach is 
to decrease hyperinflation by prolonging the 
expiratory time. With a constant VT, decreasing 
hyperinflation will decrease overdistention:
1. During assist volume or pressure control, 
reducing machine Ti (or equivalently 
increasing the inspiratory flow in volume 
control) may prolong expiratory time (if the 
respiratory frequency, and thus the total time 
of the respiratory cycle, does not change) and 
will reduce hyperinflation.
2. During pressure support, increasing the 
expiratory trigger threshold will stop the 
breath earlier, i.e., at a lower EELV, and will 
prolong expiratory time and thus, will decrease 
hyperinflation. 
Therapeutic approach to wasted efforts: What 
ventilator adjustments should be done in the 
presence of wasted/ineffective efforts?
One solution to reduce the frequency of 
wasted efforts is to decrease the level of 
excessive ventilator assistance (i.e., the 
delivered pressure or volume). This will 
decrease the EELV and with a given (or even 
Wasted efforts are due to
breath by breath increases in 
end-expiratory lung volume
due to overassistance, delayed lung 
emptying and short expiratory time
Pleural pressure
Pel(L)
0
Pel(cw)
VL
Ptr
Relaxation
Volume
wasted
expiratory
effort
Figure 5. In the case of COPD presented in this figure, the 
first inspiratory effort (orange line) triggers the ventilator. 
In the next breath that triggered the ventilator, excessive 
ventilator assistance (either pressure or volume) 
resulting in large tidal volume, combined with the long 
time constant of the respiratory system (which retards 
lung emptying) and/or a short imposed expiratory time 
(in case of volume or pressure control) result in further 
increased end-expiratory lung volume before the next 
inspiratory effort begins (green line). The ensuing 
inspiratory effort despite being equal to the previous 
effective effort is inadequate to overcome PEEPi + Ptr due 
to the increased EELV. Thus this inspiratory effort fails to 
trigger the ventilator (wasted or ineffective effort, red line). 
The following expiratory effort (blue line) decreases the 
end-expiratory lung volume. When the end-expiratory 
lung volume decreases to a level where the ensuing 
inspiratory effort exceeds PEEPi +Ptr, the ventilator is 
triggered again to deliver a machine breath (purple line). 
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increased) time for expiration will reduce 
EELV-hyperinflation and will reverse the 
pathophysiology presented above. In clinical 
practice one may start gradually decreasing 
the level of applied pressure during assist 
pressure control or pressure support in steps 
of 2 cm H2O or the delivered volume in assist 
volume control by 10%. However, this might not 
be always clinically feasible, since it might lead 
to respiratory distress and to derangement of 
blood gases.
During assist volume or pressure control 
reducing machine Ti (or equivalently increasing 
the inspiratory flow in volume control) may 
prevent ventilator delivery beyond the patients’ 
neural Ti. This will prolong expiratory time and 
will reduce wasted efforts. In practice, machine 
Ti may be reduced in steps of 10%. This titration 
may be stopped when ineffective triggering is 
eliminated or the patient shows poor tolerance.
During pressure support, increasing the 
expiratory trigger threshold will stop the 
breath earlier, and thus at a lower EELV, and 
will prolong expiratory time. Both will reduce 
wasted efforts. Practically, the insufflation 
time may be gradually reduced, by increasing 
the cycling-off criterion in steps of 10%; if 
ineffective triggering persists at the highest 
value (which depends on the ventilator), the 
insufflation time may be further reduced by 
adjusting the maximal insufflation time in 
steps of 0.2s from the mean insufflation time; 
this titration may be stopped when ineffective 
triggering is eliminated or the patient shows 
poor tolerance.
Another solution is the application of PEEP. The 
addition of an amount of external PEEP lower 
than the PEEPi (Figure 6, red dotted lines) offers 
part of the pressure required to overcome 
PEEPi plus Ptr (Figure 6). The inspiratory 
effort starts closer to the Pel(L) (the horizontal 
distance between this point and the Pel(cw) 
being the applied PEEP [PEEP external]). The 
inspiratory effort is now adequate to trigger 
the ventilator (orange curve). 
In clinical practice, one may begin by applying 
small amounts of PEEP (e.g., 2 cmH2O) and 
gradually increase the applied PEEP until 
wasted efforts obtain their minimal value. 
Increasing the applied PEEP above a certain 
value, i.e. the value of PEEPi (which is, 
however, difficult to measure), will increase 
the end inspiratory lung volume and will start 
to predispose again to wasted efforts. The 
greater the increase of applied PEEP above 
PEEPi, the more likely the reappearance or 
increase in the number of wasted efforts.
Measurement of PEEPi
It becomes obvious that an accurate 
measurement of PEEPi is needed. In passive 
Application of external PEEP
can attenuate wasted efforts
Pleural pressure
Pel(L)
0
Pel(cw)
VL
Ptr
Relaxation
Volume
PEEP external 
 
Figure 6. In the presence of increased EELV (green 
line), addition of an amount of external PEEP lower than 
the PEEPi (red dotted lines) offers part of the pressure 
required to overcome PEEPi+Ptr. The inspiratory effort 
starts closer to the passive pressure-volume curve of 
the lung (Pel(L)). The horizontal distance between this 
point and the passive pressure- volume curve of the 
chest wall (Pel(cw)) is the applied PEEP (PEEP external). The 
inspiratory effort is now adequate to trigger the ventilator 
(orange line).
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mechanically ventilated patients, PEEPi is 
routinely measured under static conditions 
(PEEPi,st, or static PEEPi) as the plateau in 
airway pressure during a prolonged end-
expiratory airway occlusion. In spontaneously 
breathing mechanically ventilated patients 
estimation of PEEPi is difficult without the 
placement of esophageal balloons and gastric 
balloons. In actively breathing patients on 
assisted ventilation, PEEPi has been assessed 
dynamically from records of esophageal 
pressure (Pes) obtained with the placement 
of an esophageal balloon. The decrease in Pes 
needed to abruptly bring expiratory flow to 
zero during unoccluded breathing is taken as 
dynamic PEEPi (PEEPi,dyn). 
However, expiratory muscle activity (which 
causes an expiratory rise in gastric pressure 
measured with a gastric balloon [Pga,exp 
rise]) can increase the end-expiratory 
alveolar pressure independently of dynamic 
hyperinflation, leading to an overestimation 
of PEEPi. In spontaneously breathing and 
actively expiring patients, PEEPi,st can be 
corrected for expiratory muscle contraction 
by synchronoussly subtracting the expiratory 
rise in gastric pressure (Pga,exp rise) from 
the end-expiratory airway pressure (Paw) 
occurring during airway occlusion (Figure 7, 
PEEPi,st sub). 
In the case that PEEPi,dyn is part of the 
decrease in Pes preceding inspiration, which 
Correction of PEEPi,st
for expiratory muscle activity
Paw
(cm H2O)
10-
0-
1-
0-
10-
0-
occlusion
PEEP1,st sub
1 sec
20-
10-
cPaw
(cm H2O)
Pga
(cm H2O)
V
(L/s)
Figure 7. Recordings of Flow (V ·), Paw, Pga, and on line 
“corrected” airway pressure (cPaw) in a representative 
actively expiring patient during airway occlusion. cPaw 
is obtained by subtracting the Pga,exp rise from Paw. Note 
a consistent end-expiratory plateau in cPaw, despite 
marked variability in Pga swings. From this plateau, the 
PEEPi,st sub is measured.
Correction of PEEPi,dyn
for expiratory muscle activity
Pes
(cm H2O)
Pga
(cm H2O)
Pdi
(cm H2O)
ΔPes PEESi,dyn
Pga, total decay
Pga, exp rise
V
(L/s)
10-
0-
10-
0-
10-
0-
1-
0-
Figure 8. Tracings of esophageal pressure (Pes), gastric 
pressure (Pga), transdiaphragmatic pressure (Pdi) and flow 
(V ·) in a patient actively expiring during a spontaneous 
breathing trial through the ventilator (pressure support of 
6 cm H2O). The three vertical lines are passed through the 
onset of inspiratory muscle activity (i.e., beginning of Pes 
decay) and the beginning and the end of inspiratory flow, 
respectively. Note the large increase of Pga and Pes during 
expiration due to expiratory muscle recruitment. ∆Pes is 
the increase in end-expiratory Pes relative to its level at 
the onset of spontaneous breathing trial, when expiratory 
muscle activity was nil. Pga,total decay represents the 
abrupt decrease in Pga from its maximum end-expiratory 
value to its minimum value at the beginning of inspiration 
due to relaxation of the abdominal muscles. Pga,exp rise 
is the Pga rise from its minimal end-inspiratory level to 
the maximal level at end expiration. The decay in Pes 
between the first two vertical lines represents dynamic 
intrinsic positive end-expiratory pressure (PEEPi,dyn). 
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is measured as PEEPi,dyn, is actually due to 
relaxation of the expiratory muscles, rather 
than contraction of the inspiratory muscles to 
counterbalance PEEPi. The amount of pressure 
due to expiratory muscle activity that should 
be subtracted from the measured PEEPi,dyn to 
obtain the actual (“true”) PEEPi,dyn elicited by 
dynamic hyperinflation is either the increase in 
gastric pressure over the course of expiration 
(Pga,exp rise) attributed to expiratory muscle 
contraction or the total decrease in gastric 
pressure observed at the beginning of 
inspiration attributed to expiratory muscle 
relaxation (Pga,total decay); the latter being 
somewhat more accurate than the former 
(Figure 8). 
HEMODYNAMIC CONSEQUENCES OF 
HYPERINFLATION
At the end of a normal expiration, alveolar 
and airway pressures are zero relative 
to atmosphere, and esophageal pressure 
is negative (around -5 cmH2O in normal 
conditions). However, in the presence of 
hyperinflation (because of either dynamic 
airway collapse or inadequate time to exhale), 
the alveolar pressure remains positive 
throughout expiration. This positive alveolar 
pressure is transmitted to the pleural-
intrathoracic cavity to varying degrees 
depending on the compliance of the lung. In the 
case of COPD patients, the lungs are compliant, 
so most of the positive alveolar pressure is 
transmitted to the intrathoracic cavity. This 
increases the mean intrathoracic pressure 
during the whole respiratory cycle. The effect 
is more pronounced in the passive patient, 
because during inspiration (pressure or flow 
delivery by the ventilator), the intrathoracic 
pressure becomes even more positive than 
the pressure existing at the end of expiration. 
In the spontaneously breathing mechanically 
ventilated patient, the inspiratory effort of 
the patient decreases the mean inspiratory 
pressure and thus the mean intrathoracic 
pressure. However the average, i.e., the mean 
intrathoracic pressure, is still positive. The 
more positive the mean intrathoracic pressure, 
the more pronounced its hemodynamic effects. 
The hemodynamic effects of hyperinflation are 
the result of a complex interaction between 
changes in preload, secondary to changes 
in the venous return, right—left ventricle 
interactions, direct effects of lung inflation 
and changes in afterload. At moderate 
degrees of hyperinflation, decreased venous 
return is the main mechanism leading to 
decreased cardiac output. The hyperinflated 
lung compresses the pericardium and 
especially the pericardial fossa, increasing 
their pressure (pericardial and juxtacardial 
respectively). This pressure is transmitted to 
the right atrial cavity increasing the right atrial 
pressure, which is the downstream pressure 
for venous return. However, hyperinflation 
with the resulting PEEPi also elevates the 
upstream pressure driving venous return (i.e., 
the mean systemic pressure) by both reflex 
and mechanical means, independent of the 
abdominal pressure. The positive intrathoracic 
pressure also changes the resistive and elastic 
properties of peripheral veins, increases 
venous resistance, and directly compresses 
the inferior vena cava. The net effect of all 
these phenomena is a decrease in the venous 
return.
At the same time that hyperinflation decreases 
the preload of the right ventricle, it also 
increases its afterload, i.e., the pulmonary 
vascular resistance. The more lung volume 
increases above the relaxation volume of 
the respiratory system, the more the intra-
alveolar vessels are compressed, creating 
a starling resistor phenomenon. This 
dominates over vessel recruitment, resulting 
in increased pulmonary vascular resistance. 
The combination of decreased preload and 
increased afterload of the right ventricle 
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results in decreased stroke volume, and thus in 
decreased preload of the left ventricle. Despite 
the fact that the elevations in intrathoracic 
pressure decrease the transmural pressures 
of the left heart, and thus its afterload, the net 
effect is a decrease in cardiac output and/or 
hypotension. 
Of course, the effects of hyperinflation on 
hemodynamics also depend on the contractile 
function of the right and left heart and the 
volume status of the patient. The more 
hypovolemic (volume depleted) a patient is, the 
more vulnerable they become to the effects 
of hyperinflation on the venous return and 
the right ventricular afterload; thus, the more 
vulnerable the patient to the development of 
hypotension and decreased cardiac output.
In spontaneously breathing mechanically 
ventilated patients, application of external 
PEEP is beneficial to counterbalance intrinsic 
PEEP (see above). The hemodynamic effects of 
this PEEP application depend on its magnitude. 
Positive end-expiratory pressure amounting to 
85-90% of PEEPi have no hemodynamic effects, 
whereas levels of PEEP above this level and 
especially well above PEEPi (e.g., by 5cmH2O) 
decrease cardiac output. It is needless to say 
that levels of PEEP that are higher than PEEPi 
are counterintuitive, and should not be used. 
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Key Points
1.
Surgical approaches for lung hyperinflation 
remain largely underused in practice.
2.
The key for a successful surgery is careful 
patient selection where the benefits clearly 
exceed the risks.
3.
As a rule of thumb, a chronic obstructive 
pulmonary disease patient should only be 
considered for a surgical approach when 
dyspnea remains a limiting symptom, 
despite optimal pharmacological therapy and 
effective pulmonary rehabilitation.
4.
The ideal candidate for bullectomy is a chronic 
obstructive pulmonary disease patient with 
a FEV1< 50% pred. showing a large bullae 
(greater than one-third of the hemithorax) 
compressing a relatively normal lung.
The ideal candidate for lung volume 
reduction surgery is a chronic obstructive 
pulmonary disease patient with emphysema 
predominance showing heterogeneous 
disease with upper lobe predominant disease 
and poor exercise capacity.
5.
Despite potential subjective and functional 
improvements in well-selected candidates, 
the beneficial consequences of any surgical 
approach tend to deteriorate over time.
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INTRODUCTION
There is long-standing interest in establishing 
effective and lasting surgical alternatives 
to reduce lung volumes in patients with 
emphysema. These approaches make sense, 
as emphysema is, by definition, a destructive 
and non-reversible process. In fact, the 
efficacy of medical/pharmacological options 
in deflating the lungs is limited when the main 
mechanism of lung hyperinflation is no longer 
expiratory flow limitation, but the anatomical 
consequences of alveolar destruction per se. 
As expected, the main challenge facing the 
physician is to balance the potential benefits 
against the risks of offering surgery to severely 
disabled patients in which chronic obstructive 
pulmonary disease (COPD) frequently coexists 
with several morbidities. This chapter will 
provide an up-to-date guide on how to reach 
the best decision on whether a patient may 
or may not benefit from a surgical procedure 
aimed at deflating the lung(s). Although several 
surgical procedures have been proposed in the 
past 80 years, only the few which have survived 
the test of time will be discussed herein.
Bullectomy
Definitions
Lung bullae are air-filled spaces exceeding 
1cm in diameter with a wall thickness less 
than 1mm. The outer surface of a typical 
bulla is made of visceral pleura, but the inner 
surface consists of fibrous tissue formed 
by the pleura and underlying destroyed 
pulmonary parenchyma. A bulla which 
becomes substantially enlarged and occupies 
a large volume (at least one-third) of the chest 
cavity is called a “giant bulla”. Giant bullous 
emphysema (vanishing lung syndrome) is an 
idiopathic and distinct clinical syndrome that 
affects young men, usually smokers (including 
marijuana), and is characterized by extensive, 
predominantly asymmetric upper lobe bullous 
emphysema. The following classification of 
bullae is useful to guide treatment options:
Group I: Single large bulla with underlying 
normal/relatively-normal lung;
Group II: Multiple bullae with underlying 
normal normal/relatively-normal lung;
Group III: Multiple bullae with underlying 
diffusely emphysematous lung;
Group IV: Multiple bullae with underlying lung 
affected by other diseases.
Procedures 
Bullectomy (also known as reduction 
pneumoplasty) is a thoracic surgery procedure 
aimed at excising one or more lung bullae. The 
bullae can be resected via an “open” technique; 
usually a thoracotomy (staged or simultaneous 
bilateral) or sternotomy. Alternatively, a 
video-assisted thoracoscopic surgery (VATS) 
approach may be feasible in selected cases. 
If the bulla has destroyed or replaced much 
of the lung parenchyma, then an anatomical 
resection (segmentectomy or lobectomy) 
may be required. Giant bullectomies can also 
be concomitantly done with lung volume 
reduction surgery (LVRS) on the ipsilateral and 
contralateral lung. An alternative approach 
for frail patients with a large single bullae is 
the Monaldi procedure (Brompton technique), 
in which the bulla is drained percutaneously 
and a catheter is left behind. The catheter 
is put under suction for a few days, after 
which the broncho-cutaneous fistula closes 
spontaneously after removal. 
How does bullectomy work?
It is widely believed that bullae form when 
adjacent areas of paraseptal emphysema 
coalesce, which explains why they are usually 
subpleural in distribution. The right upper lobe is 
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disproportionately affected, probably because 
alveoli from this lobe are characteristically 
over-distended compared to those from other 
lobes. Although small bullae may increase 
due to a “ball-valve mechanism” in which gas 
enters the lesion but cannot escape, larger 
bullae have negative intra-bullous pressure 
(i.e., similar to pleural pressure). This explains 
why they are preferentially ventilated during 
inspiration. Air trapping ensues because there 
is little inward recoil, forcing the air to leave the 
bulla. The final consequence is compression of 
lung tissue immediately adjacent to a bulla. 
As detailed in the preceding chapters, the 
resulting hyperinflation of the chest interferes 
with normal respiratory mechanics, increasing 
the work of breathing with associated exercise 
limitation and dyspnea.
The physiological changes underlying the 
benefits of bullectomy are quite similar to 
those described after LVRS (Figure 1).  First 
and foremost, there is a significant reduction in 
total lung capacity (TLC) and functional residual 
capacity (FRC); consequently, tidal volume 
(VT) becomes positioned on a more compliant 
portion of the pressure-volume relation of the 
respiratory system. The inspiratory muscles 
may derive large mechanical benefits due 
to: 1) diaphragmatic lengthening and partial 
reconfiguration of its normal curvature; 2) 
improved length-tension relationship; 3) partial 
restoration of the zone of apposition with more 
effective coupling of the costal diaphragm and 
the lower intercostal muscles; and 4) reduced 
elastic loading. Improvement in expiratory 
flow rates after bullectomy is likely secondary 
to recruitment of functioning airways because 
forced expiratory volume in one second (FEV1) 
usually increases in tandem with forced vital 
capacity (FVC), i.e., FEV1/FVC does not change 
remarkably. Tidal expiratory flow limitation, 
however, may persist, albeit at lower lung 
volumes (Figure 2). On the other hand, if the 
excised bullae are not communicating with 
the larger airways, little effect is expected on 
absolute dead space (VD). More importantly, 
however, VD relative to VT may decrease as a 
result of volume recruitment secondary to 
bullous deflation. The ultimate consequence 
may be lower ventilatory requirement to meet 
a given metabolic demand, as a small fraction 
of VT is “wasted”. Additional potential effects of 
Emphysema / Bullae Excision
Volume Recruitment Lung Elastic Recoil
Alveolar
Ventilation 
PaCO2
Insp Muscle
Work 
Expiratory
Flow Rates  
Lung
Hyperinflation 
Dyspnea
Exercise Tolerance PaO2
PAO2
PvO2
Improved V/Q Matching
Cardiac
Output 
Neuromechanical
Coupling 
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.
Figure 1. Potential physiological 
and sensory benefits of surgical 
volume reduction contributing 
to increase exercise tolerance 
in patients with COPD. Key 
mechanisms are highlighted 
in bold and thicker connectors. 
See text for elaboration. insp: 
inspiratory; V: ventilation; Q: 
perfusion; VO2 : oxygen uptake; 
PaO2 : arterial partial pressure 
for oxygen; PaCO2 : arterial partial 
pressure for carbon dioxide. PαO2 , 
alveolar partial pressure for 
oxygen.
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bullectomy on pulmonary gas exchange and 
central hemodynamics are discussed below
Several mechanisms may explain why 
bullectomy may improve exertional 
breathlessness (Figure 3), including reductions 
in impedance to inspiratory muscle action, 
functional inspiratory muscle weakness 
and ventilatory demand. In fact, one study 
found that 99% of improvement in exertional 
breathlessness at a standardized work rate 
was explained by the combination of decreased 
operating lung volumes, decreased breathing 
frequency, and reduced mechanical constraints 
on VT, i.e., direct or indirect consequences of 
less hyperinflation. In summary, the main aim 
of bullectomy is to improve patients’ dyspnea 
and respiratory-related quality of life by: 
• promoting expansion of compressed 
normal adjacent lung tissue, thereby 
recruiting additional lung parenchyma for 
gas exchange and blood perfusion;
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Figure 2. Changes in lung volume as a function of 
changes in pleural pressure (represented by esophageal 
pressure (Pes )) (upper panel) and flow (lower panel) at 
rest (thin lines) and exercise (thick lines) in a patient with 
advanced emphysema who underwent bullectomy and 
LVRS. Note that after surgery (“post”): a) lower variations 
in Pes were required to elicit greater changes in volume, 
i.e., dynamic compliance (CLdyn) improved and b) tidal 
expiratory flow limitation persisted, albeit at lower lung 
volumes.
Adapted from: O’Donnell DE, Webb KA, Bertley JC, 
Chau LK, Conlan AA. Mechanisms of relief of exertional 
breathlessness following unilateral bullectomy and 
lung volume reduction surgery in emphysema. Chest. 
1996;110(1):18-27.
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Figure 3. Lung deflation post-bullectomy results in a 
more harmonious relationship between inspiratory effort 
(ratio between esophageal and maximal inspiratory 
pressures (Pes/PImax) and chest wall displacement). 
The improvement in neuro-mechanical dissociation is 
centrally interpreted as a relief of respiratory difficulty 
(“shortness of breath”).
Adapted from: O’Donnell DE, Webb KA, Bertley JC, 
Chau LK, Conlan AA. Mechanisms of relief of exertional 
breathlessness following unilateral bullectomy and 
lung volume reduction surgery in emphysema.Chest. 
1996;110(1):18-27.
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• improving ventilatory mechanics and work 
of breathing.
Who are the best candidates for bullectomy?
Patients should only be considered for 
bullectomy if they report chronic dyspnea and 
poor respiratory-related quality of life, despite 
maximal medical treatment. Bullectomy 
can also be indicated for bullae-related 
complications, including infection, bleeding or 
carcinoma. There is a widespread notion that 
total resection of the bullae is of importance 
due to increased risk of development of 
bronchogenic carcinoma. Group I and Group II 
patients of bulle classification are considered 
the best candidates (Table 1). The size of the 
bulla also matters: best functional results 
are obtained when it is greater than 1/3 of 
the hemithorax. An estimate of the bulla size 
can also be obtained by comparing TLC by 
body plethysmography with that obtained by 
inhalation of a dilution gas (such as helium): 
the amount by which the second method 
underestimates TLC equals the bulla volume. 
There are also radiological techniques to 
estimate the volume of a bulla.  Excision of 
bulla with volumes greater than 20% of the 
body plethysmographic-determined TLC 
usually results in functional improvement. 
Data from several case series and uncontrolled 
observational studies suggest that a significant 
and sustained functional and symptomatic 
improvement (up to 5 years) can be achieved 
in most (60-90%) of carefully selected patients.
Acute interventions due to rapidly progressing 
dyspnea, pneumothorax and/or prolonged air 
leak after chest tube insertion, are associated 
with greater risk. Surgery is usually 
contraindicated in patients who continue 
to smoke, have significant comorbidities 
(pulmonary hypertension, corpulmonale), 
present with hypercapnia and are aged 80 
or over (Table 1). Hypoxemia per se is not a 
contraindication; as PaO2 may increase after 
lung decompression. The most common 
complications are: air leaks (up to 50%), a 
residual intrathoracic pleural space, atrial 
fibrillation, pulmonary embolism, pneumonia 
and respiratory failure requiring mechanical 
ventilation. The surgery carries a mortality of 
up to 7% in most published series.
Positive features
• Bullae occupying more than one-third of 
the hemithorax
• Vascular crowding
• Localized disease
• Compression of underlying normal lung
• Relatively good perfusion on the 
contralateral side
• Preoperative FEV1<50% pred.
Negative features / contraindications
• Extensive, diffuse emphysema
• Several small bullae
• Current smoking
• Significant cardiopulmonary 
comorbidities
• Age > 80 years
• Chronic hypercapnia
Table 1. Clinical, imaging and functional characteristics 
of patients more likely to benefit from bullectomy and 
predictors of failure or complications.
How to evaluate potential candidates for 
bullectomy
High resolution computerized tomography 
(HRCT) is the imaging technique of choice to 
determine the extent and distribution of bullous 
disease. High resolution computerized tomog-
raphy also allows assessment of coexisting 
problems such as bronchiectasis, co-infect-
ed cysts, pulmonary artery enlargement and 
pneumothorax. The basic evaluation includes 
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electrocardiogram, echocardiogram, dyspnea 
quantification (at least the Medical Research 
Council graduation), full pulmonary function 
tests (including arterial blood gases and body 
plethysmography) and a measure of func-
tional exercise capacity (at least the 6-minute 
walking test). As mentioned, comparison of 
TLC measured by body plethysmography and 
any technique based on dilution of an inert gas 
may prove useful to pre-operatively estimate 
bullae volume. 
Lung volume reduction surgery (LVRS)
Definitions
The term “lung volume reduction surgery” 
(LVRS) defines a surgical procedure aimed 
at deflating the lung by excising the most 
affected portions of the organ in patients with 
a predominant emphysema phenotype.
Procedures 
The traditional “open” approach utilizes 
a median sternotomy or posterolateral 
thoracotomy. Lung volume reduction surgery 
can also be performed with VATS (video 
assist thoracic surgery). There is no evidence 
supporting the superiority of either approach, 
although VATS may have a lower incidence 
of respiratory failure. Most retrospective 
studies suggest a bilateral procedure has 
better outcomes but markedly increase post-
operative morbidity. A unilateral procedure 
is therefore indicated in most circumstances. 
Stapled wedge resections have become the 
current gold standard of care.
How does LVRS work?
Detailed physiological studies showed that 
LVRS improves symptoms and exercise tol-
erance by multiple inter-related mechanisms 
including improved ventilatory capacity, de-
creased resting and dynamic hyperinflation 
and better diaphragmatic function. These pos-
itive effects can also benefit intra-pulmonary 
gas exchange and central hemodynamics 
(Figure 1).
Improvement in FEV1 after LVRS has been 
found to be largely explained by increases in 
vital capacity. In other words, the less diseased 
lung after LVRS would expand and ‘‘resize’’ to 
better fit the chest cavity around it. Removal of 
destroyed, space-occupying alveoli improves 
the efficacy at which a given change in pleural 
pressure is transmitted to the remaining, more 
preserved alveolar units. Consequently, the lung 
becomes intrinsically more efficient in filling up 
more compliant units. Lung volume reduction 
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Figure 4. Right and downward shift in the 
relationship between total lung capacity and 
transpulmonary pressure post-LVRS in a 
group of patients with advanced emphysema. 
This means an increased “coefficient of 
retraction” after surgery which decreases 
lung hyperinflation.
Adapted from: Sciurba FC, Rogers RM, 
Keenan RJ, Slivka WA, Gorcsan J 3rd, Ferson 
PF, Holbert JM, Brown ML, Landreneau RJ. 
Improvement in pulmonary function and 
elastic recoil after lung-reduction surgery for 
diffuse emphysema. N Engl J Med. 1996; 334: 
1095-9.
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surgery can also increase the pressure 
driving maximal expiratory flow – the elastic 
recoil of the lung (Figure 4). Expiratory flow 
rates would then increase as a result of both 
volume recruitment and enhanced emptying 
pressure. The final consequences are lower 
residual volume (RV) and a downward shift of 
the operating lung volumes, i.e., lung deflation 
(Figure 1). Similar to other lung deflating 
strategies, the diaphragm and other inspiratory 
muscles may benefit from reaching a more 
optimal length-tension relationship leading to 
greater maximal inspiratory pressures. These 
considerations are important to understand 
why patients with the highest RV/TLC ratio and 
larger amounts of macroscopically-evident 
emphysema pre-operatively are more likely to 
derive a physiological (and subjective) benefit 
from LVRS.
From the pulmonary gas exchange 
perspective, LVRS is variably associated with 
higher arterial partial pressure for O2 (PaO2) 
and/or lower PaCO2. Increases in PaO2 could 
happen if: 1) the excised tissue had overtly 
abnormal V/Q relationships and/or the post-
LVRS improvement in lung mechanics alters 
V/Q; 2) LVRS improves alveolar ventilation and 
alveolar partial pressure for O2 (PaO2), i.e.,  PaO2 
but unchanged P(a-a)O2; or 3) the mixed venous 
circulation brings less deoxygenated blood 
to the lungs due to improved cardiac output 
and higher peripheral O2 delivery and/or less 
O2 is consumed in the periphery (e.g., due to 
lower respiratory muscle work) (Figure 1). 
Figure 5 shows that all 3 factors are involved 
but with a greater relative importance of 
improved V/Q. On the other hand, decreases 
in PaCO2 can be almost entirely explained by 
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Figure 5. Relative contribution of ventilation (represented by 
arterial partial pressure for CO2 (PaCO2 )), extra-pulmonary 
factors (mixed venous partial pressure for O2 (P v O2 ) and 
ventilation/perfusion inequality (DISPRE) for changes in PaO2 
induced by LVRS. This model explained about 70% of changes in 
PaO2 after the procedure.
Adapted from: Cremona G, Barberà JA, Melgosa T, Appendini 
L, Roca J, Casadio C, Donner CF, Rodriguez-Roisin R, Wagner 
PD. Mechanisms of gas exchange response to lung volume 
reduction surgery in severe emphysema.J ApplPhysiol (1985). 
2011; 110:1036-45.
Figure 6. Relative contribution of intrinsic positive 
end-expiratory pressure (PEEPi), residual volume / 
total lung capacity ratio (RV/TLC), tidal volume (VT) 
and maximal inspiratory pressure (MIP) for changes 
in arterial partial pressure for CO2 (PaCO2 ) induced 
by LVRS. Note that all contributors are directly or 
indirectly related to lower lung hyperinflation. This 
model explained about 95 % of changes in PaCO2 after 
the procedure.
Adapted from: Cremona G, Barberà JA, Melgosa T, 
Appendini L, Roca J, Casadio C, Donner CF, Rodriguez-
Roisin R, Wagner PD. Mechanisms of gas exchange 
response to lung volume reduction surgery in severe 
emphysema.J ApplPhysiol (1985). 2011; 110:1036-45.
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improvement in lung mechanics (Figure 6) and 
neuromechanical coupling.
As previously mentioned, another potential 
benefit of LVRS relates to enhanced central 
hemodynamics. The exact mechanisms are 
unknown, but may involve lower mean intra-
thoracic pressures, decreases in pleural 
pressure swings and recruitment of previously 
under-perfused lung vessels. The latter 
effect, in association with increased PaO2, 
may contribute to decrease right ventricular 
afterload. Of note, increases in FEV1 after 
LVRS have been associated with a fall in mean 
pulmonary arterial pressure and changes in 
exercise capacity correlated with changes in left 
ventricular volume indices and a reduction in 
pulmonary arterial pressures at end-expiration. 
In fact, at least one study found that reduction 
in lung volumes during exercise after LVRS was 
associated with an increase in O2 pulse (oxygen 
uptake/heart rate); an indirect index of stroke 
volume. Lung volume reduction surgery has 
also been associated with improvements in 
heart rate variability, suggesting a decrease in 
sympathetic tonus and a healthier autonomic 
balance. Improved hemodynamics and better 
arterial oxygenation would then increase 
peripheral O2 delivery and mixed venous O2 
content (Figure 5) which collectively are likely 
to enhance arterial oxygenation, decrease 
breathlessness and increase exercise tolerance 
after LVRS (Figure 1).
From a clinical stand point, the most striking 
effect of successful LVRS (and bullectomy) 
is the alleviation of dyspnea. Although all 
of the above-mentioned mechanisms may 
contribute, there is well-established evidence 
that post-LVRS improvement in exertional 
dyspnea is associated with decrements in end-
expiratory lung volume (EELV) and intrinsic 
end-expiratory positive pressure (PEEPi). As 
a consequence, the inspiratory muscles not 
only need to generate less pressure at the 
start of inspiration to overcome PEEPi but also 
their work is rewarded with greater volume 
displacement, i.e., better neuromechanical 
coupling (Figure 3).
Who are the best candidates for LVRS?
The National Emphysema Treatment Trial 
(NETT) was a landmark study that randomized 
more than 1200 patients to bilateral LVRS or 
best medical care. LVRS was associated with 
a lower risk of death than medical therapy in 
the 290 patients with upper lobe predominant 
emphysema and low exercise capacity. This 
subgroup was more likely to achieve ≥10W 
improvement in maximum exercise capacity 
and ≥8 unit improvement in St. George’s 
Respiratory Questionnaire (SGRQ) score after 
2 years of follow-up. In the 419 patients with 
upper lobe predominant emphysema and 
high exercise capacity, LVRS had no impact 
on survival. However, this subgroup also 
showed the same positive effects on exercise 
capacity and quality of life. In the 149 patients 
with non–upper lobe predominant disease and 
low exercise capacity, LVRS had no impact on 
survival or maximum exercise capacity, but 
quality of life was improved. Unfortunately, 
in the 220 patients with non–upper lobe 
predominant emphysema and high exercise 
capacity at baseline, LVRS increased the risk 
for death and had no effect on maximum 
exercise capacity or quality of life. Thus, the 
trial identified a subgroup of patients with 
heterogeneous emphysema and low baseline 
exercise capacity as having a reduced risk of 
death and clinically significant improvements. 
More recent studies confirmed that those 
with lower 6-min walking distance, more 
emphysema (but not homogenous/diffused), 
and greater hyperinflation at baseline are 
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most likely to respond to LVRS. The beneficial 
effects of LVRS in the NETT were sustained 
with increased survival in the LVRS group at 
a median 4.3 years of follow-up. Nowadays, 
there is a trend towards performing staged 
unilateral LVRS separated by a period of 2 to 
5 years to reduce operative risks and extend 
overall symptomatic benefit compared with 
bilateral LVRS at a single surgery.
Lung volume reduction surgery remains 
greatly under-utilized worldwide, possibly 
due to an erroneous interpretation that the 
NETT was negative and the surgery harmful. 
Although the NETT indicated that patients 
with FEV1≤20% pred. with either carbon 
monoxide diffusing capacity (DLCO)≤20% pred. 
or a homogeneous emphysema pattern are 
at greater risk of complications and mortality, 
a substantial fraction of the patients did 
derive benefit from the intervention. The 
most common complications in the trial 
were arrhythmia, pneumonia, re-intubation, 
need of intensive care unit re-admission 
and prolonged mechanical ventilation. These 
findings prompted a list of general features 
of patients at greater risk of complications in 
whom the procedure is not advised or even 
contraindicated (Table 2).
How to evaluate potential candidates for LVRS
As with the evaluation for bullectomy, 
HRCT should be used to carefully assess 
disease extension and for comparative 
analysis between upper versus lower lobe 
emphysema. Moreover, it would be helpful 
to assess coexisting problems, particularly 
a source of chronic infection or malignancy. 
Electrocardiogram, echocardiogram, dyspnea 
quantification, alpha-1-antitrypsin levels, 
quantitative ventilation/perfusion (V/Q) scan, 
full pulmonary function tests (including arterial 
blood gases and body plethysmography) 
and cardiopulmonary exercise testing with 
dyspnea measurements should be requested. 
Additional studies may be required according 
to patients’ potential comorbidities, e.g., 
dobutamine-radionuclide scan and right heart 
catheterization.
Predictors of successful surgery / lower 
risk
• Heterogeneous emphysema
• Upper lobes predominance
• Poor exercise capacity after pulmonary 
rehabilitation 
Predictors of unsuccessful surgery / 
greater risk
• FEV1≤20% pred.
• DLCO≤20% pred. 
• Homogeneous emphysema 
• Lower lobes predominance
• Major cardiopulmonary comorbidity, 
particularly heart failure and pulmonary 
hypertension
• Current smoking
• Chronic use of oral steroids
• Age >80 years 
• Chronic bronchitic phenotype
• Chronic hypercapnia
Table 2. Clinical, imaging and functional characteristics 
of patients more likely to benefit from LVRS and risk 
factors for the surgery.
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CONCLUSIONS 
The decision to refer a patient with advanced 
emphysema for any surgical approach should 
be made after careful judgement of the benefits 
and risks in an aged population where multiple 
morbidities may coexist. The best decision 
is usually reached by combining clinical, 
structural and functional data in a motivated 
patient in whom pharmacological and non-
pharmacological treatments have been 
appropriately optimized (Figure 7). Pulmonary 
transplantation remains the last alternative for 
debilitated patients with poor prognosis and/
or those not fitting the anatomical and clinical 
pre-requisites for a favourable response to 
LVRS.
Emphysema phenotype
Optimized Treatment
Pulmonary Rehabilitation
FEV1 < 50% predicted
Bullae > 1/3 hemithorax
Localized Disease
Compression of underlying lung
FEV1 ≤ 20% predicted
DLCO ≤ 20% predicted
Homogenous emphysema
Lower lobe predominance
Bullous Disease
Rule out
contraindications
Consider Bullectomy
Rule out
contraindications
Consider LVRS
YES NO
YES NO YES NO
Rule out
contraindications
Consider Lung Tx
Figure 7. Schematic algorithm for 
a practical evaluation of potential 
candidates for a surgical approach 
to lung hyperinflation in patients with 
COPD. FEV1 : forced expiratory volume 
in 1 second; DLCO: lung diffusing 
capacity for carbon monoxide; Tx: 
transplantation; LVRS: lung volume 
reduction surgery.
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Key Points
1.
Bronchoscopic lung volume reduction may 
become an alternative to surgical lung 
volume reduction method(s), to reduce 
hyperinflation.
2.
Except for the airway bypass stents, all 
other methods have shown beneficial 
effects reducing hyperinflation; improving 
lung function, 6-minute walking distance 
and health related quality of life equivalent 
to lung volume reduction surgery.
3.
However, bronchoscopic lung volume 
reduction methods are still under 
investigation, and have not yet been 
approved by the FDA for the treatment of 
severe emphysema.
4.
A major problem is collateral ventilation  
due to incomplete fissures. Common 
adverse events are pneumothorax and 
COPD exacerbations.
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INTRODUCTION
Reduction of the damaged areas of the lung 
is a very old method of medicine. During the 
last century, before the discovery of anti-
tuberculosis medications, a common technique 
was medical therapeutic pneumothoracis: 
by introducing air into the thoracic cavity, a 
compression of the lung occurred, reducing 
the tuberculus cavities, leading to healing.
This idea had been reintroduced by the results 
of lung volume reduction surgery (LVRS) for 
the treatment of severe emphysema (see 
chapter C4).
However, LVRS has significant limitations; 
such as, benefits confined to a very selective 
group, attendant morbidity and increased early 
mortality.
Bronchoscopic lung volume reduction (BLVR) 
is a method under development for a less 
invasive, less expensive, low morbidity and 
mortality alternative technique to LVRS.
Its rationale is the same as LVRS: to reduce the 
most damaged areas of the lung to decrease 
hyperinflation and thus, to improve respiratory 
mechanics and gas exchange mechanisms, as 
well as improvement in the cardinal symptom 
of dyspnea, exercise capacity and health-
related quality of life (QoL).
However, these techniques are still under 
investigation, being tested in small early-phase 
clinical trials and not having been approved by 
the U.S. Food and Drug Administration (FDA) for 
the treatment of emphysema, although they 
have shown potential benefits in lung function, 
exercise capacity and QoL.
METHODS
There are five different methods of BLVR:
1. One way valves;
2. Sealant /hydrogens (BioLVR);
3. Coil implants (LVRCs);
4. Airway bypass stents; and
5. Bronchial thermal vapor ablation (BTVA) 
therapy.
One-way Valves
These valves, when positioned in target 
airways, allow the exit of air from distal 
airways, while preventing the inspired air to 
enter these airways (Figure 1). 
There are two commercially available one-way 
valves, which are designed to be removable:
1. The Spiration® IBV is an umbrella like valve 
deployed via the working channel of the 
flexible bronchoscope. The main benefits 
were seen in QoL, without notable changes 
in lung reduction or 6-minute walking 
distance (6MWD). (Figure 2)
 The common adverse events were pneu-
mothorax, bronchospasm and pneumonia.
Figure 1. The general principles of one-way valves. (Left) 
Positioning of the valve into the bronchi of the affected 
area. (Middle) Air is exhaled from the affected area 
(collapse).
(Right) Inhalation is not going into the affected area.
Figure 2. The Spiration® one-way valve.
Reproduced permission from EMH Swiss Medical Publishers Ltd. All rights Reserved
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2. The Zephyr® Valve is a duck-billed silicone 
valve that anchors in the airways, creating 
an airtight seal with the bronchial wall. It 
allows trapped air and secretions to exit 
the valve during exhalation. This valve is 
inserted in the target airways by the flexible 
bronchoscope, as previously described. The 
Zephyr valve had been shown to improve 
forced expiratory volume in 1 second 
(FEV1) and 6MWD, but adverse effects 
include increase in exacerbations and 
hospitalizations (Figure 3).
The major limitation of one-way valves is the 
presence of collateral ventilation that does not 
allow atelectasis of the lung area distal to the 
valve. A catheter mediated device (Pulmon X) 
to measure inter-lobar collateral ventilation 
has been developed, and it has been suggested 
that its use prior to positioning of the valves 
ensures best results.
Biologic Lung Volume Reduction (BioLVR) 
(Figure 4)
The BioLVR therapy is a bronchoscopic 
administration of fibrinogen suspension and 
thrombin solution into the targeted airways 
separately. On contact, those substances 
polymerize into hydrogel that causes a local 
inflammatory reaction; leading to remodeling 
of the airways, occlusion and atelectasis 
with volume reduction seen 4-6 weeks 
later. The results of a number of clinical 
studies showed an improvement in FEV1, a 
reduction in residual volume and the ratio 
of residual volume/total lung capacity (RV/
TLC), reduced dyspnea scores, and improved 
QoL (St. George’s Respiratory Questionnaire 
[SGRQ]). The common adverse effects 
were fever, leukocytosis, and malaise and 
COPD exacerbations. In order to avoid using 
human blood products, a synthetic system 
was developed (The AeriSeal® System) 
(Figure 4). This system uses hydrogel foam 
that biodegrades as a surfactant, leading to 
atelectasis in order to increase the efficacy of 
this method. BioLVR efficacy is also affected by 
collateral ventilation; thus, fissure integrity is 
an important factor that should be evaluated 
before the procedure.
Coil Implants (LVRCs) (Re -Pnew)
When the coil is placed into the airway, it 
conforms into its predetermined shape and by 
bending in the lumen and causing compression 
of the adjacent lung tissue, creates local 
LVR. (Figure 5). It had been shown that this 
procedure improved SGRQ, FEV1, RV and 
6MWD. Exacerbations and pneumothorax are 
the common adverse events. It must be noted 
that there are very few studies using coils for 
BLVR.
Figure 4. The biologic lung volume reduction method.
Figure 3. The Zephyr® one-way valve.
Reproduced permission from EMH Swiss Medical Publishers Ltd. All rights Reserved
T R E AT M E N T
PA G E  1 3 0
HYPERINFLATION OF THE LUNG AND ITS MANAGEMENT
C5.
Medical Lung Volume Reduction
Airway Bypass Stents (Figure 6)
Airway bypass stents have been developed to 
create and sustain passages between bronchi 
and emphysematous lobes. This procedure 
usually involves the placement of three to 
four drug eluting stents in order to create 
supported fenestrations between the bronchial 
tree and the damaged lung parenchyma. The 
procedure needs a Doppler probe to find non-
vascular sites, and, of course, a highly skilled 
bronchoscopist. A multi-center bronchoscopic 
study (Exhale airway stents for Emphysema) 
[EASE]) in homogeneous emphysema patients 
had shown initial benefits in lung function and 
QoL, that were not sustained at 6 or 12 months.
Bronchoscopic Thermal Vapor Ablation (Figure 
7)
This method uses heated water to induce 
thermal injury, leading to a local inflammatory 
response resulting in permanent fibrosis and 
atelectasis. It uses a balloon catheter that seals 
the airways, while the predetermined water 
vapor is administered to the emphysematous 
lobes. This method reduces lung volume 
measured radiographically, improves FEV1, 
reduces RV, and increases 6MWD, BODE (body 
mass index, airflow obstruction, dyspnea 
and exercise capacity) index and SGRQ. 
Exacerbation of COPD was the most common 
adverse event.
Figure 7. Bronchoscopic Thermal Vapor Ablation.
Figure 5. Coil implants (Re-Pnew).
Figure 6. An airway bypass stent.
Copyright 2008, used with permission from CTSNet (www.ctsnet.org). All rights reserved
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CONCLUSIONS
A recent meta-analysis of the efficacy of 
bronchoscopic lung volume reduction methods 
concluded that, except for the airway bypass 
stents, all other methods showed efficacy in 
primary outcomes. BioLVR showed the most 
significant findings and was least associated 
with major treatment related complications. 
Finally, it was stated that BLVR showed non-
inferiority, if not equivalence, compared to 
surgical LVR. However, it must be emphasized 
that, all the above methods, although 
promising, are still under investigation and not 
approved by the regulatory agencies for the 
treatment of advanced emphysema.
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Acetylocholine Ach
Acute exacerbations of COPD AECOPD
Acute respiratory distress syndrome ARDS
Adenosine diphosphate ADP
Adenosine triphosphate ATP
Airway pressure Pao
Alpha-1 Antitrypsin A1AT
Alveolar partial pressure for O2 PAO2
American Thoracic Society/European Respiratory Society ATS/ERS
Anti-DNase B ADB
Arterial carbon dioxide pressure PaCO2
Arterial oxygen pressure PaO2
Australian Respiratory Early Surveillance Team for Cystic Fibrosis AREST-CF
Barometric pressure in cmH2O Pb
Biologic lung volume reduction BioLVR
Body mass index BMI
Body mass index, airflow obstruction, dyspnea and exercise capacity BODE index
Breathing frequency Fb
Bronchial thermal vapor ablation BTVA
Bronchoscopic lung volume reduction BLVR
Calcium Ca2
Calcium ions Ca2+
Carbon dioxide CO2
Carbon monoxide diffusing capacity DLCO
Cardiopulmonary exercise tests CPET
Chronic obstructive pulmonary disease COPD
Chronic Respiratory Disease Questionnaire CRQ
Computed tomography CT
Continuous positive airway pressure CPAP
Corrected airway pressure cPaw
Cystic fibrosis CF
Cystic Fibrosis Transmembrane Conductance CFTR
Diaphragm electromyography EMGdi
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List of abbreviations (alphabetically)
Dynamic compliance of the lung Cdyn
Dynamic hyperinflation DH
Dynamic lung hyperinflation DH
End-expiratory lung volume EELV
End-inspiratory lung volume EILV
Esophageal pressure Peso
Esophageal pressure Pes
European Network for Understanding Mechanisms of Severe Asthma ENFUMOSA
Exhale airway stents for Emphysema EASE
Expiratory flow limitation EFL
Expiratory reserve volume ERV
Forced expiratory flow 25–75% FEF25–75%
Forced Expiratory Flow at 50% FEF50%
Forced expiratory volume in 1 second FEV1
Forced vital capacity FVC
Functional residual capacity FRC
Functional residual capacity FRC
Gastric pressure Pga
Global Initiative for Chronic Obstructive Lung Disease GOLD
High-resolution computed tomography HRCT
Inert gas (helium) dilution FRCHe
Inhaled corticosteroid ICS
Inorganic phosphate Pi
Inspiratory capacity IC
Inspiratory pressure Pinsp
Inspiratory pressure support IPS
Inspiratory reserve volume IRV
Inspiratory time Ti
Inspiratory vital capacity IVC
Intensive care unit ICU
Intrinsic positive end-expiratory pressure PEEPi
Joule J
Left ventricular LV
London Cystic Fibrosis Collaboration LCFC
Long acting β2-agonist LABA
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List of abbreviations (alphabetically)
Long-acting muscarinic antagonist LAMA
Lung hyperinflation LH
Lung volume VL
Lung volume reduction coil LVRC
Lung volume reduction surgery LVRS
Magnesium Mg2
Magnetic resonance imaging MRI
Maximal expiratory pressure MEP
Maximal inspiratory pressure MIP
Maximal inspiratory pressure PImax
Minimal clinically important difference MCID
Minute ventilation V’Ε
Multi-Ethnic Study of Atherosclerosis MESA
n-acetylcysteine NAC
National Emphysema Treatment Trial NETT
Neonatal Chronic Lung Disease CLD
Nitrogen N2
Nitrogen washout FRCN2
Non-invasive ventilation NIV
Oral phosphodiesterase-4 PDE4
Oxygen O2
Peak work rate Wpeak
Physiological dead space VD
Plethysmography FRCpleth
Positive end-expiratory pressure PEEP
Pressure-volume chest wall  curve Pel(cw)
Pressure-volume chest wall curve Pcw
Pressure-volume lung curve Pel(L)
Primary Ciliary Dyskinesia PCD
Proportional assisted ventilation PAV
Provocative concentration causing a 20% drop in FEV1 PC20
Pulmonary gas trapping RV, RV/TLC
Pursed lip breathing PLB
Quality of life QoL
Quantitative ventilation/perfusion V/Q
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List of abbreviations (alphabetically)
Quartile Q)
Randomized clinical trials RCTs
Ratio of tidal volume to inspiratory capacity VT/IC
Relaxation volume Vr
Required ventilation VE
Residual volume RV
Residual volume/total lung capacity RV/TLC
Respiratory distress syndrome RDS
Respiratory neural drive RND
Respiratory syncytial virus RSV
Slope of body box volume and alveolar pressure line during panting ΔV/ΔP
Slow vital capacity SVC
St. George’s Respiratory Questionnaire SGRQ
Thoracic gas volume TGV
Tidal volume VT
Total lung capacity TLC
Total respiratory system Prs
Transdiaphragmatic pressure Pdi
Transition Dyspnea Index TDI
Trigger sensitivity Ptr
Upper limit of normal ULN
Video-assisted thoracoscopic surgery VATS
Vital capacity VC
Work of breathing WOB
6-minute walking distance 6MWD
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